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ABSTRACT 
 
With the growing demand for a therapeutic drug monitoring (TDM) in clinical 
laboratories the development of appropriate and improved analytical methods to 
monitor drug concentrations and optimize patient care has become imperative. This 
dissertation contributes in this regard by developing sensitive, specific, and reliable 
GC-MS and LC-MS/MS methods to measure drug concentrations and validating them 
according to the FDA Guidance for Industry. The methods are performed based on 
the example of the critical dose drug phenytoin (PHT), which has characteristics – 
such as a small therapeutic range, nonlinear pharmacokinetics, interactions with 
other drugs, inter-individual genetic differences in the metabolism, and long-term 
therapy – that render it a highly suitable model substance and a reliable standard for 
the development and application of analytical methods to measure concentrations 
also of other medications.  
 
Both methods allow the measurement of low drug concentrations in different body 
compartments (i.e., blood, saliva, and samples from brain tissue microdialysis with 
relatively small sample volumes) and therefore could be used to measure drug 
concentrations in the compartment of interest for various other drugs. By 
systematically comparing the two methods, the dissertation concludes that although 
GC-MS is a sensitive and suitable method (e.g., for the measurement of volatile and 
thermally stable substitutes in a sample), the LC-MS/MS method offers significant 
advantages (in terms of its sensitivity, LOD/LOQ, needed sample volume, sample 
preparation, analysis time, and costs), which make it highly suitable for larger sample 
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numbers as in pharmacokinetic/pharmacodynamic studies as well as for bedside and 
routine analyses. While these findings are based on the model substance PHT, other 
promising drugs for TDM are, for example, Midazolam, Ceftriaxon, Morphine, and 
Levatiracitam, which are often administered concomitantly in neurosurgery. In the 
future, the routinely used matrices (i.e., blood or urine) for TDM will be expanded with 
other sample sources like tissue biopsies, dried blood spots, and oral fluids. LC-
MS/MS methods provide the advantage of drug quantification in such matrices which 
are easier to handle. Thus, the dissertation concludes that LC-MS/MS methods are 
the current gold standard for TDM.  
 
Furthermore, in this dissertation also a theoretical estimation method to calculate free 
drug concentrations has been tested, which could be used in the absence of 
corresponding lab methods or data – not every hospital or institution is able to afford 
a LC-MS/MS or a GC-MS instrument. The dissertation tested the usefulness of the 
Sheiner-Tozer algorithm for the correct estimation of the free PHT concentrations in 
hypoalbuminemic patients and compared the estimated with the measured free PHT 
levels. There were no statistically significant differences between the two methods 
and the estimated values highly correlated with the measured free PHT values. The 
results support the usefulness of the Sheiner-Tozer formula to calculate free PHT 
concentrations from the total PHT and the serum albumin value of a patient. These 
findings are of interest for all drugs with a high albumin binding such as 
immunosuppressants, antibiotics, or anticancer drugs.  
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1. INTRODUCTION 
1.1  Therapeutic Drug Monitoring  
1.1.1 Factors that Indicate a Therapeutic Drug Monitoring 
 
Therapeutic drug monitoring (TDM), as a multi-disciplinary clinical approach, has 
gained wide popularity among clinicians and is aimed at improving patient care by 
monitoring drug concentrations. There are certain characteristics and criteria which 
make a range of drugs suitable for or even strongly require a TDM. The monitoring of 
drug concentrations is, for example, indicated if the pharmacological effect of the drug 
is clinically not well determinable, if the drug has a narrow therapeutic range, or in the 
case of insufficient success of a therapy despite therapeutic dosage. For a rational 
TDM, the drug needs to have a clear relationship between its concentration in 
different body compartments and its clinical effect or toxicity [1]. Drugs with these 
characteristics and criteria include, for example, antiepileptics, antibiotics, 
antimycotics, aminoglycosides, antidepressants, or immunosuppressants. For these 
drugs, an appropriate TDM becomes highly relevant for a safe and efficient drug 
treatment. As an example, TDM can make a significant contribution in the context of 
antiepileptic drug treatments (e.g., phenytoin). A TDM of antiepileptics is of great 
benefit for the treatment of uncontrollable seizures and in cases of clinical toxicity and 
assists in the individualization of the therapy and in adjusting for variable or nonlinear 
pharmaco-kinetics [2]. An individualized drug therapy (precision medicine) is even 
more indicated for patients with varying pharmacokinetics, for example, critically ill 
patients [3], patients with traumatic brain injury, organ failure, very young or elderly 
patients [4]. 
 
Therapeutic Drug Monitoring (TDM) aims to guarantee an optimally individualized 
drug therapy by maintaining drug concentrations in the specific body compartment 
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(e.g., plasma) within a targeted therapeutic range. Figure 1 illustrates the relationship 
between the pharmacokinetics (concentration levels and distribution of drug) and the 
pharmacodynamics (therapeutic and adverse effects) resulting in the therapeutic 
range which lies between the maximal therapeutic concentration and the minimal 
effective concentration.  
 
 
Figure 1: Relationship between the Pharmacokinetics and Pharmacodynamics  
of a Single Dose Administration [5] 
MTC = Maximal therapeutic concentration, MEC = Minimal Effective Concentration, 
AUC = Area Under the Curve 
 
1.1.2 Determination of Drug Concentrations for TDM 
When monitoring an individualized drug therapy in patients or investigating drug 
concentrations in forensic toxicology sensitive and specific quantification methods are 
of critical importance [6]. Critical dose drugs but also newly developed and designed 
complex drugs require new analytical methods to check for effective drug delivery to 
target tissues and to minimize toxicity in sensitive organs or cells.  
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In a hospital setting, an adequate analysis time is crucial for an appropriate TDM and 
an individualized drug dosing. Bedside analysis is therefore the most appropriate way 
to measure individual drug concentrations and to swiftly adapt the dose regimen or 
treatment. For bedside analysis usually homogenous enzyme immune tests (EMIT) 
are used, which are often sufficient for the determination of drug plasma 
concentrations and dosage adjustments. For low concentrations in other body 
compartments, however, these EMITs are not suited.  
 
A more precise and sensitive method to measure drug concentrations in different 
body compartments and already at very low concentrations is the liquid 
chromatography combined with mass spectrometry (LC-MS or LC-MS/MS). The 
recent growth in the availability of LC-MS instruments in many hospitals enables to 
measure drug concentrations on site and allows to react quickly for an adjusted and 
efficacious drug therapy. The sample volume needed for the analysis with LC-MS 
method is very small (5-20µl). Therefore, it is possible to measure drug 
concentrations even in less accessible body compartments as liquor or brain micro 
dialysates or in small (pre-term) infants.  
 
1.1.3 Microdyalisis as a Sampling Method in Brain Tissue 
Of the existing drugs in Switzerland in 2017, medications to treat diseases of the 
central nervous system such as painkillers and drugs to treat Parkinson’s disease, 
mental illness, and epilepsy had the highest market share (16.3%) [7]. The use of 
antiepileptic drugs has increased during the last decades. In Switzerland, two third of 
the 70-80’000 affected patients are seizure free due to appropriate antiepileptic 
medication [8] (see also chapter 1.2.1 of this dissertation).  
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For antiepileptic drugs such as Phenytoin (PHT), the brain is the site of action and 
therefore the compartment of interest for an accurate determination of the drug 
concentration. Brain microdyalisis has been established – especially in neurosurgical 
patients to monitor the status and the metabolism with selected biomarkers or 
substrates – for sampling and collecting small-molecular-weight substances from the 
interstitial tissue such as glucose, pyruvate, lactate, LPR, or glutamate. Microdyalisis 
(MD) therefore also enables to collect drugs passing the blood-brain barrier and 
acting in the brain [9]. MD is a minimally invasive neuro-monitoring technique which 
uses the principle of dyalisis. In Figure 2 the principles of MD are depicted. The 
microdialysis catheter consists of two concentric tubes. The perfusate ﬂows through 
the external tube down to the tip (red circle), where the ﬁnal 10 mm of the catheter 
consists of a semipermeable dialysis membrane. The substances present in higher 
concentrations in the brain interstitial tissue diffuse into the dialysis perfusion fluid 
(red arrow). This perfusate now called MD can then be collected in microvials for 
analyses. The direction of movement can be changed by adding substances to the 
perfusion fluid (blue arrow) [10, 11].  
 
An important advantage of the MD method is that it does not affect the compartment 
volume and therefore the drug concentrations in this compartment do not vary. 
Furthermore, MD allows a continuous sampling and a nearly unlimited number of 
samples could be collected. The range of the flow rate for the perfusion fluid can be 
set from 0.1 - 3 μl/min. Usually, the perfusion fluid rate is set to 2 μl/min resulting in 
collection times between 10 and 12.5 min for 20 - 25 μl sample volume.  Therefore, 
the sampling is rather fast and makes the MD also suitable for bedside drug analysis 
for TDM and timely dose adjustment. 
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Figure 2: Bedside Cerebral Microdialysis Monitoring [10] 
 
 
 
1.2  Therapeutic Drug Monitoring of Critical Dose Drugs: The Example of 
Phenytoin  
 
1.2.1 Phenytoin and its Use in Medicine 
Epilepsy is one of the most important neurological disorders. About 50 million people 
(1% of the world population) worldwide are affected [12,13]. The annual incidence 
ranges from 20 to 70 cases per 100’000 and the prevalence is 0.4 to 0.8% [10]. 
Generalized epilepsies occur in approximately one-third of patients [12]. The 
treatment of epilepsy is based on stopping seizures or minimizing their frequency as 
well as mitigating undesirable side-effects [13]. 
 
Phenytoin (PHT) is a well-established and one of the most widely prescribed 
anticonvulsants for the treatment and the prevention of seizures and status 
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epilepticus [14]. The use of PHT in adults with severe traumatic brain injuries before 
and after neurosurgical intervention has been shown to be effective as prophylaxis. 
The risk for an early posttraumatic seizure after acute, traumatic brain injuries can be 
diminished significantly [15,16,17,18]. The use of antiepileptic drugs to treat patients 
who have developed post-traumatic epilepsy is common practice [19]. PHT is the only 
antiepileptic drug for which an optimal therapeutic range (serum concentrations) is 
clearly defined and which is effective in preventing early seizures after acute brain 
injury [15, 20]. 
 
1.2.2 Chemical and Physical Characteristics of Phenytoin  
PHT is a hydantoin derivative (5,5-Diphenylhydantoin) with the structure formula 
C15H12N2O2 and the molecular weight of 252.3 g/mol (see Figure 3). PHT is nearly 
insoluble in water and ethanol 96%, but is soluble in alkaline solutions because of the 
weak acidic character (pKa = 8.33) [21, 22]. In contrast, PHT-sodium salt (4-oxo-5,5-
Diphenyl-4,5-dihydro-1H-imidazol-2-olat) C15H11N2NaO2 has a molecular weight of 
274.2 g/mol and is soluble in water as well as in ethanol 96% [23]. PHT is a white, 
crystalline, odorless, and flavorless powder. The sodium salt is also white, crystalline, 
and lightly hygroscopic [24].  
 
 
Figure 3: Chemical Structure of PHT [25,26] 
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1.2.3 Pharmacokinetics and Pharmacodynamics of Phenytoin 
The therapeutic range of PHT has been defined between 40-80 μmol/L (10-20 
μg/mL). As most drugs, PHT is highly bound to serum proteins. More specifically, 
PHT has a protein binding (especially to albumin) of 85-95%. Thus, in the case of 
PHT, only 5-15% unbound or free drug is pharmacologically active [27]. The absolute 
oral bioavailability of PHT is 85% [28] and the volume of distribution in the body is 0.8 
L/kg [29]. PHT has a nonlinear, saturable Michaelis-Menten kinetic; that means the 
half-life increases with larger but still therapeutic doses. PHT shows a dose 
dependent half-life of more than 30 hours [30] for therapeutic doses and a clearance 
ranging from 0.016 to 0.042 L/kgh [24]. The antiepileptic effect of PHT results from 
the voltage-dependent blockade of the sodium channels in the neuronal cell-
membrane. Thus, rapid potentials along the axons can be interrupted and repeated 
unloading can be suppressed [24, 31]. Characteristically for the effect of PHT is the 
dependence of the action from the opening-probability of a channel (so called use-
dependence) [32]. 
 
1.2.4 Metabolism of Phenytoin  
PHT is metabolised nearly completely in the liver. Only about 5% of a dosage is 
excreted unchanged and the metabolites have no important anticonvulsive effect [33, 
34]. PHT is a substrate of the cytochrome P450 (CYP) superfamily, especially of the 
CYP 2C19 and CYP 2C9 subfamilies, and is therefore subject to various genetic 
polymorphisms. In the world’s population exist more than 10 different mutations of 
CYP 2C19, resulting in poor metabolisers and extensive metabolisers [35]. There can 
be up to a twofold difference in the hepatic elimination rate, which leads to different 
PHT concentrations. Furthermore, the frequencies of different mutations vary among 
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ethnic populations, so that experiences in the dosage of PHT cannot directly be 
transferred from one population to another [36].  
 
1.2.5 Suitability of Phenytoin as a Reference Substance for TDM 
The inter-individual genetic differences in the metabolism of PHT combined with the 
narrow therapeutic range of PHT, non-linear, saturable Michaelis-Menten 
pharmacokinetics, and long-term therapy as well as relevant interactions with other 
drugs require a therapeutic drug monitoring (TDM) for adequate PHT dosing. PHT 
shows a high correlation between drug plasma level and drug efficacy or toxicity [37] 
and hence fulfills the key prerequisite for a useful TDM.  
 
To maintain an efficacious and safe longtime therapy with PHT, the control of the 
PHT serum levels in treated patients and the resulting dose adjustments are 
nowadays standard. An effective TDM depends on rapid, sensitive, specific, and 
reliable analytical techniques. Lab testing for total PHT in serum is routinely available 
in larger hospitals. In most cases, total drug concentration in blood/plasma is 
appropriate for TDM; except when the relative concentration in plasma is either too 
low (<50 %) or highly variable [27]. The total concentration of drugs is easier to 
determine compared to the unbound fraction, as validated methods for the latter are 
only available in a few labs. In addition, tests used to analyze total drug levels in 
plasma or serum are less costly and time consuming than special analyses such as 
free PHT assessment [27, 38, 39].  In some cases, however, an estimation of the 
unbound, free fraction of PHT is mandatory (e.g., in unstable ICU patients) for an 
appropriate dosing decision (see also chapter 3.3 of this dissertation).  
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To summarize, the high level of evidence for a TDM of PHT and its complex 
characteristics make this antiepileptic drug a highly suitable model substance and a 
reliable standard and comparator for the development and application of TDM for 
other medications with less evidence.  
 
 
  
Advances in Therapeutic Drug Monitoring with a Focus on Phenytoin Analysis 
 
 
Raphael Hösli Dissertation, University of Basel  18 
2. AIMS OF THE DISSERTATION 
An accurate TDM of critical dose drugs is essential in order to achieve maximum 
efficacy of the drug as well as to avoid drug toxicity. Critical dose drugs are often used 
to treat critically ill patients in unstable conditions with disturbed physiological 
functions and tissue barriers (e.g., neurosurgery patients). For these patients a TDM 
and the resulting individualized drug therapy is highly beneficial, which has also been 
demonstrated in precision medicine that tries to optimally use the therapeutic window 
of a medication [1].  
 
As mentioned above, a minimal invasive sample collecting technique and sensitive, 
specific, and reliable analytical methods are crucial when studying the 
pharmacokinetics and pharmacodynamics in humans.  Thus, the overall aim of this 
dissertation is to develop and validate such analytical methods to determine drug 
concentrations in different body compartments. Thereby, the development, validation, 
and comparison of different analytical methods is performed by analyzing PHT, which 
serves as a highly suitable model substance for understanding and improving TDM. 
PHT is an important substance to prevent complications (i.e., seizures) in 
neurosurgery patients. Its plasma levels vary to a great extent because of highly 
interindividual, partly genetically determined differences in metabolism (see also 
1.2.4). As mentioned, PHT shows a narrow therapeutic range and a high correlation 
between the concentration in different body compartments and its clinical effect or 
toxicity. Therefore, PHT serves as a suitable model substance, where correlating 
plasma levels with tissue levels and comparing concentrations with easy accessible 
probes such as saliva samples is possible. Based on the example of PHT, the findings 
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may serve as a foundation for the TDM of other substances and the methods may be 
extrapolated across different drugs.  
 
The common method to measure total PHT in plasma concentrations is a 
homogenous enzyme immune test (e.g., Syva corporation; Siemens Medical 
Devices) [40]. Homogenous enzyme immune tests (EMIT) have been shown to be 
sufficient for most simple dosage adjustments (based on a classical TDM using 
plasma samples), as PHT shows a high correlation between total drug plasma level 
and drug efficacy or toxicity [37]. These commonly used methods, however, do not 
meet the requirements for more sophisticated pharmacological investigations such 
as pharmacokinetic studies in different body compartments (e.g., brain micro 
dialysates), correlation studies between the PHT concentration in blood plasma and 
the site of action, or the quantification of the free PHT fraction – mostly due to 
insufficient sensitivity and missing validation in other sample matrices [41]. 
 
Researchers and practitioners are interested in specific, sensitive, robust, and cost-
effective methods to identify PHT concentrations. Thus, a first objective of the present 
dissertation was to establish a highly selective and sensitive GC-MS method which 
allows the determination of PHT in different human biological samples, especially in 
brain microdialysates. The first publication deals with this research question [42]. 
 
Recently, also LC-MS/MS methods have become commonly available in routine 
medical labs for measuring drug concentrations, as they offer some advantages over 
other sensitive methods such as GC-MS [43]. Therefore, a second objective of the 
dissertation was to develop and validate a LC-MS/MS method for the measurement 
of PHT concentrations in different body compartments such as blood and saliva as 
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well as samples from brain tissue microdialysis often clinically used in neurology and 
neurosurgery, and to compare its performance with established, validated methods 
(e.g., GC-MS [42]). These further investigations are documented in the second 
publication [44]. 
 
As there are not always the required resources in hospitals for the necessary sample 
processing and for specific, demanding lab testing instruments such as GC-MS or 
LC-MS/MS units to measure the free unbound fraction of a drug, a third objective was 
to calculate the free fraction of PHT from conventional total drug TDM with EMIT using 
the Sheiner-Tozer equation and individual albumine levels. Thereby, the estimated 
values have to be compared with measured concentrations in samples from patients 
of different ages and with different diseases – factors which are known to influence 
the free drug fraction [27]. In such cases, the knowledge of the free PHT fraction 
would be useful in TDM and lead to improved dosing decisions. This objective is 
addressed in the third publication [45].  
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3. METHODS AND RESULTS 
According to the outlined objectives, the dissertation is based on three PubMed cited 
peer-reviewed publications, which are included in their specific journal layout in 
chapters 3.1 – 3.3 of this dissertation.  
 
The first article describes the development and validation of a gas chromatography–
mass spectrometry (GC–MS) method to identify and quantitate PHT in brain 
microdialysate, saliva, and blood from human samples. A solid-phase extraction 
(SPE) with a nonpolar C8-SCX column was used for sample clean-up and PHT 
extraction. The eluate was evaporated with nitrogen (50°C) and derivatized with 
trimethylsulfonium hydroxide before GC–MS analysis. The internal standard was 5-
(p-methylphenyl)-5-phenylhydantoin. The MS was run in scan mode and the 
identification was made with three ion fragment masses. All peaks were identified 
with MassLib. Spiked phenytoin samples showed recovery after SPE of ≥94%. The 
calibration curve (phenytoin 50 to 1,200 ng/mL, n = 6, at six concentration levels) 
showed good linearity and correlation (r2 >0.998). The limit of detection (LOD) was 
15 ng/mL and the limit of quantification (LOQ) was 50 ng/mL. Dried extracted samples 
were stable within a 15% deviation range for ≥4 weeks at room temperature. The 
method met ISO 17025 standards and was able to detect and quantify PHT in 
different biological matrices and patient samples.  
 
The second article describes a newly developed LC-MS/MS method for the 
measurement of PHT concentrations in different body tissues (i.e., human brain 
dialysate, blood, and saliva) and compares it with the GC-MS method [42]. The two 
methods are evaluated and compared based on their analytical performance, 
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appropriateness to analyze human biological samples, including corresponding 
extraction and cleanup procedures, and their validation according to ISO 17025 and 
FDA Guidance for Industry. 
 
The LC-MS/MS was more sensitive, needed a smaller sample volume (25 μL) and 
less chemicals, was less time consuming (cleaning up, sample preparation, and 
analysis), and resulted in a 15 times better LOD (<1 ng/mL) and 5 times better LOQ 
(10 ng/mL). The calibration curve of the LC-MS/MS method showed linearity over a 
larger range (i.e., 10–2000 ng/mL compared to 50–1200 ng/mL for the GC-MS) with 
correlation coefficients r2 > 0.995 for all tested matrices (blood, saliva, and dialysate). 
The investigation indicates that for larger sample numbers as in clinical or non-clinical 
pharmacokinetic / pharmacodynamics studies and for bedside as well as routine 
analyses, the LC-MS/MS method offers significant advantages over the GC-MS 
method. 
 
In addition to the published results, the LC-MS/MS method was further used for 
analyzing blinded MD samples from three patients with a cranial trauma. Each patient 
received 125 mg PHT as an intravenous injection at time t0 (red arrow). Samples were 
then collected and analyzed hourly (for 24h) (see Figure 4). As depicted in the figure, 
the PHT concentrations in the MD of the patients varied between 0 and 12 ng/mL and 
increased differently (with a 24hrs peak value between 3 and 11 ng/mL). This 
illustrates that this LC-MS/MS method is able to determine very low PHT 
concentration levels. The limit of detection of the GC-MS method was 15 ng/mL and 
therefore could not be used for these patient samples.  
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Figure 4: Measured PHT Concentrations in MD Samples from  
three Patients with Cranial Trauma 
 
To further illustrate the suitability of the LC-MS/MS method for measuring drug 
concentrations in MDs we have also analyzed another antiepileptic drug (i.e., 
levetiracetam). In a first test, we were able to accurately measure levetiracetam 
concentrations in blinded MD samples of 4 patients with cranial trauma using an 
existing LC-MS/MS method at the Institute of Forensic Toxicology and Chemistry, 
University of Bern (see Appendix A). The application of levetiracetam in these 
patients was off label since levetiracetam was given to prevent seizures after 
neurosurgical interventions. Thus, these measurements could be of use to 
understand the pharmacokinetics / pharmacodynamics of this drug in this specific 
patient population and could help physicians to optimize the therapy.   
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Finally, the third article investigated the suitability of the Sheiner-Tozer algorithm to 
estimate the free fraction of PHT (> 90% albumin binding) in hypoalbuminemic 
patients. Free PHT plasma concentration was calculated from total PHT 
concentration and compared with the measured free PHT of 23 patients. The patients 
were separated into a low (35 ≤ albumin ≥ 25 g/L) and a very low group (albumin < 
25 g/L) for comparing and statistically analyzing the calculated and the measured free 
PHT concentration. 
 
The calculated (1.2 mg/L; SD = 0.7) and the measured (1.1 mg/L; SD = 0.5) free PHT 
concentration correlated. The mean differences in the low and the very low albumin 
group were: 0.10 mg/L (SD = 1.4) (n = 11) and 0.13 mg/L (SD = 0.24) (n = 12), 
respectively. No statistically significant differences between the groups were found. 
The Bland–Altman plot including the regression analysis revealed no systematic 
differences between the calculated and the measured value [M = 0.11 (SD = 0.28)]. 
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This study describes the development and validation of a gas
chromatography–mass spectrometry (GC–MS) method to identify
and quantitate phenytoin in brain microdialysate, saliva and blood
from human samples.
A solid-phase extraction (SPE) was performed with a nonpolar C8-
SCX column. The eluate was evaporated with nitrogen (508C) and
derivatized with trimethylsulfonium hydroxide before GC–MS ana-
lysis. As the internal standard, 5-(p-methylphenyl)-5-phenylhydantoin
was used. The MS was run in scan mode and the identiﬁcation was
made with three ion fragment masses. All peaks were identiﬁed with
MassLib. Spiked phenytoin samples showed recovery after SPE of
94%. The calibration curve (phenytoin 50 to 1,200 ng/mL, n5 6, at
six concentration levels) showed good linearity and correlation (r2 >
0.998). The limit of detection was 15 ng/mL; the limit of quantiﬁcation
was 50 ng/mL. Dried extracted samples were stable within a 15% de-
viation range for 4 weeks at room temperature. The method met
International Organization for Standardization standards and was able
to detect and quantify phenytoin in different biological matrices and
patient samples. The GC–MS method with SPE is speciﬁc, sensitive,
robust and well reproducible, and is therefore an appropriate candi-
date for the pharmacokinetic assessment of phenytoin concentrations
in different human biological samples.
Introduction
Epilepsy is a disorder of the central neural system characterized
by recurrent unprovoked seizures caused by excessive dis-
charge of electrical activity (1). Epilepsy can be treated with
different antiepileptic drugs that generally render 80% of
newly diagnosed patients seizure-free (2). Phenytoin (PHT)
[C15H12N2O2 (3); molecular weight: 252.3 (3)] is a well-
established antiepileptic drug designed to prevent and treat sei-
zures (4). It is routinely used on neurosurgical intensive care
unit patients with brain injuries.
PHT has a small therapeutic index; its therapeutic concentra-
tion range in blood serum is 10–20 mg/L (40–80 mmol/L) (5)
for adults and children older than 3 months. Ingestion of more
than 20 mg/kg in humans [normal oral dosage for adults is
6 mg/kg (5)] usually results in clinical toxicity (6). PHT can
produce signiﬁcant dose-related toxicity because of its
complex pharmacokinetics (PK). The limited therapeutic
index, combined with the large inter-individual variability of
metabolism [half life 16–60 h, depending on plasma levels
(7, 8)], and the nonlinear pharmacokinetics of PHT (9, 10)
highlight the importance of therapeutic drug monitoring
(TDM). On the other hand, relatively few studies have been
able to demonstrate the beneﬁts of TDM of antiepileptic drugs
(11). However, therapeutic monitoring of PHT using Bayesian
forecasting was successfully applied to rapidly achieve thera-
peutic plasma levels using an easy-to-apply PHT loading dose
regimen in a hospital setting (12).
The monitoring of brain tissue biochemistry during intensive
care cerebral microdialysis is well established (13). Samples
generated by brain microdialysis have the potential to correlate
PHT concentrations at the site of action, with plasma values
mostly used for TDM (14, 15).
The correlation of toxicity and plasma level concentration is
well established. However, the PK in critically ill patients, and
its potential change related to the characteristics of the blood-
brain barrier, contribute to the lack of understanding of the
kinetics and mode of action of antiepileptics in the brain. The
correlation between PK in blood and the target tissue in brain
is not established. To investigate correlations of PHT concentra-
tion in blood plasma, saliva (oral ﬂuid) and tissue microdialy-
sate, a sensitive and speciﬁc analytical method is needed
(16, 17). Saliva has been shown to serve as an alternative
sample to blood plasma for TDM (18).
Commonly used analytical methods without mass spectrom-
etry (MS) detection do not reach the sensitivity needed to quanti-
tate the free fraction of PHT and the low biological PHT
concentrations (19). For clinical trials, a validated method is
required by authorities such as the Food and Drug Administration
(FDA). Gas chromatography (GC) with MS is effective and specif-
ic to separately analyze parent PHT and its metabolites (20).
However, current published GC–MS methods are not accurate
and sensitive enough to identify and quantify the expected low
levels of PHT in microdialysate samples from the human brain.
Also, the high sample volume of 500 mL used in a recently pub-
lished study is far too large for the usual microdialysis sampling in
patients, with a 2 mL/min ﬂow rate, and therefore not appropriate
for TDM (21). GC–MS analysis needs an extraction step such as
solid-phase extraction (SPE) to clean the sample and to eliminate
interfering biological matrix materials like proteins and lipids
prior to injection into the GC–MS system. Furthermore, to detect
PHT with sufﬁcient sensitivity by GC–MS, a derivatization of PHT
is necessary (22, 23). A structural analogue to PHT (C16H14N2O2;
molecular weight: 266.3), 5-(p-methylphenyl)-5-phenylhydantoin
(MPPH), is chosen as an internal standard (IS) (24).
The aim of the present analytical study was to establish a se-
lective and sensitive GC–MS method allowing the determin-
ation of PHT in different human biological samples, especially
in brain microdialysates. The analytical method should cover a
therapeutic range of free PHT concentration ranging from 50 to
1,200 ng/mL. A further objective of this study was to develop a
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simple and effective sample extraction method, which can be
used for different biological matrices like blood, dialysate or
saliva to reproducibly provide stable, reliable and clean analytes
for GC–MS analysis. The suitability of the analytical GC–MS
method has to be demonstrated by validation according to
International Organization for Standardization (ISO) 17025 to
be used in corresponding investigations with samples from
patients (clinical trials). The resulting analytical method is a
prerequisite for further PK and pharmacodynamic (PD)
investigations.
Material and Methods
Chemicals and samples
The PHT reference was purchased from Desitin Pharma GmbH
(Liestal, Switzerland) and from the European Pharmacopoeia
(Strasbourg, France). The IS, MPPH (C16H14N2O2; molecular
weight¼ 266.29), purity .99% was purchased from
Sigma-Aldrich Chemie (Steinheim, Germany). Calcium chloride,
citric acid monohydrate, potassium chloride, magnesium chlor-
ide hexahydrate, sodium chloride and sodium hydroxide and the
solvents methanol (MeOH), acetic acid (100%) and acetone
were of analytical grade and purchased from Merck (Darmstadt,
Germany). Trimethylsulfonium hydroxide (TMSH), 0.2M in
MeOH for derivatization, was purchased from Macherey-Nagel
(Oensingen, Switzerland). Nitrogen (analytical grade) for extract
drying, and helium (analytical grade) for GC, were obtained
from Carbagas (Liebefeld, Switzerland).
Artiﬁcial cerebrospinal ﬂuid (aCSF), composed of 8.59 g NaCl,
0.2013 g KCl, 0.1332 g CaCl2 and 0.1758 g MgCl2  6(H2O), was
prepared according to the pre-clinical device company CMA
(Stockholm, Sweden; dialysate solution) (25). CPDA-1 blood (an
anticoagulant citrate phosphate dextrose adenine solution; sub-
sequently referred to as blood plasma) was obtained from the
Blood Donor Center in Bern, Switzerland. Saliva was provided by
a volunteer. Ex situ brain tumor tissue, which had been surgically
removed from patients treated with PHT, was dialyzed against
aCSF with a ﬂow rate of 2 mL min, yielding a sample of approxi-
mately 60 mL. Approximately 2 mL of patient CPDA-1 blood
samples with PHT were collected. Both samples (dialysates
and CPDA-1 blood) were provided by the Department of
Neurosurgery (Kantonsspital Aarau AG, Switzerland). The sam-
pling procedure was presented to the ethical committee of the
Kantonsspital Aarau, which did not require formal ethical ap-
proval because the dialysates were made ex situ. All biological
samples (CPDA-1 blood plasma and dialysate) were frozen im-
mediately after sampling at –248C. For transportation, a refriger-
ation chain (–20+28C) was guaranteed. Before extraction and
analysis, the samples were thawed at room temperature for
30 min and then vortexed for 1 min.
IS, calibrator standard solutions, quality controls,
system suitability test and sample preparation
MPPH (IS) 1 mg/mL in MeOH was prepared as a stock solution
and stored at 2–88C. This stock solution was diluted with
MeOH to 100 ng/mL for addition to solutions [internal standard
solution (ISS), 100 ng/mL]. The PHT reference stock solution
containing 1 mg PHT/mL MeOH was stored at 2–88C. To obtain
calibration standard solutions (Cals) of 1,200 (Cal 6), 1,000 (Cal
5), 800 (Cal 4), 300 (Cal 3), 150 (Cal 2) and 50 ng/mL (Cal 1),
the stock solution was diluted freshly each time with MeOH for
each measurement. To each calibrator standard (Cal), 1,200 ng/
mL MPPH (12 mL ISS) was added as IS. To each Cal, 1 mL of
biological matrix (aCSF, blood plasma or saliva) was added for
validation purposes. For quality control (QC), solutions were
prepared with 100 ng/mL (QC 1) and 1,000 ng/mL (QC 2)
PHT, also containing 1,200 ng/mL MPPH (12 mL ISS) as IS and
1 mL of blood plasma, aCSF or saliva matrix. The system suitabil-
ity test (SST) was prepared with the PHT reference solution and
IS, to a ﬁnal probe of 100 ng/mL PHT and 1,200 ng/mL MPPH
(12 mL ISS).
Samples from patients were included to test the method in
real biological probes. PHT-containing microdialysis samples
(volume of 50 mL) from six patients (requiring approximately
25 min of collection time) were added to 450 mL aCSF and
1,200 ng MPPH (12 mL ISS) as IS prior to extraction. Blood
plasma samples (volume of 500 mL) from PHT-treated patients
were spiked with 1,200 ng MPPH (12 mL ISS) as IS. The
volumes of dialysate and blood were not identical to the
volumes used in the validation procedure; however, they were
useful for comparing artiﬁcial and real samples.
SPE procedure
For SPE, cartridges were used with nonpolar C8 sorbent and a
strong cation exchanger (SCX) (Bond Elute LRC Certify,
130MG; Varian). The extraction procedure is shown in Figure 1.
The method was adapted from literature (26). After equilibration
of the SPE columns with 1 mL acetonitrile for approximately
2 min, the pH was adjusted with 1 mL citric buffer, pH 5.0
(20.1 g/L citric acid, 8.0 g/L NaOH plus pH adjustment with
1 M HCl) (27). The calibrators (1 mL), QCs (1 mL) and samples
(0.5 mL) were applied to the SPE columns (Figure 1). The SPE
columns were washed with 1 mL citric buffer, followed by 1 mL
of 0.01 M acetic acid for pH adjustment (pH 3.5). After appli-
cation of a vacuum (approximately 0.5 bar) and drying for 5 min
(using a vacuum pump; Vac Master KNF LAB Laboport), PHT
was eluted with 2  1 mL acetone. The columns were vacuum-
dried again for 1 min at 0.5 bar. The eluate was transferred into
a 2 mL vial and evaporated with nitrogen at 508C. The reconsti-
tution and derivatization were performed with 50 mL TMSH
immediately before GC–MS analysis at room temperature and
vortexed for 10 s (22, 28, 29).
GC–MS analysis
To demonstrate the robustness of the developed method, two
different GC–MS systems available in the same lab were used.
An HP5890 gas chromatograph was used, connected to an
HP5971 mass selective detector (with Chemstation software
supplied by Hewlett Packard). The backup system was an
Agilent 6890N/5973 Inert GC–MS. An autosampler and an in-
jector were connected to both systems (Agilent 7673 with an in-
jection syringe of 10 mL volume). Two microliters of the
prepared samples were injected to the liner prior to the GC
column. The GC column was a polysiloxane Agilent J&W
Capillary 122-5532, DB-5MS, length, 30 m; i.d., 0.250 mm; ﬁlm,
0.25 mm; for temperatures from –60 to 3508C. The temperature
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program was set to 1208C for 1 min, then raised by 108C/min to
3008C and held for 6 min. The carrier gas was 99.95% high
purity helium with a ﬂow of 1.6 mL per min. The MS systems
were on scan mode to additionally check for interfering materi-
als. The temperature of the MS detector was 1508C. The settings
for the ion source and the transfer line were 230 and 2808C, re-
spectively. The scan range was between 50 and 650 amu. The
reference window for the data analysis parameters for PHT was
2 min, with a non-reference window of 1 min. All chromato-
graphic peaks were analyzed with MassLib (www.masslib.com),
allowing mass spectra identiﬁcation by both similarity and
identity. The search algorithm Search for Similar and
Identical Compounds (SISCOM) originates from Henneberg,
Weimann, and Ziegler (Max-Planck-Institute, Mu¨hlheim a.d.
Ruhr, Germany) and was developed in the 1970s (30).
Validation procedure
The validation according to ISO 17025 includes the assessment
of selectivity, accuracy, recovery of PHT after SPE, reproducibil-
ity, suitability of the calibration curves, stability of PHT and
matrix effects. Indicators for the sensitivity of the method
were the accurate assignment of the ions in different matrices
and the limit of detection (LOD) and limit of quantiﬁcation
(LOQ). Blank samples from six different sources were used to
demonstrate selectivity.
Furthermore, the selectivity of the method was determined
by using the selected GC column combined with an MS detect-
or. The selectivity was veriﬁed based on the retention time and
the allocation of one quantiﬁer ion and two qualiﬁer ions. The
accuracy was tested at the same levels as the calibrators and
with two additional levels at QC 1 (100 ng/mL) and QC 2
(1,000 ng/mL) (n ¼ 6). Two different solutions (prepared from
different stock solutions) were used to prepare the calibration
and QC samples. The recovery of PHT was analyzed by measure-
ment of QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3),
with QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3)
without SPE. The reproducibility and suitability of calibration
curves was measured by 2  3 complete series of Cal 1 to Cal 6
samples, including the extraction step. Inter-assay percent rela-
tive standard deviation (RSD), linearity and regression coefﬁcient
were calculated. PHT stability was analyzed with QC 1 samples
after extraction for both non-derivatized [5 weeks at room
temperature (n ¼ 10)] and derivatized samples (33 h without
speciﬁc cooling). Matrix effects were analyzed by comparing the
calibration curves generated with the three matrices: aCSF
(n ¼ 6 series), blood (n ¼ 3 series) and saliva (n ¼ 3 series).
Thus, the values of each calibrator and matrix were also
compared.
Statistical methods
The statistical data were calculated with Microsoft Excel and
PASW Statistics 18.0. To show the similarity between the differ-
ent matrices, a one-way analysis of variance (ANOVA) was used.
Furthermore, for each matrix, the six calibrator levels were
checked with t-tests to determine whether the measured
values differed signiﬁcantly within each level.
Results and Discussion
GC–MS analysis of PHT (separation and identiﬁcation
of PHT and MPPH), retention time, ion fragment mass,
LOD and LOQ
PHT and MPPH have different, but comparable, retention times
consistent with their chemical characteristics. The GC-MS
chromatogram of PHT showed a retention time (RT) of
15.12 min and the IS has an RT of 16.15 min. The relative RT
was 1:1.015. The suitability of MPPH as IS for GC–MS analysis
of PHT was further supported by the chromatogram (Figure 2).
The observed molecular fragment masses were [280, 203, 194,
118] for PHT and [294, 203, 194, 118] for MPPH. These
minimal differences in the RT, and the comparable molecular
fragment mass spectra, illustrate the strong similarity between
the analyte PHT and the IS, MPPH. The calculation of the
sample concentration was made only with the ion fragment
masses that were identiﬁed for PHT and MPPH.
The MassLib system could easily detect PHT and MPPH sep-
arately by their mass chromatogram differences. Because of the
independence of the data type and the format of the analyte,
MassLib has been successfully used in earlier GC–MS studies,
and is now widely used as a standard to identify chemical sub-
stances in toxicology (31). Also, these results were in line with
prior studies and conﬁrmed the suitability of this tool for the
GC–MS analytical method to identify and quantify PHT.
The LOD was calculated as signal to blank noise ratio (S/N)
(.3:1). The LOD for this method in aCSF, saliva and blood was
15 ng/mL, according to the FDA guidelines or Deutsches
Institut fu¨r Normung (DIN) standards (32, 33). Following the
Figure 1. Schematic sample process: generation of the three sample matrices,
processing during SPE and derivatization prior to GC–MS measurement.
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FDA guidelines, the LOQ was 50 ng/mL PHT and calculated as
ﬁve times the response/blank noise. Thus, the LOQ was reached
at Cal 1 level (50 ng/mL PHT). This also corresponds to the FDA
guidelines, claiming 20% reproducibility at the LOQ level (32,
33), which was reached with Cal 1.
Accuracy of the calibrators, repeatability precision
and laboratory precision
For assessment of the accuracy, the calibrators and QCs of six
individual measurements (n ¼ 6) were performed. The accur-
acy was tested with two non-identical solutions, the stock solu-
tions for calibration and the one for QC samples. The results of
the one-way ANOVA showed no signiﬁcant differences for all
matrices (F ¼ 0.0002; p ¼ 0.9998). In the target range of thera-
peutic PHT concentrations in microdialysates (.50 ng/mL,
,1,200 ng/mL), accuracy was between 104.6 and 98.9%. As
expected, the largest deviation was observed at the LOQ and at
the lowest concentration level (Cal 1 at 50 ng/mL) of the cali-
bration curve, showing an accuracy value of 104.6% (Table I).
The calibrator values showed minimum and maximum percent
deviations of 20% in Cal 1, 7% in Cal 2, 3% in Cal 3, 1% in Cal
4, 9% in Cal 5, 6% in Cal 6, 12% in QC1 and 6% in QC2
(Table I). Statistically, the deviations of each concentration
value did not differ for the entire calibration, demonstrating
that there were no outliers. All of the values were within the
maximum allowed bias of 15% (32). Repeatability precision
(inter-assay variability), the minimum and maximum deviation
of all levels of measurements, was within 15% of the coefﬁcient
of variation (CV) (Table I).
Regarding laboratory precision (intra-assay variability), for
the QC 1 and QC 2 measurements (n ¼ 6), the mean percent
deviation from the target value was 2.7% for QC 1 (100 ng/mL)
and 0.6% for QC 2 (1,000 ng/mL). As with the calibrators, the
QC 1 and QC 2 also showed a deviation from the nominal
value of less than 15% CV. These results support the robustness
of the method. Neither the operator nor the day of preparation
inﬂuenced the results in a detectable manner. There was no
difference in the characteristics of the chromatogram when
changing from the GC–MS HP system to the backup (Agilent
Systems). The laboratory in which the investigations were
made is part of the forensic laboratories in Switzerland and
takes part in all necessary proﬁciency tests to be ISO 17025
certiﬁed.
Linearity and regression coefﬁcient of calibration curve
The linearity of the calibration was tested with replicates of Cal
samples for the PHT concentration range of 50 to 1,200 ng/mL
in aCSF (n ¼ 6), saliva (n ¼ 3) and blood (n ¼ 3). As shown in
Table I, the calibration curve for PHT showed a linear regres-
sion coefﬁcient (r2) greater than 0.998 (r2blood plasma ¼ 0.998,
r2dialysate ¼ 0.999 and r2saliva ¼ 0.999) in all three matrices, indi-
cating excellent linearity in the target concentrations (Table I).
The calculations, including the linearity check of the calibra-
tion curves, were directly conducted by the ChemStation
software.
The one-way ANOVA showed no statistically signiﬁcant differ-
ences in calibrator-spiked samples of the different matrices: F ¼
0.0002, p ¼ 0.999. Each calibrator level was tested for consist-
ency using a t-test. The t-test showed no statistically signiﬁcant
deviation at each calibration level. This allows for the validation
procedure to be simpliﬁed by analyzing only one matrix and ex-
trapolating the results to the other matrices. It is standard that
the deviation of the lowest Cal from the nominal value should
be within +20%. For all other Cals, the deviation from the
nominal value should be within +15%, as required by FDA
Figure 2. Total ion chromatograms (TICs) and MS fragment spectra of PHT (50 ng/mL) and MPPH (1,200 ng/mL). GC–MS chromatograms: (A) PHT; (B) IS MPPH; (C) MS
fragments and a 2.0 mL injection of a 50 ng/mL PHT solution LOQ; (D) time-related peaks and 1,200 ng/mL MPPH. (A) The ion fragments for PHT are [280,203,194,118], (C)
RI33: TIC chromatogram; chromatograms of the mass fragments at m/z 280, 203 and 194 and (B) for MPPH the fragments are [294,203,194,118], (D) RI33: TIC chromatogram;
chromatograms of the mass fragments at m/z 294, 217 and 208.
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guidelines (32). The presented method fulﬁlled these require-
ments and even performed superiorly.
SPE; recovery with and without SPE
To produce reproducible GC–MS data from biological samples,
an appropriate clean-up procedure of the samples is necessary
to eliminate the matrix components that may potentially inter-
fere with the analysis, to maintain the responsiveness, and to
keep the method consistent and reliable, even after larger
series of sample analyses. SPE is widely used for the extraction
procedure in GC–MS analyses. SPE columns are commercially
available, which allows high-grade and reproducible quality
characteristics. The mixed-mode silica SPE columns used in
this investigation are also frequently used in forensic toxicol-
ogy to extract basic and cationic drugs, and are also very effect-
ive for the extraction of a wide range of compounds from
aqueous matrices like urine, dialysate or blood (34). They are
appropriate for small sample volumes and low concentrations
of the investigated substances (28, 29), as was the objective
in this study.
A single extraction required 40 min, including the time for
admixing the solvents, equilibration, ﬂow through the sorbent
and drying of the eluate. This indicates that the method is not
intended for routine serial TDM analyses, but fulﬁls the require-
ments for research.
The recovery was analyzed by the measurement of spiked
QC 1 and QC 2 samples extracted in SPE columns, compared
with spiked QC 1 and QC 2 samples without extraction. The
difference between the PHT values of QC 1 and QC 2 with and
without SPE was within an 8% range for QC 1 and 6% for QC
2, which demonstrates the efﬁciency and reliability of the SPE
(n ¼ 3). The inter-assay CVs (%) of the recovery were 15% for
QC1 and 2% for QC2. The recovery of more than 90% of
the spiked samples was consistent and reproducible (n ¼ 6)
and demonstrated that the SPE columns are suitable for the
extraction of PHT from biological samples such as human
blood plasma, saliva or brain microdialysate (32). The amount
of PHT recovered after SPE was 94.1% for 100 ng/mL and
94.3% for 1,000 ng/mL, compared to the amount found in
unextracted QC samples (100%) (n ¼ 3).
Stability of the extracted PHT samples
The stability of the processed samples was tested over time by
preparing and extracting QC 1 10 times. The eluate was evapo-
rated (Figure 1) and the dried QC 1 samples were stored at
room temperature. These samples were derivatized with TMSH
at Weeks 0, 2, 3, 4, and 5 and measured immediately after deri-
vatization. The variations of the measured concentration over
time were within 15%. No signiﬁcant changes, deviation or
trend for degradation were detectable in the GC vials during
storage. This leads to the conclusion that the dried PHT eluate
was highly stable at room temperature and no time-dependent
degradation occurred during the 5 weeks. In practical terms,
these results demonstrate that the processed PHT samples
(cleaned up) are stable and can be stored at room temperature
without loss of PHT before TMSH derivatization for the
GC–MS analyses.
The short time stability testing of derivatized QC samples,
stored without artiﬁcial cooling at ambient temperature of ap-
proximately 308C, performed three times at 0, 23 and 33 h,
showed an even smaller deviation than those in the underiva-
tized study over 5 weeks. The deviations from the ﬁrst meas-
urement were within 4% at 100 ng/mL and 1% at 1,000 ng/mL.
There was also no statistically signiﬁcant decrease in the con-
centrations of PHT or IS over time, demonstrating the stability
of the derivatized samples over at least 24 h at slightly elevated
temperatures (e.g., in a probe tray or autosampler), even when
the vial cap was perforated by the injection needle. The ana-
lysis of the underivatized stored samples after SPE showed at
100 ng/mL a deviation from the ﬁrst measurement within 3%,
and at 1,000 ng/mL a deviation of 5%. The stability data from
the derivatized and non-derivatized groups that were simultan-
eously assessed showed no signiﬁcant variations between the
groups. Therefore, biological PHT probes (after SPE and evapor-
ation) are very stable at room temperature over more than a
month, and are not affected by conditions encountered in an
ordinary analytical lab. No speciﬁc storage precautions are
needed.
Selectivity and speciﬁcity
The selectivity and speciﬁcity were demonstrated in all three
matrices (blood plasma, dialysate and saliva) by good peak dif-
ferentiation and quantiﬁcation of PHT. Both the blank biological
samples without IS and those with IS were negative; hence, any
false positive blank samples could be excluded (aCSF: n ¼ 6;
saliva: n ¼ 3; blood plasma: n ¼ 3).
Samples from patients receiving PHT
To test the method on real human biological samples, ex situ
brain tumor microdialysates and blood samples from six patients
treated with PHT were analyzed. The volumes of dialysate and
blood were not identical to the sample amount in the validation
(described previously). Nevertheless, the ﬁrst indication on the
use of the method was observed in non-spiked biological
samples (patients’ probes). The results of the dialyses samples
were (in ng/mL) 54.8 for Patient 1, 162.6 for Patient 2, 45 for
Patient 3, 63.4 for Patient 4, 353.2 for Patient 5 and 661 for
Patient 6. The corresponding blood values (in ng/mL) were
2,245 for Patient 1, 3,078 for Patient 2, 5,676 for Patient 3,
19,073 for Patient 5 and 16,349 for Patient 6. No blood was avail-
able from Patient 4. The blood and dialysate data from the indi-
vidual patients were consistent. Only 1–5% of blood plasma in
brain ex situ dialysates resulted, which corresponds to approxi-
mately half of the assumed free serum PHT concentration (10%
free PHT in plasma). The measured PHT concentrations were in
the tested range of the method. It has to be speculated that in
the monitored ICU patients, either steady-state conditions
in the brain (deep compartment) were not yet achieved, or
other speciﬁc PK conditions existed, indicating a more compli-
cated extrapolation from plasma to the brain values (blood-
brain-barrier or leaking central compartment). No saliva (oral
ﬂuid) samples were collected and analyzed from patients. The
results show the importance of testing and validating a new
TDM analysis. The need for parameter validation, including
correct modeling of data, is crucial for reliable drug
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concentration tracking in biological materials intended to inves-
tigate PK/PD correlations in such critical patients. Such studies
could result in safer, more efﬁcacious and rational drug dosing
in patients.
Conclusions
The goal of the study was to establish a selective and sensitive
GC–MS method that allows for the determination of PHT in
different biological samples matrices such as blood plasma,
saliva or brain microdialysate for TDM and related PK/PD
investigations.
The robustness of the method was illustrated by using two
different analytical systems, which did not show any differences
in the response and results. There was no deviation between
the measurements made for the calibration curve with different
matrices, and furthermore, the QC of the measurements with
different matrices also showed no differences. The presented
method has been proven for PHT detection and quantiﬁcation
in the aimed investigated human biological matrices. This
reveals the exemplary robustness of the method.
The cleaned samples are stable for at least one month at
room temperature before derivatization for GC–MS. They were
stable for more than 30 h in derivatized form, ready to be ana-
lyzed in an autosampler. The LOD (15 ng/mL) and the LOQ
(50 ng/mL) meet the requirements of FDA guidelines and the
method meets analytical standards according to ISO 17025.
Therefore, the method is suitable for assessing PHT in different
tissues, including liquor/brain microdialysate at therapeutic
concentrations (100–200 ng/mL). The method might be of
primary interest for research purposes such as toxicity, clinical
trials or PK/PD investigations of patients in critical care with
brain surgery/trauma in which microdialysis is used.
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Phenytoin (PHT) is one of the most often used critical dose drugs, where insufficient or excessive dosing can have severe con-
sequences such as seizures or toxicity. Thus, the monitoring and precise measuring of PHTconcentrations in patients is crucial. This
study develops and validates an LC-MS/MS method for the measurement of phenytoin concentrations in different body com-
partments (i.e., human brain dialysate, blood, and saliva) and compares it with a formerly developed GC-MS method that measures
PHT in the same biological matrices. The two methods are evaluated and compared based on their analytical performance, ap-
propriateness to analyze human biological samples, including corresponding extraction and cleanup procedures, and their validation
according to ISO 17025/FDA Guidance for Industry. The LC-MS/MS method showed a higher performance compared with the
GC-MS method. The LC-MS/MS was more sensitive, needed a smaller sample volume (25 μL) and less chemicals, was less time
consuming (cleaning up, sample preparation, and analysis), and resulted in a better LOD (<1 ng/mL)/LOQ (10 ng/mL). The
calibration curve of the LC-MS/MS method (10–2000 ng/mL) showed linearity over a larger range with correlation coefficients
r2> 0.995 for all tested matrices (blood, saliva, and dialysate). For larger sample numbers as in pharmacokinetic/pharmacodynamic
studies and for bedside as well as routine analyses, the LC-MS/MS method offers significant advantages over the GC-MS method.
1. Introduction
Sensitive and specific quantification methods are of critical
importance whenmonitoring individualized drug therapy in
patients or investigating drug concentration in forensic
toxicology [1]. Critical dose drugs but also newly developed
and designed complex drugs require analytical methods to
check for effective drug delivery to target tissues and to
minimize toxicity in sensitive organs or cells. When such
drugs have to be used in patients with varying pharmaco-
kinetics (PK) (e.g., ICU patients), an appropriate therapeutic
drug monitoring (TDM), which allows, for example, to
correlate the drug concentration in easy accessible plasma
samples with those in the tissue of action, becomes even
more relevant for a safe and efficient drug treatment [2].
Phenytoin (PHT) belongs to the most widely prescribed
drugs to prevent and control most types of seizure disorders
and to treat epilepsy [3]. It is one of the most often used
critical dose drugs where insufficient or excessive dosing can
have severe consequences such as seizures or toxicity. Thus,
the monitoring and precise measuring of PHT concentra-
tions in patients is crucial [4, 5]. As an example, in forensic
toxicology, epilepsy patients under PHT treatment who have
been involved in an accident have to be analyzed in order to
verify whether the PHT concentration was adequate or
possibly the reason for the accident [6]. However, there are
several characteristics of PHT including a relatively low
therapeutic index, difficult pharmacokinetics (PK) and phar-
macodynamics (PD), saturable oxidative biotransformation,
and the nonlinear clearance, which complicate a therapeutic
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drug monitoring (TDM) aimed at preventing intoxication of
patients or treatment failures [7].
Thus, researchers and practitioners are interested in
specific, sensitive, robust, and cost-effective methods to
identify PHT concentrations in patients. Thereby, several
compartments to measure the PHT concentration could be
addressed such as blood, saliva, and CNS fluid (micro-
dialysate). The correlation of PHT in different body com-
partments is not yet completely understood and has only
recently been addressed by researchers who have compared
the measurement of PHT in these different compartments
with a GC-MS method [8]. While the GC-MS has long been
the standard method in forensic testing, LC-MS/MS methods
have become more common, as they generally offer some
advantages over GC-MS [9]. Recently, researchers have de-
veloped an LC-MS/MS method to measure PHT in one
specific body compartment (i.e., blood plasma or serum) [10].
Missing, however, is a thorough comparison of the perfor-
mance of these two analytical methods in the detection and
analysis of PHT in different body compartments (i.e., blood,
saliva, and samples from brain tissue microdialysis).
The aim of the present study was to develop and validate
an LC-MS/MS method for the measurement of PHT con-
centrations in different body compartments such as blood
and saliva, as well as samples from brain tissue microdialysis
often used in neurology and neurosurgery, where antiepi-
leptic therapy is often mandatory [11, 12], and to compare its
efficiency with a formerly developed GC-MS method [8].
The fact that this established GC-MSmethod measured PHT
in the same biological matrices (i.e., blood, saliva, and hu-
man brain dialysate) enables a reliable comparison with
regard to the performance of GC-MS versus LC-MS/MS in
measuring PHT in different body compartments. The two
methods are evaluated and compared based on their ana-
lytical performance, appropriateness to analyze human bi-
ological samples, including corresponding extraction and
cleanup procedures, and their validation according to ISO
17025/FDA Guidance for Industry [13]. Finally, the suit-
ability of the two analytical methods for PK/PD studies,
bedside measurement, and forensic use is discussed. In
addition, the LC-MS/MS method developed in the current
study is compared with an established LC-MS/MS method
which measured PHT in blood plasma samples [10].
2. Materials and Method
2.1. Chemicals and Samples Used for the Development of the
LC-MS/MS Method and Its Validation. PHT reference
substance was purchased from Desitin Pharma GmbH
(Liestal, Switzerland) and from the European Pharma-
copoeia (PHT Ph. Eur. Standard, EDQM, Strasbourg,
France). The IS for LC-MS/MS was PHT-D10 (PHT D-10,
C15H2D10N2O2, MW 262.33) in methanol (MeOH)
(100 μg/mL) from Cerilliant (Round Rock, TX).
Calcium chloride, perchloric acid, citric acid mono-
hydrate, potassium chloride, magnesium chloride hexahy-
drate, sodium chloride, sodium hydroxide, and the solvents
(methanol, acetic acid 100%, and acetone) were of analytical
grade and purchased from Merck (Darmstadt, Germany).
Artificial cerebrospinal fluid (aCSF; dialysate solution) was
prepared according to M Dialysis AB (Stockholm, Sweden)
[14]. Blood CPDA-1 (anticoagulant citrate phosphate dex-
trose adenine solution; to simplify only named blood in the
following) was obtained from the Blood Donor Center
(Bern, Switzerland). Saliva was obtained from one of the
investigators. 20–60 μL PHT-containing samples from pa-
tients collected from a 2 μL/min flow rate brainmicrodialysis
and 2mL of CPDA containing PHT patient blood samples
were provided by the Department of Neurosurgery (Kant-
onsspital Aarau AG, Switzerland and Centre Hospitalier
Universitaire Vaudois, Switzerland). All biological samples
(blood and dialysates) were frozen and stored at −24°C.
Before sample analysis, the samples were thawed at room
temperature for 30 minutes and homogenized by shaking
with a vortex for one minute.
2.2. Internal Standards, Calibrator Standard System Suit-
ability Testing, and Sample Preparation. The internal stan-
dard (IS) stock solution was prepared by adding 100 μL of
the PHT-D10 (100 μg/mL) to 9900 μL of MeOH. 5mL of this
solution was added to 95mL of 1M perchloric acid aqueous
solution to get the final concentration of 50.0 ng/mL, which
is used as IS working solution. The PHT reference stock
solution (1.00mg/mL) was used to obtain eight calibration
(Cal) solutions with concentrations of 2000, 1000, 500, 250,
100, 50, 20, and 10 ng/mL PHT. 20 μL of these Cal solutions
were added to 980 μL of the biomatrices to get the Cal
working solutions. For quality control (QC), solutions with
1600, 400, 30, and 10 ng/mL PHTwere prepared out of PHT
reference stock solution (1.00mg/mL).
The IS working solution of 75 μL was added either to an
aliquot of 25 μL Cal working solution, QC solutions, or 25 μL
sample from patients containing PHT. The sample prepa-
ration for the LC-MS/MS consisted of pipetting 75 μL of IS
working solution to 25 μL sample into a deep well plate
(0.6mL, Chemie Brunschwig AG, Basel, Switzerland) cov-
ered by a sealing mat (Silicone, Chemie Brunschwig AG,
Basel, Switzerland). The well plates were rigorously shaken
for 5 minutes and then centrifuged (4.500U/min; Mikro
22R, Hettich Instruments, Andreas Hettich AG, Ba¨ch,
Switzerland) for 30 minutes at about 8°C (Figure 1). The
processed samples were ready for the LC-MS/MS analysis.
2.3. LC-MS/MS Settings. The prepared samples were placed
into the autosampler (Dionex WPS-3000TSL Olten, Swit-
zerland) which was set at 8°C. With a100 μL syringe from the
autosampler, 10 μL of the prepared samples was injected into
a 130 μL loop. The solvent rack (Dionex SRD-3600, Olten,
Switzerland) carried the mobile phase A (H2O+HCOOH
(100+ 0.1, v + v)) and phase B (MeCN+HCOOH (100+ 0.1, v
+ v)). These mobile phases were delivered by three pumps
(binary pump 1 (flow 0.350mL/min) and isocratic pump 2
(flow 0.200 to 1.000mL/min) (Dionex pump HPG-3200A,
Olten, Switzerland), and binary pump 3 (Dionex pump ISO-
3100A, Olten, Switzerland)) connected to a triple stage
quadrupole mass spectrometer with linear ion-trap capability
(3200 QTrap, Analyst Software Version 1.5.1, Applied
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Biosystems/MDS Sciex, Toronto, Canada) (Table 1). For the
mass spectrometric detection, SRM scan mode (selective
reaction monitoring) was used. SRM transitions and mass
spectrometric conditions were as follows: transition:
253.1→ 182.2 (PHT) and 253.1→ 192.2 (PHT-D10); orifice (V):
36; collision energy (eV): 41 (PHT) and 51 (PHT-D10); and
dwell time (msec): 100. Electrospray ionization was per-
formed in positive ion mode for the analyte and the IS. The
following instrument parameters for ionization were used: ion
source voltage: 5000 volt, curtain gas: 25, gas 1: 40 and gas
2: 60; and the CAD gas was set to 5 (arbitrary units for the
gas settings). As trapping column, a Phenomenex Gemini
Polar column (2.0×10mm, 5μm; Brechbu¨hler AG, Schlieren,
Switzerland) temperated to room temperature was used. The
main column Phenomenex Synergy Polar RP column
(2.0× 50mm; Brechbu¨hler AG, Schlieren, Switzerland) was
placed into the column oven (Cluzeau Info Labo CrocoCil)
set on 50°C with a column thermostat (Dionex TCC-3100,
Olten, Switzerland) including switching valve (Figure 2).
This systemwas operated by Analyst Software (Version 1.5.1,
AB Sciex, Toronto, Canada).
2.4. Validation of the LC-MS/MS Method according to ISO
17025/FDA Guidance for Industry. The validation was car-
ried out according to ISO 17025/FDAGuidance for Industry
including selectivity, sensitivity, accuracy, recovery of PHT,
reproducibility and suitability of the calibration curves,
stability of PHT, and matrix effects. The selectivity and
sensitivity (absence of PHT) were verified by analyzing blank
samples without PHT (extraction andmatrix effects). For the
accuracy, QCs and Cal samples were analyzed. The recovery
of PHT was analyzed by measuring QCs at different levels.
The reproducibility and suitability of the calibration curves
was measured by a complete series of Cal 1 to Cal 8
(LC-MS/MS) analyses. The limit of detection (LOD) and
the limit of quantification (LOQ) were analyzed using Cal 1
(LC-MS/MS 10 ng/mL PHT). The LOD was checked as a
signal-to-noise (S/N) ratio of more than 4 :1. The LOQ was
considered as 5 times the response to a blank sample. The
stability tests consisted of the freeze-thaw stability of PHT,
which was determined after 3 freeze-thaw cycles. The short-
term stability was analyzed by keeping the samples thawed at
ambient temperature for at least 6 hours, frozen for at least
12 hours at −25°C± 5°C, and again thawed, worked-up, and
analyzed. Postpreparative stability was evaluated to determine
whether an analytical run can be reinjected in the case of
instrument failure and, furthermore, whether the preparation
of a large number of samples could be done at once.
Therefore, one of the validation runs was analyzed a second
time after 7 days. The described criteria for Cal curves, QC,
accuracy, and precision had to be met.
25 μL sample and
75 μL of HCIO4 with
D10-PHT was
pipetted into the
deep well plate
(DWP)
The DWP was
certrifuged for 30 min
(4500 U/min) at 8ºC
The centrifuged DWP
was placed into the LC-
MS autosampler and 10 μL
of the worked-up
sample was injected
Figure 1: Sample preparation for the LC-MS/MS analyses for blood, saliva, and aCSF samples.
Table 1: Settings of the HPLC program.
Time
(minutes)
Pump 1 (main column (MC)) Pumps 2 and 3 (trapping column (TC))
%B Flow(μL/min) Comments %B
Flow
(μL/min)
Flow pump 5
(H2O+ 0.1% HCOOH) (μL/min)
Switching valve
0 35
500
Start MS and pumps 50 300 800 TC → waste, MC → MS (loading)
0.5 35 Start gradient 50 300 800 TC → MC → MS (eluting)
0.6 ↓
50 20 201 97.5
2 97.5 TC → waste, MC → MS
2.5 35 50 300 800 Reequilibration
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Matrix effects were analyzed by comparing the cali-
bration curves generated with the three matrices aCSF,
blood, and saliva. PHT microdialysis and blood samples
from patients were analyzed to demonstrate the suitability of
the method for biological samples from patients.
2.5. Comparison of the LC-MS/MS and the GC-MS
Method. The LC-MS/MS method was evaluated and com-
pared with the GC-MS method published by Ho¨sli et al. [8]
with regard to its analytical performance, appropriateness to
analyze human biological samples, including corresponding
extraction and cleanup procedures, and its validation
according to ISO 17025/FDA Guidance for Industry.
The statistical data were calculated with Microsoft Excel
and IBM SPSS Statistics 22. To compare the different ma-
trices, a one-way ANOVA was calculated. The corre-
sponding values were checked for significance by t-tests.
3. Results
3.1.Validation of the LC-MS/MSMethod. The retention time
(RT) for PHT and for PHT-D10 (IS) was about 2.8min
(Figure 3). The selectivity and sensitivity were checked; all
blank samples were negative. The recovery of PHT after
precipitation with HClO4 was 89.5% for QC1 (10 ng/mL)
and 97.1% for QC3 (1600 ng/mL) compared to the amount
found in unprepared samples (100%). The LOD calculated
as S/N ratio of 4 :1 for this method in aCSF, saliva, and blood
was set at <1 ng/mL. The LOQ calculated as 5 times the
response/blank was 10 ng/mL PHT. For the accuracy, the
Cal 1 to Cal 8 were assessed. The calibrator values showed
min–max deviations of 1–8% for Cal 2 (20 ng/mL) to Cal 8
(2000 ng/mL) with 3% for Cal 1 (10 ng/mL). The calibration
curves for all three matrices were linear. The regression co-
efficients (r2) of the three different matrices were r2blood 0.996
(n  3), r2dialysate  0.997 (n  6), and r2saliva 0.995 (n  3).
Reinjection after 7 days showed no difference in accuracy.
The sample volume needed was 25 μL. The sample prep-
aration time was about 2min per sample (6 hours for
182 samples). The run time for one LC-MS/MS analyses
was 7min.
3.2. Comparison of the LC-MS/MS with the GC-MS
Method. After validation of the LC-MS/MS method, it
was compared with the referred GC-MS method [8]. Table 2
shows the comparative results of the two methods for their
analytical performance, appropriateness to analyze human
biological samples, including corresponding extraction and
cleanup procedures, and its validation according to ISO
17025/FDA Guidance for Industry (Table 2).
The selectivity and the sensitivity were met by both
methods, and the recovery showed no differences (Table 2).
But the accuracy differed between the twomethods.The GC-
MS method showed a higher variation at Cal 1 (20%) than
the LC-MS/MS method (Cal 1 3%). As expected, the
biggest difference in terms of analytical performance
between the two methods was observed by the LOQ (GC-
MS 50 ng/mL; LC-MS/MS 10 ng/mL) and LOD (GC-
MS 15 ng/mL; LC-MS/MS<1 ng/mL) (Table 2).
Both methods showed linear regression coefficients (r2)
higher than 0.995 in all three different matrices for the PHT
calibration curve. The calibration range of the LC-MS/MS
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ESI-MS/MS
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Autosampler
Waste
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Eluting
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Figure 2: LC-MS/MS settings.
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(from 10 ng/mL to 2000 ng/mL) is twice as large as of the
GC-MS (50 ng/mL to 1200 ng/mL). The stability of the
samples after extraction and cleaning up was demonstrated
for both methods. The sample preparation procedure is
demonstrated in Figure 1 for LC-MS/MS and Figure 4 for
GC-MS.
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Figure 3: Chromatogram of phenytoin (illustrated for LOQ (10 ng/mL) and QC3 (400 ng/mL)) with PHT-D10 as IS (50 ng/mL).
Table 2: Comparison of the GC-MS [8] versus LC-MS/MS method.
Criterion GC-MS LC-MS/MS
Retention time PHT 15.12min, IS MPPH 16.15min PHT and PHT-D10 2.8min
Selectivity/sensitivity
(absence of PHT)
Good peak differentiation and quantification
of PHT. All blank samples were negative
(no presence of PHT)
All blank samples were negative
(no presence of PHT)
Recovery 94.1% for QC2 (100 ng/mL) 89.5% for QC1 (10 ng/mL)94.3% for QC5 (1000 ng/mL) 97.1% for QC3 (1600 ng/mL)
LOD (calculated as S/N ratio of 4 :1) 15 ng/mL <1 ng/mL
LOQ (calculated as 5 times the
response/blank) 50 ng/mL 10 ng/mL
Accuracy
The calibrator values showed min–max
percent deviations of 1–20% for
Cal 1 (50 ng/mL) to Cal 6 (1200 ng/mL)
The calibrator values showed min–max
percent deviations of 1–8% for
Cal 1 (10 ng/mL) to Cal 8 (2000 ng/mL)
Regression coefficient, r2
r2blood 0.998 (n 2)
r2dialysate 0.999 (n 8)
r2saliva 0.999 (n 2)
r2blood 0. 996 (n 3)
r2dialysate 0.997 (n 6)
r2saliva 0.995 (n 3)
Calibration range 50–1200 ng/mL 10–2000 ng/mL
Run time per analysis 30min 7min
Injection volume of the sample 2.0 μL 10 μL
Sample preparation time 5 h for 25 samples 6 h for 182 samples
Stability of the processed samples
Dried extracts were stable for ≥4 weeks
(min/max deviation 4%). No effect by reinjection
and storage (33 h) on the autosampler
Reinjection after 7 days showed
no difference in accuracy
Sample volume needed 50 μL 25 μL
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3.3. Comparison of the LC-MS/MS Method with a Formerly
Established LC-MS/MS Method. Recently, a LC-MS/MS
method has been developed which measures PHT in blood
plasma or serum [10]. For the measurement of PHT in blood,
the newly validated LC-MS/MS method can hence also be
compared with this recently published study. The two
methods show some similarities such as an identical IS
(100 μg/mL PHT-d10), similar sample volumes needed (25 μL
versus 20 μL [10]), and a comparable retention time (2.8min
versus approximately 2.1min [10]). Both methods showed
linear regression coefficients (r2) higher than 0.99 in the blood
matrix. The accuracy was similar as both studies showed
deviations of <10%. With regard to the calibration range and
the calibration solution, the two LC-MS/MS methods differ.
While the LC-MS/MSmethod developed in this study showed
a calibration range from 10ng/mL to 2000 ng/mL, the cali-
bration curve of the published LC-MS/MS method [10]
ranged from 100 ng/mL to 4000ng/mL. The calibration so-
lution in the current studywas the respective biological matrix
(e.g., blood). In the published study [10], phosphate-buffered
saline was used as the calibration solution.
4. Discussion
In this study, a LC-MS/MS method to measure PHT in
different biological samples was successfully validated and
compared with a similarly validated GC-MS method [8].
Overall, the LC-MS/MS method showed to be a more
specific analytical method with a higher general perfor-
mance (Table 2).The LC-MS/MSmethod needed less sample
volume, less chemicals, and less analytical time and therefore
resulted in less costs for the sample preparation.
Concerning the LOD, there was a huge difference be-
tween the two methods.The LOD of the LC-MS/MS method
was 15 times better than the one of the GC-MS methods: the
LOD of the LC-MS/MS method was <1 ng/mL compared to
15 ng/mL for the GC-MS method (increments by a factor of
ten). Similarly, the difference in LOQ was 5 times lower in
LC-MS/MS (10 ng/ml) compared to GC-MS (50 ng/mL).The
LOQ for the LC-MS/MS could be set even lower than
10 ng/ml PHT (Cal 1). The FDA guidelines which claim
a minimal reproducibility at the LOQ level of 20% were well
below (deviation to target PHT amount: <8% in aCSF (n 6),
<4% in blood (n 3), <9% in saliva (n 3); accuracy: aCSF
103%, blood 101%, and saliva 106%). The LOQ of the GC-
MS method and hence the lowest concentration level (Cal 1
at 50 ng/ml) of the calibration curve showed a deviation
value of 19%. The LC-MS/MS method, in contrast, showed
a value of only 3% deviation at the lowest Cal (10 ng/mL).
This difference is of high importance, as samples with even
lower concentrations could be reliably analyzed.
The calibration range (from 10 ng/mL to 2000 ng/mL) of
the LC-MS/MS method was twice as large as of the GC-MS
method (50 ng/mL to 1200 ng/mL). This indicates that the
LC-MS/MS method is more powerful and effective over
a larger range of concentration, since the linearity is given
over a larger area (10 ng/mL–2000 ng/mL) compared to the
GC-MS method (50 ng/mL–1200 ng/mL).
As IS, two different substances were used. MPPH as
a structurally related compound was used for the GC-MS
method. As IS for LC-MS/MS, deuterated PHT (PHT-D10)
was used, which is the same molecule as PHT and differs only
by the molecular mass (+1). All the physicochemical pro-
cesses upon cleanup and analysis are identical or highly
Sample 
collected 
during 30 min
Aliquot of 
50 μl +  
450 μl 
matrix 
+ IS
Reconstitution 
and methylation
(derivatization)
SPE
(1) Acetonitrile (1 ml)
(2) Citric buffer pH 5 (1 ml)
(3) Sample
(4) Citric buffer pH 5 (1 ml)
(5) Acetic acid (1 ml)
(6) Elute with acetone (2x with 1 ml)
aCSF
Semipermeable 
membrane
Inlet 
(perfusate)
Flow rate 
(2 μl/min)
Injection 
of 2 μl
Blood 
sample
Saliva 
sample
Outlet 
(dialysate)
Figure 4: Sample preparation for the GC-MS analyses [8].
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similar for PHT and PHT-D10. MMPH, however, could be
chemically affected in a different way than PHT, which could
lead to a systematic bias in a given situation [15].
Regarding the sample preparation procedure, the LC-
MS/MS (Figure 1) showed an important advantage com-
pared to the GC-MS method as it only needs 3 steps of
sample preparation compared to 11 steps necessary for the
GC-MS method including a solid-phase extraction (SPE)
and derivatization with a more critical chemical trime-
thylsulfonium (TMSH) (Figure 4). This resulted in signifi-
cant shortening of the overall analysis: Preparation of the
samples before injection for GC-MS is about ten times more
time consuming than for the LC-MS/MS. For the GC-MS
method, researchers needed 5 hours to prepare 25 samples (5
samples/h), whereas for the LC-MS/MSmethod 182 samples
were prepared in 6 hours (30.3 samples/h), which corre-
sponds to 6 times the amount of prepared samples per hour
compared to the GC-MS method.
From the exposure side, the volumes are much larger
and the exposure to the chemicals aremore prolongedwith the
GC-MS method compared to the sample cleanup for the LC-
MS/MS method. Especially, the derivatization agent TMSH is
critical to handle because of toxicity. The risk of serious and
even irreversible effects through inhalation, skin contact, or
eye exposure is well known. TMSH is also considered to be
teratogenic. Therefore, the potential health risk for the labo-
ratory staff handling the samples can be reduced by the LC-
MS/MS method and the elimination of a safety critical agent.
The amount of biological samples needed for the GC-MS
method (50 μL) was twice as much as for the LC-MS/MS
(25 μL). The sample volume is a critical point for PK/PD
studies, where, for example, by continuing dialysis from
brain in neurosurgical patients only small volumes of
samples per time point/period are available. For 50 μL di-
alysate about 25 minutes collecting time is necessary at the
usual flow rate of ?2 μL per minute [12, 16]. Therefore, not
a requested specific time point, but a rather large time
segment is represented which can influence the requested
results. The reduced sample volume needed (25 μL) for the
LC-MS/MS analyses reduces the dialyses time needed per
sample to about 15 minutes. The smaller the dialysis time,
the more precise correlations of the respective tissue con-
centration with plasma/blood samples can be made.
Furthermore, LC-MS/MS also has the shorter run time.
The time needed for 100 GC-MS analyses would be ap-
proximately 50 hours. The LC-MS/MS method, in contrast,
needs only 11 hours and 40 minutes for 100 analyses. This is
a time saving of more than 38 hours. While this may not be
highly relevant for forensic purposes, for bedside and
routine analyses (real-time) and PK/PD studies with larger
numbers of samples, this factor is relevant. Also, when the
time between taking a sample and the result needed is short,
as it is in TDM to adjust subsequent dosing for PHT
treatment, this time saving is crucial.
The costs for one way materials per sample was about
50% lower for the LC-MS/MS compared to the GC-MS
method. Especially because no SPE device was needed. Also,
the reduced work load for the laboratory technician must be
considered as an imported cost factor.
Finally, the appropriateness of the method also depends on
the biological matrix. Both methods can generally be used to
measure PHT in blood and saliva, as the sample volume is less
limiting. As mentioned before, however, for dialysates, the
most difficult aspect is to get enough sample volume.Therefore,
the LC-MS/MSmethod needing only half of the sample volume
compared to the GC-MS method is more suited for micro-
dialysate measurements. With respect to the LOD/LOQ, the
LC-MS/MSmethod is also better suited for PK/PD studies, as it
allows to include patients with low PHT dosages.
In addition, the newly established LC-MS/MS method
was compared with a recently published LC-MS/MS method
[10]. While this study measured PHT only in one body
compartment (i.e., blood plasma or serum), the current LC-
MS/MS method was developed and validated for the mea-
surement of PHT in different body compartments (i.e., blood,
saliva, and samples from brain tissue microdialysis often used
in neurology and neurosurgery). The calibration range of the
published LC-MS/MS method [10] (from 100ng/mL to
4000 ng/mL) is appropriate for the measurement of PHT in
blood plasma. As the PHT concentrations in brain tissue
dialysates are much smaller than in blood plasma, the LC-
MS/MSmethod of the current studywasmore appropriate for
such samples, showing a lower calibration range from
10 ng/mL to 2000 ng/mL. Finally, as the aim of this study was
to measure PHT in different biological matrices, a general
substitute solution for blood plasma such as phosphate-
buffered saline [10] could not be used. Instead, the fluid of
the respective body compartment was used as calibration
solution (e.g., artificial cerebrospinal fluid (aCSF) for the
measurement of PHT in the brain tissue dialysates). This also
eliminates a potential analytical bias due to matrix effects.
5. Conclusion
In this study, a LC-MS/MS method to measure PHT in
different biological samples (i.e., human brain dialysate,
blood, and saliva) was developed and validated under cir-
cumstances that ensured a high comparability with an
established GC-MSmethod [8]. Overall, the study concludes
that LC-MS/MS is not only better performing in human
PHT concentration measuring or comparable drug PK/PD
studies but is the only one to be used for bedside analysis.
The time-consuming sample preparation and the long run
time of the GC-MS method delay the result, which is critical
in TDM. The higher sensitivity, the smaller needed sample
volume, the better LOD/LOQ, the less time-consuming
cleaningup and sample preparation procedure, and the
shorter run time make the LC-MS/MS method the preferred
analytical procedure.
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Abstract Background Total serum drug levels are rou-
tinely determined for the therapeutic drug monitoring of
selected, difficult-to-dose drugs. For some of these drugs,
however, knowledge of the free fraction is necessary to
adapt correct dosing. Phenytoin, with its non-linear phar-
macokinetics,[90 % albumin binding and slow elimina-
tion rate, is such a drug requiring individualization in
patients, especially if rapid intravenous loading and sub-
sequent dose adaptation is needed. In a prior long-term
investigation, we showed the excellent performance of
pharmacy-assisted Bayesian forecasting support for opti-
mal dosing in hospitalized patients treated with phenytoin.
In a subgroup analysis, we evaluated the suitability of the
Sheiner-Tozer algorithm to calculate the free phenytoin
fraction in hypoalbuminemic patients. Objective To test the
usefulness of the Sheiner-Tozer algorithm for the correct
estimation of the free phenytoin concentrations in hospi-
talized patients. Setting A Swiss tertiary care hospital.
Method Free phenytoin plasma concentration was calcu-
lated from total phenytoin concentration in hypoalbu-
minemic patients and compared with the measured free
phenytoin. The patients were separated into a low
(35 B albumin C 25 g/L) and a very low group (albumin
\25 g/L) for comparing and statistically analyzing the
calculated and the measured free phenytoin concentration.
Main outcome measures Calculated and the measured free
phenytoin concentration. Results The calculated (1.2 mg/L
(SD = 0.7) and the measured (1.1 mg/L (SD = 0.5) free
phenytoin concentration correlated. The mean difference in
the low and the very low albumin group was: 0.10 mg/L
(SD = 1.4) (n = 11) and 0.13 mg/L (SD = 0.24)
(n = 12), respectively. Although the variability of the data
could be a bias, no statistically significant difference
between the groups was found: t test (p = 0.78), the
Passing–Bablok regression, the Spearman’s rank correla-
tion coefficient of r = 0.907 and p = 0.00. The Bland–
Altman plot including the regression analysis revealed no
systematic differences between the calculated and the
measured value [M = 0.11 (SD = 0.28)]. Conclusion In
absence of a free phenytoin plasma concentration mea-
surement also in hypoalbuminemic patients, the Sheiner-
Tozer algorithm represents a useful tool to assist thera-
peutic monitoring to calculate or control free phenytoin by
using total phenytoin and the albumin concentration.
Keywords Phenytoin  Serum concentrations  Sheiner-
Tozer equation  Therapeutic Drug Monitoring (TDM)
Impact on practice
• The Sheiner-Tozer algorithm can be successfully used
to calculate a missing free phenytoin plasma concen-
tration using the total phenytoin and the albumin
plasma levels in hypoalbuminemic patients.
• The Sheiner-Tozer algorithm represents a useful and
shortly available calculation tool to assist Therapeutic
Drug Monitoring and appropriate dose adjustment of a
critical dose drug based on the free dose fraction, e.g.
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the antiepileptic phenytoin and other highly albumin-
bound narrow therapeutic index drugs.
• The Sheiner-Tozer algorithm can be successfully
implemented for dose checking to reduce and manage
medication errors in critical dose drugs.
Introduction
Phenytoin (PHT) is a well-known antiepileptic drug which
has also shown effectiveness in post-traumatic surgery [1].
Its targeted therapeutic concentration range in blood serum
for adults and children older than three months is
10–20 mg/L (40–80 lmol/L) [2]. PHT shows 90 % plasma
protein binding corresponding to 1–2 mg/L for free PHT in
the therapeutic range. Due to its complex, non-linear and
highly variable pharmacokinetics, and its significant dose-
related toxicity, determining the correct dosage of this drug
is difficult and of critical importance for hospitalized [in-
tensive care unit (ICU)] patients. Doses higher than 20 mg/
kg in adults consistently result in clinical toxicity. Addi-
tionally, the normal lower dosage of 6 mg/kg body weight
in adults, or conventional rapid drug loading, frequently
leads to over or under dosing [2, 3]. Defining the correct
dose of PHT is challenging due to its narrow therapeutic
index, highly variable, dose-dependent, non-linear kinetics
(with elimination ‘‘half-lives’’ ranging from 16 to 60 h),
and the significant risk of drug interactions. This highlights
the importance of rapidly available Therapeutic Drug
Monitoring (TDM) for total and in selected patients-free
PHT serum concentrations in order to facilitate appropriate
and safe adjustment of the medication [4–7].
PHT fulfills the prerequisites for a useful TDM with its
narrow therapeutic index, high dose variability and most
importantly, the existing correlation between drug plasma
level and drug efficacy or toxicity. Lab testing for total
PHT in serum is routinely available in larger hospitals. In
most cases, total drug concentration in blood/plasma is
appropriate for TDM; except when the relative concentra-
tion in plasma is either too low (\50 %), or highly variable
[8]. The total concentration of drugs is easier to determine
compared to the unbound fraction, as validated methods for
the latter are only available in a few labs. In addition, tests
used to analyze total drug levels in plasma or serum are less
costly and time consuming than special analyses such as
free PHT assessment [8–10]. The concentration of the free
drug fraction is useful or required for the TDM of drugs
with narrow therapeutic index and for those with highly
variable metabolism rates affected by the patient’s genet-
ically-determined enzyme patterns. It is also useful for
medications with [90 % plasma protein binding and
variable binding plasma protein concentrations such as for
example PHT in the presence of low plasma albumin
levels.
The Sheiner-Tozer formula has been proposed to help
estimate the free PHT fraction [6]. Total PHT and the
serum albumin level must be known for this calculation. As
indicated above, hypo-albuminaemia has a significant
impact on PHT plasma protein binding and, in the end,
only the free available fraction diffuses into tissue or
organs like the brain.
Albumin concentration is influenced by diseases such as
uremia, decreased kidney function or chronic liver diseases
[8]. Albumin might also be low in elderly patients, burn
victims and/or critically ill patients, or pregnant women.
This translates into variable amounts of bound and
unbound PHT fractions as compared to a ‘‘standard’’
patient [11, 12]. A reduced bound fraction of PHT might
also result from interacting co-medications that are com-
peting for the same drug protein binding site in serum.
Acidic, highly protein-bound drugs as well as free fatty
acids are able to force PHT from the plasma protein
binding sites, resulting in higher (toxic) free PHT con-
centrations without changing total PHT concentration [8, 9,
13, 14]. The Sheiner-Tozer algorithm has been designated
to determine the free drug fraction (Fig. 1). There are
conflicting reports regarding the value of calculated free
PHT levels in patients. To further evaluate the Sheiner-
Tozer formula in clinical practice, we performed a sub-
analysis of our large, long-term PHT single center study on
an unselected group of hospitalized low albumin patients
treated with PHT, whose total and free PHT values were
also available [15].
Aim of the study
This investigation evaluated the usefulness of the Sheiner-
Tozer algorithm (Fig. 1) to calculate the free PHT dose
fraction using total PHT serum levels in unselected patients
with low albumin (\35 g/L) in a hospital setting.
Calculated free PHT =             Total PHT concentration   ×  0.1 
Albumin concentration 
                44 
1.0+×9.0
Fig. 1 The Sheiner-Tozer formula: the calculated free PHT (dphCF)
[g/L] is determined with the knowledge of the total PHT (dphT) [mg/
L] and the serum albumin value of the patient. 0.9 is the protein
bound PHT fraction (90 %) and 0.1 is the free PHT fraction (10 %).
44 is the mean serum albumin value [g/L]
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Ethical approval
Additional ethical approval of this retrospective subanalysis
of the previously published and approved investigation by
the local ethics committee was deemed unnecessary, as the
investigation had no influence on the phenytoine therapy or
outcome of the anonymously investigated patients.
Method
This subanalysis was carried out as a study cohort collected
over more than 10 years and included all patients in a
tertiary care hospital who had undergone PHT serum
concentration testing. They were investigated on the value
of Bayesian PHT dose forecasting. Those patients whose
free PHT calculated concentration could be compared with
measured levels were selected [15]. All patients with a
serum albumin concentration of B35 g/L (hypo-albu-
minaemia) who had both total and free PHT serum con-
centration measurements were included. Of the initial 2500
patient cohort, 23 fulfilled these criteria. Their age ranged
from 7 to 86 years; 8 patients were male and 15 female.
The patients were hospitalized on different wards: ICU
n = 3; dialysis n = 2; surgery n = 4; internal medicine
n = 10; pediatrics n = 1; neurosurgery n = 2; orthopedic
n = 1. The patients were separated into two groups: the
low group (35 B albumin C 25 g/L, n = 11), and the very
low group (albumin\ 25 g/L, n = 12).
Total PHT in serum (dphT) was determined using a
homogenous enzyme immune test, EMIT, Syva corpora-
tion (Siemens Medical Devices) [16]. The immuno assay
produced the following precision values: Level 1: 7.9 lg/
mL, Level 2: 16.2 lg/mL, Level 3: 27.4 lg/mL. The range
of analyte values that can be measured directly from the
specimen without any dilution or pretreatment is
0.4–40.0 lg/mL. Samples with results in excess of
40.0 lg/mL were repeated on dilution. The measured free
PHT concentration in serum (dphF) was quantified from
the probe after centrifugation for 20 min (at 1000–2000g)
through a 30 kD cut-off filter to eliminate the protein-
bound fraction. Free PHT from the filtered centrifugate was
quantitated by HPLC (Agilent Technologies). Calculation
of the free PHT fraction dphCF from the dphT was per-
formed using the Sheiner-Tozer formula (Fig. 1). This
included: serum albumin concentration, total PHT serum
concentration [dphT (mg/L)] and the theoretical unbound
serum fraction (10 % for PHT) which corresponded with
factor 0.1 in the algorithm [17]. In the formula denomi-
nator, the estimated bound fraction of PHT (90 %) is rep-
resented by factor 0.9. This bound fraction is multiplied by
the normalized serum albumin value [individual albumin
concentration (g/L) divided by the mean serum albumin
value of 44 g/L] and added to the free PHT fraction (10 %)
of 0.1 in order to determine the values for free concen-
tration in g/L.
The data was compared with the measured free PHT
concentration and statistically assessed using non-para-
metric Spearman’s rank correlation coefficient tests, t tests,
Passing–Bablok regression analyses, as well as a Bland–
Altman plot.
Results
Table 1 presents the PHT and albumin data of the 23
subjects. The following mean values and standard devia-
tions (SD) were obtained: dphT = 7.5 mg/L,
SD = 4.0 mg/L; dphF = 1.1 mg/L, SD = 0.5 mg/L;
dphCF = 1.2 mg/L, SD = 0.7 mg/L. The mean albumin
level in the patients (n = 23) was 25.5 g/L, SD = 4.7 g/L.
In the low albumin group (35 B albumin C 25 g/L), the
mean difference between dphF and dphCF was 0.10
(SD = 1.4). In the very low albumin group (\25 g/L), the
mean difference was 0.13 (SD = 0.24). An independent
sample t test revealed no significant discrepancy in the
mean differences between dphF and dphCF in the two
groups t(21) = -0.28, p = 0.78.
The prediction for the calculated free PHT (dphCF)
correlated highly with the measured free PHT (dphF); the
Spearman’s rank correlation coefficient showed a value of
r = 0.907, p = 0.00. A linear regression analysis based on
the Passing and Bablok [18] procedure further revealed that
the calculated free PHT (dphF) and the measured free PHT
(dphCF) were nearly identical (Fig. 2). Both hypotheses
b = 1 (slope value of 1 was enclosed in the 95 % confi-
dence interval) and a = 0 (the 95 % confidence interval
for the intercept contained the value 0) were accepted.
A Bland–Altman plot (Fig. 3) further supported that there
were no systematic differences between dphCF and dphF,
and a regression analysis showed no significant relationship
in the discrepancies between the measurements and the true
value (proportional bias). The regression coefficient of the
difference between the methods on the average of the two
methods was b = -0.35, p = 0.10.
Discussion
The results support and validate the use of the Sheiner-
Tozer formula to calculate free PHT concentrations in the
hospital setting, confirming its usefulness in the absence of
a free PHT determination. The data presented in this study
are comparable to a similar investigation by Dager et al.
[19], which reported a relative difference of 12.4 %
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between measured and calculated values. The characteris-
tics of the two studies are also similar: 23 patients in this
study and 29 in Dager’s, and both include adults with hypo-
albuminaemia levels of \35 and \25 g/L, respectively.
The patient subgroups in this study with\25 g/L albumin
showed no significant deviation differences when com-
pared to the whole group. Hong et al. [20] presented a
much higher mean difference between measured and cal-
culated free PHT of 0.65 mg/L (SD = 0.88 mg/L), which
compromised the accuracy and the usefulness of the
results. However, our study population was different to
those in the Hong et al. investigation, as ours were Euro-
pean/Caucasian instead of Asian. This can influence the
metabolic pattern for PHT significantly due to the different
genetic effects on its drug metabolism as well as on the free
versus total PHT concentration and their kinetics. In their
study, Wolf et al. [21] determined a difference between
calculated and measured free PHT concentration of
0.31 mg/L (SD = 0.5 mg/L), which is also much higher
than the results of this study. However, they reported solely
on critically ill pediatric patients whereas we had only one
pediatric patient. We looked at a much broader range of
patients; not only with respect to age, but also severity of
disease, and individuals outside the ICU. The data vari-
ability in our patient group, also indicated by the relatively
high SD may explain why one (Bland–Altman plot) and
two (Passing–Bablok regression) of the values were outside
of the 95 % confidence interval, respectively. The values,
Table 1 Total PHT levels [dphT] and measured free PHT fractions [dphF] in the investigated 23 subjects
Nr. Total PHT level
(mg/L) [dphT]
Measured free PHT fraction
(mg/L) [dphF]
Calculated free PHT fraction
(mg/L) [dphCF]
Albumin
(g/L)
1 2.58 0.30 0.38 28
2 3.20 0.35 0.49 27
3 3.83 0.38 0.54 30
4 2.88 0.51 0.56 20
5 4.75 0.57 0.67 30
6 2.50 0.59 0.44 23
7 2.83 0.60 0.55 20
8 4.78 0.67 0.78 25
9 8.73 0.91 1.10 34
10 3.68 0.96 0.75 19
11 11.03 0.97 1.39 34
12 8.35 0.98 1.28 27
13 5.08 0.98 0.92 22
14 9.80 1.24 1.66 24
15 6.70 1.37 0.94 30
16 10.38 1.53 1.76 24
17 10.58 1.64 2.00 21
18 11.05 1.70 2.09 21
19 16.15 1.78 2.33 29
20 10.68 1.78 1.87 23
21 9.95 1.89 1.32 32
22 9.30 1.93 1.90 19
23 14.40 1.93 2.44 24
Mean 7.5 1.1 1.2 25.5
SD 4.0 0.5 0.7 4.7
Albumin\ 25 (n = 12) Albumin C 25 (n = 11) t Statistic
Independent samples t test of the mean difference between dphF and dphCF for patients with: albumin\ 25 (n = 12) compared to
albumin C 25 (n = 11)
Mean difference = 0.13
(SD = 0.24)
Mean difference = 0.10
(SD = 1.4)
t(21) = -0.28, p = 0.78.
The calculated free PHT level [dphCF] was determined according to the Sheiner-Tozer algorithm. SD Standard deviation
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however, were nearly very close to the limits of agreement
of the statistical analysis. Accordingly the Sheiner-Tozer
equation was helpful in estimating the free concentration
needed for careful dose adaptation—even in an unselected
patient group. Continuing investigations with a more
highly defined patient group could further validate the
equation for its timely and correct use in clinical settings;
especially when free drug concentrations are not available
to guide optimal dosing of such a critical dose drug.
The importance of albumin and the related binding
capacity in strongly protein bound drugs like PHT is con-
troversially discussed in the context of a PHT TDM.
According to Hong et al., hypo-albuminaemia not only
modifies the ratio of free/total PHT concentration, but also
the total PHT concentration, yielding incorrectly calculated
results. This would also explain their data, at least for the
pediatric patients [20]. They suggest determining free PHT
in hypoalbuminemic patients using a suitable lab test, but
such testing is often difficult to access or delivers data too
late to be used for timely dose modification at bedside. One
must also bear in mind that non-routine lab tests also result
in higher administrative costs (availability, time and
expenses). Therefore, such lab tests are often only ordered
in specific situations when PHT dosing problems or a lack
of drug effectiveness have occurred or is presumed. Our
study demonstrates that in such cases, a lacking free lab
PHT concentration can be calculated using the Sheiner-
Tozer formula which was useful in a general hospital
population, including patients with other potentially inter-
acting medical treatments and a variety of diseases.
According to Krasowski and Penrod [22], the Sheiner-
Tozer equation for calculating free PHT concentrations
more frequently underestimates than overestimates the
measured free PHT relative to the respective therapeutic
ranges. Nevertheless, they also conclude that if measured
free PHT concentration is not available, PHT concentra-
tion—adjusted according to the Sheiner-Tozer equation
can supplement total PHT concentration and assist proper
dosing. This was illustrated in this study on patients with
low plasma albumin, a common condition in acute care
hospitals. Our results in an unselected patient group with
partial and even severe hypo-albuminaemia showed the
Sheiner-Tozer formula to be an useful tool which yields
comparable data to specific lab testing for free PHT. This
facilitates a good TDM and provides additional informa-
tion for drug dosing. In partial contrast to the published
data, the measured free PHT concentrations values in our
(almost completely) adult patient group varied only mini-
mally. In addition, we did not detect any higher variation,
either in low or very low hypo-albuminaemia in this small
study group, nor was there a trend or indication of over-
estimation or underestimation of PHT concentrations. As a
consequence, we were able to validate the usefulness of
calculating the dphCF according to Sheiner-Tozer and can
support its use in absence of measured free PHT values for
an easy to do and appropriate dose adaptation at almost no
Passing-Bablok Regression 
Fig. 2 Results of the linear regression analysis (n = 23) based on the
Passing and Bablok [18] method, which revealed that the calculated
free PHT (dphCF) and the measured free PHT (dphF) are comparable.
Both hypotheses b = 1 (the slope value of 1 was enclosed in the 95 %
confidence interval) and a = 0 (the 95 % confidence interval for the
intercept contained the value of 0) were accepted. Slope b = 1.245,
95 % CI [0.994, 1.419]. Intercept a = -0044, 95 % CI [-0.295,
0.112]. The solid line represents the linear regression. The dotted lines
show the 95 % confidence interval
Fig. 3 Bland–Altman plot of the dphF and dphCF measurements
(n = 23). The mean difference is M = -0.11 (SD = 0.28), which is
not significantly different from zero t(22) = 0.07. The solid line
represents the mean difference. The dotted lines show the limits of
agreement (representing ±1.96 SD). In addition, regression analysis
showed a non-significant relationship in the difference between the
measured and the true values (proportional bias). The regression
coefficient of the difference between the methods on the average of
the two methods was b = -0.35, p = 0.10
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costs of hospitalized patients, when a TDM including free
PHT determination is missing.
Finally, such a tool is also helpful to avoid medication
errors in individualized patient treatment when checking a
critical PHT dosing, or even in cases of polymedication
with potentially interacting drugs, e.g. in relation to albu-
min binding despite a specific variable for interacting drugs
in the equation.
Although the subjects came from different wards and
medical disciplines, a limitation of our study is the rela-
tively small number of patients and the low number of
infants and younger children. Therefore, a comparison of
different types of subjects, for example from ICU, surgical
or internal medicine patients was not possible. To further
elucidate our findings and add necessary details, a
prospective study would assist in expanding and strength-
ening the evidence demonstrated to optimize TDM and the
use of the Sheiner-Tozer equation for critical dose medi-
cations. It could then also validate the cost-effectiveness of
the tool to avoid medication errors for better PHT man-
agement in hospitalized patients, as also indicated by von
Winckelmann et al. [23]. Such medication support could be
passed on to a multidisciplinary team and involve the
pharmacist taking responsibility for an appropriate TDM
service or to support the drugs and therapeutics committee
by implementing therapeutic guidelines. Despite potential
pharmacological interactions (most of the patients were
receiving multiple drug therapy in ICU) we were not able
to identify a distinct subgroup due to the small patient
number. The data presented only minor discrepancies and
were too variable to elucidate significant differences [see
also the Passing–Bablok regression or the Bland–Altman
plot where 2/23 and 1/23 patients felt outside of the 95 %
limit, respectively (Figs. 2, 3)]. Nevertheless, the investi-
gation indicated the potential benefit of the Sheiner-Tozer
equation and suggests its use when a specific TDM for free
PHT is not available. It provides a simple method to esti-
mate free drug concentration in the clinical setting.
Therefore and to further confirm our findings and add
necessary details, an appropriately powered prospective
study, could expand and strengthen the evidence demon-
strated to optimize TDM and its usefulness for critical dose
medications in such patients where there is a need to know
the free drug concentration in hypo-albuminaemia.
Conclusion
Calculation of free PHT concentrations using the Sheiner-
Tozer formula is a useful method to obtain additional
information from total PHT concentration values and the
albumin concentration in hypoalbuminemic patients in the
absence of a specific, potentially time-consuming and
costly free PHT determination. This study on a small group
of patients could not detect any specific difference in pre-
dicting the free PHT fraction between hospitalized patients
from different wards, and from those with differing medi-
cal conditions.
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4. DISCUSSION 
 
In a first part of this dissertation project, we have developed and validated a GC-MS 
method (including an appropriate clean-up method) to identify and quantitate PHT in 
brain microdialysate, saliva, and blood from human samples [42]. The GC-MS 
method is specific, sensitive, robust and well reproducible, and is therefore an 
appropriate candidate for the pharmacokinetic and pharmacodynamic assessment of 
PHT concentrations in different human biological samples. Analytical standards 
according to ISO 17025 and FDA guidelines have been met.  
 
In contrast to the established EMITs which can only be applied for plasma samples 
(total drug concentrations), the new GC-MS method is able to determine total and 
free PHT concentrations in a variety of different biological samples. The GC-MS is 
therefore highly suited for non-routine TDM and more sophisticated pharmacological 
investigations such as pharmacokinetic studies in different body compartments (e.g., 
brain micro dialysates), correlation studies between the PHT concentration in blood 
plasma and the site of action, or the quantification of the free PHT fraction [41].  
 
We were able to show that GC-MS is an analytical method which generates reliable 
results in different body compartments. This is an important advantage for an 
additional and improved TDM as almost all tissues can be addressed by the GC-MS 
(if appropriate samples are available) and the drug concentrations at the site of action 
can be correlated with the common standard plasma concentrations. The applicability 
of the GC-MS in different body compartments opens up new opportunities for the 
TDM as it allows analyzing the concentrations of an extended variety of drugs such 
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as antibiotics, antimycotics, aminoglycosides, antidepressants, immunosup-
pressants, or opiates with adapted GC-MS methods. For example, GC-MS is used in 
forensic toxicology to find poisons or steroids in biological samples of victims. 
Furthermore, in anti-doping laboratories GC-MS methods are often used to test 
athlete’s urine samples for prohibited performance enhancing drugs (e.g., anabolic 
steroids) and in food analysis GC-MS detects and measures potentially harmful 
contaminants, spoilage, and adulteration of food [46]. 
 
The method might be of primary interest for research purposes such as toxicity, 
clinical trials, or pharmacokinetic and pharmacodynamic investigations of patients in 
critical care with brain surgery / trauma in which microdialysis is used. In 
neurosurgery, for example, the drugs Midazolam (as a short-acting hypnotic-sedative 
drug with amnestic properties), Ceftriaxon (as infection prophylaxis), Morphine (as 
pain killer), and antiepileptic drugs such as PHT or Levatiracitam are often 
administered concomitantly. For all these drugs the side of action is the brain. Thus, 
an adapted GC-MS method which analysis brain MD samples would allow a 
simultaneous TDM for all four substances.  
 
The developed method certainly also has some limitations. The internal standard for 
the GC-MS method was MPPH, a structurally related compound to PHT. The fact that 
MPPH could be chemically affected in a different way than PHT may lead to a 
systematic bias. For further GC-MS method developments it would be of advantage 
to use deuterated molecules (e.g., in the case of PHT it would be better to use PHT-
D10). Furthermore, the clean-up and extraction procedure with solid phase cartridges 
and 11 steps was very time consuming and costly. Thus, with regard to time and 
costs, further GC-MS methods could be optimized in the future.   
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Considering these limitations and the growing availability of LC-MS/MS methods in 
analyzing drugs, we have further enhanced the measurement of PHT by developing 
a LC-MS/MS method. The LC-MS/MS method combines the advantages of LC and 
MS/MS analysis. While LC has the ability to separate individual compounds from 
other drugs and metabolites, selective MS techniques result in superior sensitivity 
and specificity. We were able to validate the LC-MS/MS method according to the FDA 
guidelines, which are the standard when developing and validating analytical 
methods for new drugs in phase one. Therefore, this LC-MS/MS method would be 
accepted with a high probability by the FDA for investigations in humans. Thus, to 
ensure the real applicability of new analytical methods, it should become standard in 
research to use the FDA guidelines when developing and validating LC-MS/MS 
methods for other substances as described above (e.g., midazolam, ceftriaxone, or 
morphine) for TDM. Our study can thereby provide some guidance.  
 
In order to address our objective of comparing the performance of the LC-MS/MS 
with the GC-MS method, we developed both methods under circumstances that 
ensured a high comparability. Table 1 summarizes the main advantages and 
disadvantages of the methods.  
 
Regarding the sample preparation procedure, the LC-MS/MS showed an important 
advantage compared to the GC-MS method as it only needs 3 steps of sample 
preparation compared to 11 steps for the GC-MS method including a solid-phase 
extraction (SPE) and derivatization with the critical chemical trimethylsulfonium 
(TMSH). This resulted in significant shortening of the overall analysis: Preparation of 
the samples before injection for GC-MS is about ten times more time consuming than 
for the LC-MS/MS. For the GC-MS method, we needed 5 hours to prepare 25 
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samples (5 samples/h), whereas for the LC-MS/MS method 182 samples were 
prepared in 6 hours (30.3 samples/h), which corresponds to 6 times the amount of 
prepared samples per hour compared to the GC-MS method.  
 
The sample volume is a critical point for TDM and PK/PD studies, where, for example, 
by continuing dialysis from brain in neurosurgical patients only small volumes of 
samples per time point / period are available. Another major problem with regard to 
the volume of plasma samples arises in pre-term infants with a small total blood 
volume, which impedes the available sample size required for lab analyses. 
Therefore, only a method which needs small sample volumes allows to perform a 
TDM for pre-term infants and other specific patient groups. The volume of biological 
samples needed for the GC-MS method (50 μL) was twice as much as for the LC-
MS/MS (25 μL). For 50 μL dialysate about 25 minutes collecting time is necessary at 
the usual flow rate of ~2 μL per minute. Therefore, not the specific time point, but a 
rather large time segment is represented which can influence the requested results. 
The smaller sample volume needed (we were able to measure PHT in only 5 μL MD) 
for the LC-MS/MS analyses reduces the dialyses time per sample to about 15 min or 
even less. The shorter the dialysis time, the more frequent and therefore more precise 
correlations of the respective tissue concentration with plasma/blood samples can be 
made.  
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Criterion GC-MS LC-MS/MS 
Retention time PHT 15.12min,   IS MPPH 16.15 min PHT and PHT-D10 2.8 min 
Selectivity / Sensitivity 
(absence of PHT) 
good peak differentiation and 
quantification of PHT all 
blank samples were negative 
(no presence of PHT) 
all blank samples were negative 
(no presence of PHT) 
Internal standard (IS) MPPH 100 µg/mL PHT-D10 
Recovery  94.1% for QC2 100ng/mL  94.3% for QC5 1000ng/mL  
89.5 % for QC1 10ng/mL 97.1% 
for QC3 1600ng/mL 
LOD [calculated as S/N 
ratio of 4:1] 
15ng/mL 
 
<1ng/mL  
 
LOQ [calculated as 5 
times the response / 
blank] 
50ng/mL 10ng/mL 
Accuracy 
The calibrator values showed 
min-max percent deviations 
of 1-20% for Cal 1 (50ng/mL) 
to Cal 6 (1200ng/mL) 
The calibrator values showed 
min-max  percent deviations of 
1-8% for Cal1 (10ng/mL) to Cal8 
(2000ng/mL)  
Regression coefficient 
r2 
r2blood = 0.998, n=2  
r2dialysate = 0.999, n=8  
r2saliva = 0.999, n=2 
r2blood = 0. 996, n=3  
r2dialysate = 0.997, n=6  
r2saliva = 0.995, n=3 
Calibration range 50-1200ng/mL 10-2000ng/mL 
Run time per analysis 30 min 7 min 
Injection volume of the 
sample 2.0 µL 10 µL 
Sample preparation 
time 5 h for 25 samples 6 h for 182 samples 
Sample preparation 
steps 11 3 
Stability of the 
processed samples 
Dried extracts were stable for 
≥ 4 weeks (min/max deviation 
4%). No effect by reinjection 
and storage (33h) on the auto 
sampler  
Reinjection after 7 days showed 
no difference in accuracy 
Sample volume needed 50 µL 25 µL 
 
Table 1: Comparison of the GC-MS and LC-MS/MS Method [44] 
 
The LC-MS/MS method is able to measure drug concentrations in different body 
compartments such as, for example, saliva. Small amounts of saliva (25 - 50 μL) are 
very easy to obtain and do not significantly affect drug concentrations in the blood. 
Thus, analytical methods which can analyze drug concentrations in saliva are a 
promising alternative to blood sample analysis for TDM.  
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As IS for the LC-MS/MS, deuterated PHT (PHT-D10) was used, which is the same 
molecule as PHT and differs only by the molecular mass (+1). All the physicochemical 
processes upon cleanup and analysis are identical or highly similar for PHT and PHT-
D10. Thus, the potential bias when using a structurally related compound could be 
eliminated.  
 
In most body compartments or tissues (e.g., saliva) or with sampling methods such 
as MD low drug concentrations and small sample volumes prevail. Thus, analytical 
methods which are able to detect low drug concentrations are preferable. Concerning 
the LOD, there was a huge difference between the two methods. The LOD of the LC-
MS/MS method (<1 ng/mL) was 15 times better than the one of the GC-MS methods 
(15 ng/mL). Similarly, the difference in LOQ was 5 times lower in LC-MS/MS (10 
ng/ml) compared to GC-MS (50 ng/mL). The LOQ for the LC-MS/MS could be set 
even lower than 10 ng/ml PHT (Cal 1). The FDA guidelines which claim a minimal 
reproducibility at the LOQ level of 20% were well below (deviation to target PHT 
amount: <8% in artificial MD (n=6), <4% in blood (n =3), <9% in saliva (n= 3); 
accuracy: artificial MD 103%, blood 101%, and saliva 106%). Thus, with the LC-
MS/MS method also samples with low concentrations can be reliably analyzed. This 
is of great importance for the TDM of different substances where MD samples are 
used.  
 
In general, one of the most critical points for the usefulness of an analytical method 
for TDM is the time needed between sampling and result. In this regard, the LC-
MS/MS method shows important advantages over the GC-MS method and is the only 
one to be used for bedside analysis. The time needed for 100 GC-MS analyses would 
be approximately 50 hours. The LC-MS/MS method, in contrast, needs only 11 hours 
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and 40 minutes for 100 analyses. This represents a time saving of more than 38 
hours. The time-consuming sample preparation and the long run time of the GC-MS 
method delay the result, which is critical in TDM.  
 
Overall, the higher sensitivity, the smaller sample volume needed, the better LOD / 
LOQ, the less time-consuming cleaning-up and sample preparation procedure, and 
the shorter run time make the LC-MS/MS method the preferred analytical procedure 
for TDM. These advantages of LC-MS/MS methods come especially into effect when 
analyzing large sample batches, which is the case in pharmacokinetic, 
pharmacodynamic, and toxicology studies during new drug development.  
 
In the third paper, we compared the measured free PHT concentrations with 
calculated free PHT concentrations using the Sheiner-Tozer formula [45]. We were 
able to show that, in the absence of a specific, costly, and potentially time-consuming 
free PHT determination, also this indirect calculation method can be useful to obtain 
additional information from total PHT concentration values and the albumin 
concentration in hypoalbuminemic patients. This study on a small group of patients 
could not detect any specific differences in predicting the free PHT fraction between 
hospitalized patients from different wards and with differing medical conditions. 
 
The calculated (1.2 mg/L, SD = 0.7) and the measured (1.1 mg/L, SD = 0.5) free PHT 
concentrations significantly correlated (r = 0.907, p = 0.00). Furthermore, the mean 
differences in the low (0.10 mg/L, SD = 1.4, n = 11) and the very low albumin group 
(0.13 mg/L, SD = 0.24, n = 12) were comparable. Although the variability of the data 
could provide some bias, no statistically significant difference between the groups 
was found: t test (p = 0.78). A linear non-parametric regression analysis based on the 
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Passing and Bablok procedure, which is highly suitable for method comparisons, 
revealed that the calculated free PHT and the measured free PHT were nearly 
identical.  
 
Our findings may be extrapolated to other drugs with a high protein binding such as 
tacrolimus and cyclosporin (immunosuppressants) as well as vancomycin and 
ceftriaxon (antibiotics), or anticancer drugs such as abraxane (a protein bund 
paclitaxel for brain cancer treatment). For these drugs an estimated free fraction is 
highly useful to optimize the therapy and to perform a TDM for drug safety and 
successful treatment. However, as we only studied a small patient sample, research 
has to further investigate the utility and limitations of this theoretical approach. 
 
Overall, for the development of a rational TDM sensitive, specific, reliable, and fast 
analytical methods are crucial. This dissertation shows that LC-MS/MS methods fulfill 
these criteria and are highly suited for analyzing drug concentrations in various 
matrices (body compartments). When developing a TDM an important first step is the 
determination of the correlation between the drug concentration at the site of action 
and the concentration in an easy accessible sample such as blood. The analytical 
method therefore has to be able to measure the drug concentrations in both body 
compartments. Both, the GC-MS and the LC-MS/MS method fulfilled this criterion as 
both measure concentrations in different body compartments and therefore allow to 
draw conclusions from the drug concentrations in the blood to the concentration at 
the site of action. Once established, these analytical methods provide reliable data 
which, in a next step, can be compared with less costly and simple estimation 
methods (e.g., Sheiner-Tozer) to calculate the free fraction of drugs based on albumin 
values and easy access total drug concentrations.   
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5. CONCLUSIONS 
The number of drugs, which are recommended for a TDM is growing [47], including 
not only newly developed and designed complex drugs but also already established 
(critical dose) drugs [48]. With this growing demand for TDM in clinical laboratories 
and optimal patient care, there is a high need to develop methods with enhanced 
analytical performance. Based on the highly suitable reference substance and critical 
dose drug PHT, the present dissertation makes an important contribution in this 
regard by developing and validating different methods to measure or estimate drug 
concentrations.  
 
The analytical methods (GC-MS, LC-MS/MS) as well as estimation methods (with 
mathematical algorithms) developed in this dissertation all have advantages and 
disadvantages for the use in TDM. The suitability of each method depends on the 
specific characteristics of a drug and the sample. GC-MS is, for example, highly 
suited for volatile and thermally stable substitutes in a sample and lipids in the lower 
mass range from 10 up to 600 Dalton. LC-MS/MS better performs for the separation 
of isomers, larger and non-volatile drugs, and complex peptides. Finally, estimation 
methods are reasonable if the correlation of the drug concentration between target 
tissue (free fraction) and drug concentration in blood is well established. Research 
needs to consider these aspects when developing new TDM methods in different 
situations and for different drugs. Overall, we can draw the following conclusions, 
which may serve as a foundation for the development of a TDM for other substances:   
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1. The GC-MS method is sensitive, specific, and robust and especially suited for 
plasma samples with relatively high drug concentrations and large sample 
volumes – characteristics which are often met in forensic and legal medicine. 
However, the method also shows major disadvantages as it is very time 
consuming regarding the sample preparation as well as the measurement time. 
Furthermore, for samples with low drug concentrations the LOD/LOQ meets not 
the required range and it may be that the GC-MS method cannot be extrapolated 
to drugs in MD samples.  
 
2. The LC-MS/MS method was able to overcome these limitations. Compared to the 
GC-MS, it showed a higher sensitivity, needed a smaller sample volume, had a 
better LOD and LOQ, was less time-consuming in the cleaning-up and sample 
preparation procedure, had a shorter analysis time, and allows the simultaneous 
measurement of multiple drugs, which makes the LC-MS/MS method the 
preferred analytical procedure for (bedside) TDM and pharmacokinetic / 
pharmacodynamic studies. While the results are based on the model substance 
PHT, other promising drugs for TDM using MD samples are, for example, 
Midazolam, Ceftriaxon, Morphine, and Levatiracitam, which are often 
administered concomitantly in neurosurgery. In the future, the routinely used 
matrices (i.e., blood or urine) for TDM will be expanded with other sample sources 
like tissue biopsies, dried blood spots, and oral fluids. LC-MS/MS methods 
provide the advantage of drug quantification in such matrices which are easier to 
handle [49]. Thus, the dissertation concludes that LC-MS/MS methods are the 
current gold standard for TDM.  
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3. In the absence of the possibility to measure free PHT with analytical methods, 
the calculation with the Sheiner-Tozer formula represents a reasonable 
alternative to calculate free PHT concentrations from the total PHT and the serum 
albumin value of a patient to obtain an idea of the concentration levels in patients. 
These findings may be extrapolated to other drugs with a high protein binding 
such as immunosuppressants (e.g., tacrolimus and cyclosporin), antibiotics (e.g., 
vancomycin and ceftriaxon), or anticancer drugs (e.g., abraxane).  
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6. FUTURE RESEARCH 
A better understanding of the pharmacokinetics and pharmacodynamics of a 
respective drug and an accurate TDM have essential benefits in clinical outcome, 
including quality of life of the patient. The number of drugs which are recommended 
for a TDM will further grow and the development of specific cost-effective and easy 
to use methods to measure the concentration of various drugs such as antimycotics, 
aminoglycosides, antidepressants, immunosuppressants as well as opioids deserves 
attention of researchers. When expanding the indication of already existing drugs or 
for new formulations of nano-drugs (e.g., Abraxane) new TDM methods can help to 
optimize treatments by preventing adverse drug reactions and therefore shorten 
hospitalizations [48]. TDM is also highly important for innovative and complex drugs 
and for advanced formulations using captured drugs (delivering substances 
specifically to target tissue in needed concentration), where the pharmacokinetics 
and pharamcondynamics are not yet completely investigated. An enhanced 
knowledge of the drug concentration at the site of action as well as the correlation 
between plasma drug concentration and free fraction will help to optimize drug 
therapy in different fields. The methods of this dissertation may serve as foundation 
for future studies in the following areas:    
 
 The enhancement of TDM methods for drugs such as antibiotics to treat 
meningitis would be an interesting avenue for future research, as these drugs 
need to have a certain concentration at the specific body compartment (in this 
case the brain). The selection of the appropriate antibiotic therapy is difficult due 
to the potential of under-dosing, developing resistances, and prolonging 
hospitalization. Therefore, further studies may evaluate existing methods or 
Advances in Therapeutic Drug Monitoring with a Focus on Phenytoin Analysis 
 
 
Raphael Hösli Dissertation, University of Basel  63 
develop and validate new accurate methods to measure antibiotic drug 
concentrations in MD samples of patients suffering from meningitis.  
 
 Substances used in anticancer therapy are often characterized by a strong 
relationship between dose and response, a narrow therapeutic window, and 
inter-individual pharmacokinetic variability. Although these drugs have 
characteristics which would require a TDM, today, these therapies are often 
applied without any accurate TDM [50]. Thus, for optimizing anticancer therapy 
in terms of better medical outcome due to dose adaption, future research needs 
to further develop the analytical methods for TDM of cancer therapies.  
 
The oral administration of anticancer drugs (oral targeted therapies such as 
tyrosine kinase inhibitors) generates another complex issue in the 
pharmacokinetics of these drugs [51]. In addition, most of the oral targeted 
drugs are extremely expensive. Thus, further research to ensure that their 
therapeutic potential is maximized also appears justified in terms of a public 
health viewpoint. Future efforts should concentrate to optimize dozing of these 
oncology therapies.  
 
 A further important avenue for future research is to analyze antiepileptic drugs 
in MD samples. We were able to demonstrate the appropriateness of LC-
MS/MS methods for the analysis of concentrations of PHT as well as 
levetiracetam. By comparing the concentrations in MD samples with the blood 
concentration a better understanding of the pharmacokinetic and pharmaco-
dynamics of these drugs in critically ill patients would be possible and the 
therapy could by individualized.   
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Appendix A: Measurement of Levetiracetam Concentrations 
 
 
 
Measurement of levetiracetam concentrations in MD samples of 4 Patients with 
cranial trauma. The patients received different dosages of levetiracetam at time T0.  
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Appendix B: Method SOPs 
1. Methoden SOP zur Bestimmung von Phenytoin mittels GC-
NPD-MS (IRM Bern) 
Bestimmung von freiem Phenytoin im ZNS-Mikrodialysat / Liquor mittels GC-MS-NPD (Inv. 
283). Die SOP wurde durch A. Tobler und R. Hösli erarbeitet. Da die Analysen am IRM in 
Bern durchgeführt wurden, wurde die SOP dem Qualitätsmanagement des IRM’s angepasst. 
Dies geschah mit der Unterstützung von Martine Gasser. 
 
Zweck, Prinzip und Bedeutung 
Die vorliegende Methode beschreibt die quantitative und qualitative Bestimmung von freiem 
Phenytoin im Mikrodialysat (ZNS, Liquor). Die Probenvorbereitung besteht in der Zugabe 
eines Internen Standards. Anschliessend wird die vorbereitete Probe mittels Festphasen-
Extraktion (SPE) gereinigt. Der Extrakt wird derivatisiert und mit GC/MSD-NPD analysiert.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Eigene Darstellung nach: Trimethylsulfonium Hydroxide: A New Methylating Agent; Kiyoshi Yamauchi, Toshizumi Tanabe, 
Masayoshi Kinoshita; J. Org. Chem., Vol. 44, No. 4, 1979 und Selective 2-O-Methylation of Pyrimidine-Ribonucleosides by 
Trimethylsulfonium Hydroxide in the Presece of Mg2+ and Ca2+ Ions; Kiyoshi Yamauchi, Toshizumi Tanabe, Masayoshi 
Kinoshita; Bull. Chem. Soc. Jap; Vol. 59; 2947-2949; 1986] 
 
Plasmakonzentrationen von Phenytoin: 
 
Phenytoin Therapeutischer Bereich [ng/mL] Toxischer Bereich [ng/mL] 
Gesamt-Phenytoin (Plasma) 10'000-20'000 >20'000 
Freies Phenytoin (Plasma bzw. 
Mikrodialysat) 
600-2'400 >2'400 
 
Geltungsbereich 
 
Die Bestimmung von freiem Phenytoin im Mikrodialysat (ZNS, Liquor) wird im Rahmen der 
Dissertationen von Frau Andrea Tobler und Herrn Raphael Hösli durchgeführt. Diese 
Analysenmethode ist somit für das IRM nicht bindend, kann aber vom IRM verwendet 
werden. 
 
  
 
Methylierung von Phenytoin mit TMSH 
 
 
 
 
 
 
 
 
 
 
 
 
+ 
H2O 
 
+ 
 
(CH3)2S  
CH
H3
C
H 
Advances in Therapeutic Drug Monitoring with a Focus on Phenytoin Analysis 
 
 
Raphael Hösli Dissertation, University of Basel  80 
Begriffe und Abkürzungen (alphabetisch)  
aCSF artificial cerebrospinal fluid (künstliche Hirnflüssigkeit) 
BW(-Dialysat) Blindwert(-Dialysat) 
HAc Essigsäure 
ISTD Interner Standard (hier: MPPH)   
Kal. X  Kalibrator x 
LOD Limit of detection (Detektionsgrenze) 
LOQ Limit of quantification (Bestimmungsgrenze) 
MPPH 5-(p-Methylphenyl)-5-Phenylhydantoin  
GC- MS-NPD Gaschromatgraph mit Massenselektivem und Stickstoff-Phosphor-Detektor 
P Probe(n) 
PDL Phenhydanlösung 
PHT Phenytoin 
PhtL Phenytoinlösung 
Px-A Probenbezeichnung des Biosamples x der Serie A  
Px-B Probenbezeichnung des Biosamples x der Serie B 
QC quality control, Qualitätskontrolle 
QCx-A Probenbezeichnung der Qualitätskontrolle x der Serie A 
QCx-B Probenbezeichnung der Qualitätskontrolle x der Serie B 
RG Reagenzglas 
RW Richtwert 
SPE Solid phase extraction, Festphasenextraktion 
SST System suitability test 
TMSH Trimethylsulfoniumhydroxid (Derivatisierungsmittel) 
ZNS Zentrales Nervensystem 
 
Benötigte Materialien und Chemikalien 
Glaswaren, Geräte und weitere Ausrüstung 
 
Glaswaren 
Messzylinder 50 mL 
Messkolben 10 mL mit Deckel 
Messkolben 20 mL mit Deckel 
Messkolben 50 mL mit Deckel 
Messkolben 500 mL mit Deckel 
Messkolben 1000 ml mit Deckel 
Glas-RG mit Schraubdeckel 
GC-Vials mit Alu-Caps 
Diverse Glaswaren zum Aufbewahren der hergestellten Lösungen (Schott-, Pyrex-, Duran-
Flaschen) 
 
Pipetten 
Pasteur-Pipetten 
Diverse Micropipetten: 
Socorex 2-20 µL, 20-200 µL, 100-1000 µL 
Gilson bis 10 µL, bis 25 µL 
Diverse Glasvollpipetten   
 
Geräte 
GC-MS-NPD (Inv. 283)  
Software HP Chem Station 
GC-Säule: 
Vacmaster, Vac Elut SPS 24CK (Inv. 2417), Varian 
Vortex Genie 2 (z.B. Inv. 740) 
Abdampfblock (Inv. 2361), witec ag 
Oberschalenwaage (Inv. 2420), Mettler Toledo 
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Sonstiges 
Extraktionssäulen, Bond Elut® Solid Phase Extraction LRC-Certify, 130MG, Art. Nr. 
12113050,Varian 
Capper, Decapper 
Sofern nicht ausdrücklich ausgeschlossen können vergleichbare Glaswaren und Geräte 
verwendet werden.  
 
 
Chemikalien und Reagenzien 
 
Methanol z.A., Hersteller Merck, Art. Nr.: 1.06009.1000 
Aceton z.A., Hersteller Merck, Art. Nr. 1.00014.1000 
Essigsäure 100% (Eisessig) z.A., Hersteller Merck, Art. Nr.: 1.00063.1000 
Reinstwasser Typ I 
pH-Indikatorstäbchen 0-14, Hersteller Merck, Art. Nr.: 1.09535.0001 
SPE-Extraktionssäulen Bond Elut Certify 130 mg LRC, Hersteller Varian 
Stickstoff (N2), Hersteller Carbagas 
Helium, Hersteller Carbagas 
Citronensäure Monohydrat, Ph. Eur. /USP, ADM Ringaskiddy Ireland 
Natriumhydroxid in Plätzchen, Hersteller Merck, Art. Nr. 1.06498.1000 
Magnesiumchlorid-Hexahydrat z.A., Hersteller Merck, Art. Nr. 1.05833.0250 
Calciumchlorid z.A., Hersteller Merck, Art. Nr. 2083 
Natriumchlorid, Hersteller Merck, Art. Nr. 6404 
Kaliumchlorid z.A., Hersteller Merck, Art. Nr. 1.04936.0500 
Trimethylsulfoniumhydroxid (TMSH) 0.2 M in Methanol, Hersteller Macherey-Nagel AG, Art. 
Nr. 701520.110, Schweiz 
0.2 M NaOH (aus Natriumhydroxid in Plätzchen, Hersteller Merck, Art. Nr. 1.06498.1000) 
1 M HCl, IRM 
0,01 M HAc (aus Essigsäure 100% (Eisessig) z.A., Hersteller Merck, Art. Nr.: 1.00063.1000) 
 
Sofern nicht ausdrücklich ausgeschlossen, können vergleichbare Chemikalien und 
Reagenzien verwendet werden.  
 
Referenzsubstanzen 
Phenytoin, Referenzsubstanz, Desitin Arzneimittel GmbH, Desitin Pharma GmbH, Liestal, 
Schweiz 
Phenytoin, CRS, Council of Europe, European Pharmacopoeia, Strasbourg 
5,5-Diphenylhydantoin purum ≥96%, Fluka Chemika, Art. Nr. 43070 
Phenhydan, Injektionslösung 250 mg Phenytoin/5 mL, Ampullen, Desitin Pharma GmbH, 
Liestal, Schweiz 
Sofern nicht ausdrücklich ausgeschlossen, können Referenzsubstanzen gleicher Qualität 
anderer Hersteller verwendet werden.  
Interner Standard 
5-(p-Methylphenyl)-5-Phenylhydantoin >99%, Sigma-Aldrich Chemie GmbH, Steinheim, 
Deutschland 
 
Referenzdialysate 
Es wird selber hergestellte, künstliche Hirnflüssigkeit ( aCSF) verwendet. Herstellung sieht 
unter Kapitel 0.  
 
Blindwerte 
Zurzeit sind keine vorhanden. Es ist geplant, Blindwerte von der Neurochirurgie Aarau zu 
bekommen. Falls dies nicht möglich sein sollte, wird NaCl 0,9% als Blindwert verwendet.  
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Vorgehen 
 
Flussdiagramm 
 
 
  
Lösungen herstellen und Behältnisse beschriften
SPE durchführen
Eluat bei 50°C am Heizblock eindampfen
Derivatisierung mit TMSH 
Ende
Start
GC-MS-NPD Analyse durchführen
Spektren auswerten
Erstellen Resultateblätter
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Kalibration 
 
Die Kalibration wird automatisch durch HP Chem Station berechnet, sofern die Kalibratoren  
Kal.1-Kal.6 auch als solche im Programm eingetragen sind. Die Kalibratoren werden aus den 
Kalibrationslösungen hergestellt, wie unter Kapitel 0 beschrieben.  
 
 
Lösungen 
 
Arbeitslösungen 
 
Citrat-Pufferlösung pH 5.0 R: 
20.1 g Citronensäure und 8.0 g Natriumhydroxid ad 1000 mL H2O; gut mischen, bis zur 
vollständigen Auflösung. pH-Wert mit pH-Stäbchen kontrollieren. (Wenn nötig, pH-Wert mit 
verdünnter Salzsäure einstellen). Die Pufferlösung wird im Kühlschrank bei 2-8°C gelagert 
und ist ca. 6 Monate haltbar.  
[4010700 nach Ph. Eur. 5. Ausgabe, Grundwerk 2005] 
 
Künstliche Hirnflüssigkeit (aCSF): 
NaCl, KCl, CaCl2 und MgCl2 ad 1000 mL H2O, gut mischen, bis zur vollständigen Auflösung. 
Der pH-Wert dieser Lösung beträgt 7.4 (Wenn nötig, pH-Wert mit 0.2M NaOH einstellen). 
Die künstliche Hirnflüssigkeit wird im Kühlschrank bei 2-8°C gelagert und ist ca. 6 Monate 
haltbar.  
 
Zusammensetzung nach: Firma CMA, Stockholm, Schweden 
Elektrolyt(e) Massengewicht* 
M [g/mol] 
Konzentration 
[mmol/l] 
Konzentration 
[mol/l] 
Berechnete Menge [g] 
(Konz.[mol/l] x M [g/mol]) 
NaCl 58,4425 147 0,147 8,5910 
KCl 74,5510 2,7 0,0027 0,2013 
CaCl2 110,9834 1,2 0,0012 0,1332 
MgCl2x6H2O 203,3022 0,85 0,00085 0,1728 
* nach Angaben des Periodensystems der Elemente von Macherey-Nagel [www.mn-net.com] 
 
Kalibrationslösungen 
 
Phenytoin-Lösungen:   
Phenytoin-Stammlösung: 
0,050g der Referenzsubstanz wird mit Methanol ad 50 mL aufgelöst. Als Referenzsubstanz 
kann entweder Phenytoin Desitin, Phenytoin CRS oder 5,5-Diphenylhydantoin verwendet 
werden, gut mischen, bis zur vollständigen Auflösung.  
 1 mg/mL (1 ng/µL) in Methanol 
Diese Lösungen werden 1:10 mit MeOH weiterverdünnt: 100 µg/mL (100 ng/µL) in MeOH  
 PhtL  
PhtL wird 1:10 mit MeOH weiterverdünnt: 10 µg/mL (10 ng/µL) in MeOH  
 PhtL  
PhtL  wird 1:10 mit MeOH weiterverdünnt: 1 µg/mL (1 ng/µL) in MeOH  
 PhtL   
Die Phenytoin-Stammlösung wird im Kühlschrank bei 2-8°C gelagert und ist ca. 12 Monate 
haltbar. 
Diese Lösungen werden für die Herstellung der Kalibratoren verwendet.  
 
 
Phenhydan-Lösungen: 
   
Phenhydan-Stammlösung: 
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Die Stammlösung kann auch aus Phenhydan hergestellt werden. Dazu 1 mL Phenhydan® 
mit Methanol ad 50mL versehen, gut mischen, bis zur vollständigen Durchmischung  
 PDL 1 mg/mL (1 ng/µL) in Methanol 
Diese Phenhydan-Lösung wird 1:10 mit MeOH weiterverdünnt: 100 µg/mL (100 ng/µL) in 
MeOH  
 PDL  
PDL  wird 1:10 mit MeOH weiterverdünnt: 10 µg/mL (10 ng/µL) in MeOH  
 PDL  
PDL  wird 1:10 mit MeOH weiterverdünnt: 1 µg/mL (1 ng/µL) in MeOH  
 PDL  
Die Stammlösung PDL wird im Kühlschrank bei 2-8°C gelagert und ist ca. 12 Monate haltbar. 
Diese Lösungen werden für die Herstellung der QC verwendet.  
 
Interner Standard (ISTD) 
 
0.050 g 5-(p-Methylphenyl)-5-Phenylhydantoin ad 50 mL Methanol, gut mischen, bis zur 
vollständigen Auflösung (Ultraschallbad). 
 ISTD 1 mg/mL (1 ng/µL) in Methanol 
Diese Lösung (ISTD) wird 1:10 mit MeOH weiterverdünnt: 100 µg/mL (100 ng/µL) in MeOH  
 ISTD  
Die Lösung ISTD wird im Kühlschrank bei 2-8°C gelagert und ist ca. 12 Monate haltbar.  
 
Vorbereitung des SST 
 
Der SST dient zum Testen der Methode. Der SST muss vor jeder Serie neu durchgeführt 
und gemessen werden. Die Lösungen werden jeweils frisch hergestellt. 
  
 100 µL PhtL  in ein GC-Vial pipettieren 
 24 µL ISTD  dazugeben 
 Vortexen  
 Eindampfen, N2, 50°C 
 100 µL TMSH dazugeben 
 verschliessen, gut vortexen (Diese Lösung entspricht dem Kalibrator 1).  
 
Die Bestimmung von Proben (P) und Qualitätskontrollen (QC) erfolgt doppelt.  
Besondere Massnahmen: Alle Lösungen auf Raumtemperatur erwärmen lassen. 1 mL 
Dialysat oder aCSF in Pyrex-RG pipettieren. Ansätze gemäss Ansatzschema zupipettieren 
und kurz vortexen: 
 
Probe Phenytoin [ng] ISTD [ng] Zusätze / 1 mL Dialysat oder aCSF 
Kal. 1  50 1200 50 µL PhtL    + 12 µL ISTD  
Kal. 2  150 1200 15 µL PhtL    + 12 µL ISTD  
Kal. 3  300 1200 30 µL PhtL    + 12 µL ISTD  
Kal. 4  600 1200 60 µL PhtL    + 12 µL ISTD  
Kal. 5  1000 1200 10 µL PhtL    + 12 µL ISTD  
Kal. 6  1200 1200 12 µL PhtL    + 12 µL ISTD  
Kontrolldialysat:  
aCSF und SST 
1200  1200 100 µL PhtL    + 24 µL ISTD  
QC 1 100 1200 10 µL PDL    + 12 µL ISTD  
QC 2 1000 1200 10 µL PDL    + 12 µL ISTD  
BW-Dialysat  --- 1200                          + 12 µL ISTD  
Proben (Dialysat) --- 1200                          + 12 µL ISTD  
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Festphasenextraktion (SPE) und Derivatisierung 
 
SPE: 
 
 
 
 
 
 
 
 
Säulen (Bond Elut Certify 130 mg, LRC) vorgängig beschriften: 
 
1. Konditionieren mit 1 mL Acetonitril (ohne Vakuum) 
2. Äquilibrieren mit 1 mL Citrat-Puffer pH 5 (ohne Vakuum) 
nicht trocken laufen lassen 
3. Probenaufgabe: Gesamtes Volumen (mit Pasteur-Pipette), (ohne Vakuum) 
4. Säulen waschen mit 1 mL Citrat-Puffer pH 5 (mit schwachem Vakuum) 
5. 1 mL HAc 0.01M (mit schwachem Vakuum). Ca. 5 min trockensaugen, bei vollem Vakuum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Auf Position „COLLECT“ durchführen: 
                      2mL Aceton 
         6.  
 
 
 
 
 
 
 
            8. 
     7.  
 TMSH 50 μL 
 Auf Position „WASTE“ durchführen: 
1 mL Acetonitril  1mL Citratpuffer 
pH5 
     1.             2. 
Kal, QC, SST, P 
     3. 
1mL Citratpuffer pH5      1mL 0,01M 
HAc                4.              5. 
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6. Eluieren mit 2 mL Aceton (ohne Vakuum) 
Ohne Vakuum eluieren lassen, in Glas-RGs auffangen, am Schluss ca. 10 s Vakuum 
anlegen 
7. Ganzes Eluat (mit Pasteur-Pipette) in GC-Vial überführen und bei 50°C mit N2 bis zur 
Trockene eindampfen 
8. Zum Derivatisieren den Rückstand mit 50 µL TMSH aufnehmen 
GC-Vial mit Alufolie und Alu-Cap verschliessen und gut vortexen 
 
Instrumentelle Bestimmung 
 
Die Analyse des derivatisierten Extraktes erfolgt auf dem GC-MS-NPD (Inv. 283). 
Spüllösung: Methanol  
Gerätetune: atune 
 
Zur Inbetriebnahme des NPD wird, nachdem die GC-Methode geladen wurde und die 
Statusanzeige nicht mehr NOT READY anzeigt, der Einstellknopf gedreht. Der schwarze 
Riegel unter dem Knopf muss zum Drehen nach links gedrückt werden und zum Feststellen 
des Knopfes wieder nach rechts gedrückt werden. Der Knopf wird für höhere Grundwerte im 
Uhrzeigersinn und für tiefere Grundwerte oder zum Ausschalten im Gegenuhrzeigersinn 
gedreht. Es wird solange im Uhrzeigersinn gedreht bis das NPD-Signal (GC-Display Signal 
A) bei der gewählten Methode ca. 40 (Signal sollte zwischen 30 und 50 Einheiten liegen) 
Einheiten anzeigt. Der NPD muss anschliessend während 15 Minuten stabilisieren, 
ansonsten bleibt die Basislinie nicht konstant. Den eingestellten Wert (ca. 40 Einheiten) 
nochmals kontrollieren und gegebenenfalls nachregeln. Dies ist der Wert des 
Grundrauschens. 
Wenn die Probe eingespritzt wurde und den NPD erreicht, kann es für ein paar Sekunden zu 
Schwankungen kommen, das NPD Signal erholt sich dann wieder.  
 
Akquisition 
 
Die folgenden Methoden stehen zur Verfügung: 
GC-MS-Methode (Scan-Methode): PHT.M (RH06.M )    
Sequenz: PHT.S (für qualitative und quantitative Analyse, für Methodentest SST) 
 
Die eingescannte GC-Methode befindet sich im PIOS.    
 
Massen der Fragmente, Definition der Qualifier 
Analyt     Interner Standard 
Phenytoin: 280, 203, 194, 118  5-(p-Methylphenyl)-5-Phenylhydantoin: 294, 
203, 194, 118 
 
 
Methodentest (SST) 
Das Gerät muss vor jeder Messserie mit dem SST getestet werden. Dieser Test soll 
sicherstellen, dass das System für die Analyse bereit ist. Zu diesem Zweck wird ein SST (Kal. 
1 = Level 1) direkt vor der Kalibration und vor den Proben P gemessen (Herstellung siehe 
Kap. 5.3.1.3). Mit Hilfe des SST wird die Empfindlichkeit optimiert und Retentionszeiten sowie 
allfällige Interferenzen und die Chromatographie überprüft.  
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Durchführung des SST 
 
Aktualisierung der SCAN-Methode:  
 
 "Level 1" im SCAN-Modus mit der Methode PHT.M (RH06.M) messen zur Überprüfung 
der Retentionszeiten 
 wenn nötig die SCAN-Zeitfenster in der SCAN-Methode anpassen 
 
Optimierung der Empfindlichkeit:  
 "Level 1" mit der SCAN-Methode messen. Die Signalstärke muss mindestens eine 
Intensität von 100'000 haben. 
 
Kontrolle der Messungen mit der SCAN-Methode: 
 "Level 1" im SCAN-Mode mit der aktualisierten SCAN-Methode messen 
 Auswerten mit der Auswertungsmethode 
Berechnet wird mit der Kalibration der letzten Serie.  
 
 
Beurteilung des SST 
 
Kriterien für die Beurteilung der Testlösung: 
 Phenytoin wird erkannt und berechnet 
 ISTD wird erkannt und berechnet 
 Die Peaks weisen kein starkes Tailing auf 
 Die Empfindlichkeit des Systems ist ausreichend 
 Die Schwankungen der errechneten Werte an Phenytoin im Bezug auf 1. und 2. 
Einspritzung (vor Kalibration und vor Probenserie) sind gering 
 
Werden ein oder mehrere Kriterien nicht erfüllt, muss über das weitere Vorgehen entschieden 
werden.  
 
Kontrollen 
 
Blindprobe (BW-Dialysat) 
Eine Blindprobe wird bei jeder Probenserie extrahiert und analysiert. Die Probe darf keine 
Resultate im Bereich des PHT-Peaks aufweisen. Weiter sind keine Interaktionen der 
Inhaltsstoffe mit PHT zulässig, da diese die Resultate verfälschen könnten. 
 
Referenz-Dialysat (aCSF) 
Als Referenz-Dialysat wird selber hergestellte, gespikte aCSF verwendet. Dieses wird bei 
jeder Serie im Doppel extrahiert und einfach analysiert (Doppelbestimmung).  
Die gespikten Referenz-Dialysate werden gleichmässig über die Sequenz verteilt.  
 
Bezeichnung  Soll [ng/ml] PDL  [μL] PDL  [μL] ISTD  [μL] aCSF [μL] 
QC1-A; QC1-B 100  10 12 1000 
QC2-A; QC2-B 1000 10  12 1000 
 
Kriterien für die gespikten Referenz-Dialysate: 
 Phenytoin wird erkannt und berechnet 
 Abweichung < 10%  Sequenz valide 
 Abweichung >10% und < 30% Sequenz valide 
 Abweichung > 30%  Sequenz nicht valide 
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[(Resultat QC1-A + Resultat QC1-B)/2]-Soll  Abweichung in % für QC1 resp. QC2 etc. 
Die % der QC1-QC5 werden addiert und dann durch 5 dividiert  Gesamtabweichung in % 
SST direkt 
Der SST wird mitgeführt, um die Recovery und mögliche Veränderungen während der Serie 
zu überprüfen. Sämtliche Auswertungen der Kontrollproben und des SST werden im 
Serienordner abgelegt (siehe auch Kapitel 0 ff.).  
 
 
Auswertung 
 
Die qualitative und quantitative (SCAN) Auswertung erfolgt mit der Auswertungsmethode 
PHT.M (RH06.M). Wenn nötig, müssen zuerst die Retentionszeiten in der 
Auswertungsmethode (Calibrate/Edit Compounds) angepasst werden. Ist die Integration 
nicht zufriedenstellend, müssen die entsprechenden Integrationsparameter optimiert und 
abgespeichert werden.  
 
Qualitative Auswertung 
Zur Identifizierung von Phenytoin wird ein Chromatogramm (SCAN) geladen und die 
Massenspektren der jeweiligen Peaks mit den Spektren der Datenbank verglichen. 
Phenytoin ist eindeutig identifiziert, wenn Retentionszeit und Massenspektrum 
übereinstimmen.  Hierbei dient der SST zur genauen Bestimmung der Retentionszeit. Die 
Chromatogramme werden auch auf das Vorhandensein anderer Metaboliten überprüft, 
Hinweise werden auf dem Resultateblatt vermerkt.  
 
Beurteilung der Chromatogramme:  
Positiv 
Phenytoin ist sichtbar 
 Massenspektrum und Retentionszeit sind korrekt 
 Peak ist > dreimal Rauschen  
Hinweis in Spuren 
Phenytoin ist sichtbar 
 Massenspektrum und Retentionszeit sind korrekt 
Peak ist ein- bis dreimal Rauschen 
 
Negativ 
Kein Peak ist sichtbar 
 
Spektrenbibliotheken:  
Direkt über Beat Aebi d.h. el. Übertragung (offline) 
Für die Auswertung von full-scan Spektren sind diese Bibliotheken und Werte zu verwenden. 
Zu Testzwecken können auch andere Bibliotheken verwendet werden. Es ist aber wichtig, 
dass die Daten vor der Bibliothekssuche überprüft und auch so in der Methode gespeichert 
werden.  
 
Quantitative Auswertung 
 
Berechnung 
Die Berechnung der Kalibration erfolgt automatisch durch die Chemstation-Software. Es 
handelt sich um eine lineare Regression mit ISTD. In der Regel erfolgt die Berechnung mit 
Hilfe der MS-Resultate.  
 
Übertragung der Flächen (Kalibration) 
Ausgewertet wird mit Hilfe des MS. Die Übertragung der Flächen wird anhand des 
mitgeführten Referenz-Dialysates beurteilt. Die Übertragung der Flächen wird mit einer 1-
Punkt-Kalibrierung mittels Interner Standard-Methode gemacht, indem die Response des 
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ISTD für die zu bestimmenden Substanzen übernommen werden. Die Signale werden mittels 
NPD kontrolliert. Die Konzentration des ISTD in der Probe beträgt je 1200 ng/mL.  
 
Angabe der Resultate unter Berücksichtigung der LOD/LOQ: 
Negativ Keine Signale vorhanden Der Quantifier oder ein Qualifier mit S/N weniger als 3:1 
Negativ Spur Alle Signale mit S/N ≥ 3:1 vorhanden, Wert < LOD  
Positiv Wert > LOQ und < höchster Kal. WERT = XXX ng/mL 
Positiv RW Wert > LOD und < LOQ WERT = XXX ng/mL 
Positiv Stark RW Wert > höchster Kal. WERT = XXX ng/mL 
 
Konzentrationen, welche ± 15% vom oberen bzw. unteren Kal. abweichen werden als out 
bezeichnet. Die Konzentration wird hier als > bzw. < des oberen bzw. unteren Kal. 
angegeben.  
 
 
Nachweisgrenze und Bestimmungsgrenze in ng/mL  
Resultate [ng/mL] Phenytoin 
LOD  
LOQ  
 
Methodenvalidierung 
Siehe Validierungsplan und Validierungsbericht.  
Es wurden nur die GC-MS Resultate verwendet. Die Resultate des NPD können in 
Einzelfällen verwendet werden, um qualitative Resultate vom MSD zu stützen.  
 
Mitgeltende Unterlagen 
 
Eingescannte GC-Methode im PIOS 
Massenspektren von Phenytoin 
Validierungsplan 
Validierungsbericht 
 
 
Literatur 
 
Ph. Eur. 5. Ausgabe, Grundwerk 2005, Reagenz Nr. 4010700 
 
Trimethylsulfonium Hydroxide: A New Methylating Agent; Kiyoshi Yamauchi, Toshizumi 
Tanabe, Masayoshi Kinoshita; J. Org. Chem., Vol. 44, No. 4, 1979 
 
Selective 2-O-Methylation of Pyrimidine-Ribonucleosides by Trimethylsulfonium Hydroxide 
in the Presece of Mg2+ and Ca2+ Ions; Kiyoshi Yamauchi, Toshizumi Tanabe, Masayoshi 
Kinoshita; Bull. Chem. Soc. Jap; Vol. 59; 2947-2949; 1986 
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2. Validierung der Phenytoin-Methode 
2.1 Validierungsplan  
für Phenytoinbestimmung mittels GC-MSD-NPD (Inv. 283) 
Bestimmung von freiem Phenytoin im ZNS-Mikrodialysat / Liquor mittels GC-MSD-NPD 
 
2.2 Zweck, Prinzip und Bedeutung 
Anhand des vorliegenden Validierungsplanes soll überprüft werden, ob die Bestimmung von freiem 
Phenytoin im ZNS-Mikrodialysat / Liquor mittels GC-MS-NPD (Inv. 283) in der Routineanalytik der 
Forensischen Toxikologie eingesetzt werden kann und für die definierten Parameter stabil ist. Die 
Parameter für den Validierungsplan wurden in der Validierungssitzung am 27.5.2008 definiert. 
 
2.3 Validierungsparameter 
Selektivität 
Linearität der Kalibration 
Genauigkeit 
Stabilität 
Analytische Grenzen (Nachweis- und Bestimmungsgrenze) 
Wiederfindungsrate, Extraktionsausbeute 
Matrixeffekte 
Robustheit 
 
2.4 Begriffe / Abkürzungen 
LSM Lösungsmittel 
Kal. Kalibrator 
QC Qualitätskontrolle 
PP Positivprobe 
Leermatrix ohne ISTD  Double-Blank, Leerprobe 
Leermatrix mit ISTD Blank, Nullprobe 
PHT Phenytoin 
PDL Phenhydan 
MA Mitarbeitende 
SPE Festphasen Extraktion 
 
2.5 Selektivität (Selectivity)  
Selektivität ist die Fähigkeit einer Methode, verschiedene nebeneinander zu bestimmende Analyten 
ohne gegenseitige Störungen oder Störungen durch andere endogene oder exogene Substanzen 
(Metaboliten, Verunreinigungen, Abbauprodukte, Matrix) zu erfassen und sie somit eindeutig zu 
identifizieren.  
 
Spezifität ist die Fähigkeit einer Methode, einen Analyten oder eine Substanzklasse ohne 
Verfälschung durch andere in der Probe vorhandene Komponenten (s.o.) zu erfassen und sie somit 
eindeutig zu identifizieren.  
 
Bestimmung in der Praxis 
Aufarbeitung von mindestens drei verschiedenen Leerproben aus jeweils verschiedenen Chargen 
(Leermatrix ohne ISTD)  
Aufarbeitung von mindestens drei Nullproben [Leermatrix mit ISTD], hergestellt aus humanem ZNS 
Dialysat, verdünnt mit aCSF(z.B. 50 µL humanes ZNS Dialysat + 450µL aCSF).  
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Selektivität 
 
Vorgehen 
- Negativ Proben: Drei Leerproben verschiedener Probanden werden je 
einmal ohne Zusätze (Double Blank) und einmal mit ISTD-Zusatz (Blank) 
gemessen. 
Proben - Negativ Proben: Drei verschiedene Leerproben werden verwendet. 
Ausführung R. Hösli  
Kontrolle B. Aebi 
 
2.6 Linearität der Kalibration (Linearity of Calibration), nach Ref. [9]  
Die Linearität einer analytischen Methode ist ihre Fähigkeit innerhalb eines gegebenen Bereiches 
Testergebnisse zu liefern, die direkt proportional zur Konzentration (Menge) des Analyten in der Probe 
sind. 
 
Linearität 
Vorgehen Überprüfung erfolgt durch Aufarbeitung von jeweils 3 Messserien (durch zwei MA). 
Proben Kal.1 - Kal.6, QC1, QC2, BW ohne ISTD, BW mit ISTD, SST in aCSF  BW ist hier gleich aCSF 
Ausführung R. Hösli  
Kontrolle B. Aebi 
 
2.7 Kalibrationsbereich (Range)  
Der Kalibrationsbereich einer analytischen Methode ist das Intervall zwischen oberer und unterer 
Konzentration (Menge) des Analyten in der Probe (einschließlich dieser Konzentrationen), für das ein 
geeignetes Maß an Präzision, Richtigkeit und Linearität gezeigt werden konnte.  
 
Bestimmung in der Praxis 
Herstellung von sechs Kalibratoren (möglichst gleichmässig über den Kalibrationsbereich verteilt) die 
je doppelt injiziert werden. Es werden 2x 3 Serien (Doppelbestimmung) durchgeführt 
 
2.8 Messbereich 
Der Messbereich sollte wenn möglich im folgenden Bereich liegen: 
Substanz Messbereich Therapeutisch auftretender Bereich 
PHT   50-1200ng 600-2400ng/mL 
PDL 100-1000ng 600-2400ng/mL 
2.9 Genauigkeit (Accuracy)  
Unter Genauigkeit versteht man den Abstand eines einzelnen Wertes vom Sollwert, hervorgerufen 
durch systematische und zufällige Fehler.  
 
Bestimmung in der Praxis:  
Analyse von mindestens zwei QC-Proben jeder Konzentration an mindestens sechs verschiedenen 
Tagen, als Doppelbestimmungen. QC1 und QC2 werden je 2x in drei Serien gemessen 
(Doppelbestimmungen) 
 
Präzision 
- Wiederholpräzision / - Laborpräzision  
Vorgehen 
-    Wiederholpräzision: Zwei MA führen je 3 Doppelbestimmung von je 3 
Konzentrationen (Kalibratoren Kal.1, Kal.3 und Kal.6) durch. 
- Laborpräzision: Zwei eingewiesene MA führen jeweils 3 
Doppelbestimmung von einer Kontrollprobe durch 
Proben Es werden die Kontrollen QC1 und QC2 und die Kalibratoren Kal.1, Kal.3 und Kal.6 verwendet. 
Ausführung R. Hösli und A. Tobler 
Kontrolle B. Aebi 
Advances in Therapeutic Drug Monitoring with a Focus on Phenytoin Analysis 
 
 
Raphael Hösli Dissertation, University of Basel  92 
2.10 Stabilität (Stability)  
Die chemische Stabilität eines Analyten in einer gegebenen Matrix unter bestimmten Bedingungen für 
gegebene Zeitintervalle. Die Stabilität eines Analyten sollte vom Zeitpunkt der Probennahme bis zum 
Abschluss der Analyse gewährleistet sein. Die Stabilität während der Lagerung und während eventuell 
wiederholtem Einfrieren und Auftauen ist methodenunabhängig, so dass entsprechende Stabilitätsda-
ten aus der Literatur übernommen werden können.  
 
2.10.1 Stabilität aufgearbeiteter Proben (Processed sample stability)  
Die Stabilität der (derivatisierten) Analyten in fertig aufgearbeiteten Proben im Probenteller des 
Autosampler für die Dauer einer regulärem Analysenserie. Die Aufbewahrung während dem Test 
erfolgt in trockenem Zustand, da das Derivatisierungsmittel (TMSH) verdampfen kann. 
 
2.10.2 Bestimmung in der Praxis:  
Proben in trockenem Zustand nach Eindampfen lagern und dann kurz vor Messung mit 
Derivatisierungsmittel versetzen 
 
Robustheit 
Autosampler-Stabilität / Langzeit-Stabilität 
Vorgehen 
Stabilität des aufgearbeiteten Analythen:  
Die Kontrollen QC1 und QC2 werden sechsmalig aufgearbeitet und  
abgedampft. Die getrockneten QC's werden aufbewahrt und zum  
Zeitpunkt 0h (QC1.A und QC2.A), 8h (QC1.B und QC2.B), 24h  
(QC1.C und QC2.C) mit Derivatisierungsmittel (TMSH) versetzt und 
 sofort gemessen.  
Langzeit-Stabilität: Wird noch nicht bewertet. 
Proben Kontrollen QC1 und QC2 
Ausführung R. Hösli 
Kontrolle B. Aebi 
 
2.11 Analytische Grenzen  
2.11.1 Nachweisgrenze (Limit of Detection, LOD)  
Die Nachweisgrenze ist definiert als die niedrigste Konzentration, die mittels der analytischen Methode 
noch sicher vom Hintergrundrauschen unterschieden werden kann.  
Bestimmung in der Praxis:  
a) Unterster Kalibrator mit S/N (Signal/Noise) 3:1, mittels Dreisatz berechnen 
b) Reststandardabweichung der Kalibratoren ermitteln 
c) Nach DIN 32465 vorgehen 
2.11.2 Bestimmungsgrenze (Limit of Quantification, LOQ)  
Die Bestimmungsgrenze ist die niedrigste Konzentration eines Analyten in der Probenmatrix, die mit 
akzeptablem Bias- (±20%) und Präzisiondaten (RSD ≤20%) bzw. mit einer vorgegebenen relativen 
Ergebnisunsicherheit (33%, Signifikanz: 99%) bestimmt werden kann.  
Bestimmung in der Praxis 
a) Unterster Kalibrator mit S/N (Signal/Noise) 10:1, mittels Dreisatz berechnen 
b) Reststandardabweichung der Kalibratorenermitteln 
c) Nach DIN 32465 vorgehen 
 
2.12 Wiederfindungrate, Extraktionsausbeute  
2.12.1 Wiederfindungsrate (Recovery)  
Die absolute Wiederfindung ist definiert als kompletter Transfer des Analyten von der Matrix in die zu 
vermessende Lösung. Sie wird bestimmt aus einem Verhältnis der Signale einer in gleich zugesetzten 
Menge Analyt bzw. Standard zu einer biologischen Probe und einer nicht extrahierten Originallösung 
(100%). Die Bestimmung der Wiederfindungsrate bezieht sich immer auf die absoluten Messsignale. 
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Sie kann daher nur bei Methoden bestimmt werden, bei denen die letztendlich vermessene Substanz 
in reiner Form erhältlich ist. 
 
 
 
2.12.2 Wiederfindung in der Praxis 
Es wird ein Vergleich mit und ohne Extraktion mit den Kontrollen QC1 und QC2 durchgeführt.  
 Mit SPE Ohne SPE 
Wiederfindung in Kontrolle QC1 (100ng PHT) QC1 (100ng PHT) 
Wiederfindung in Kontrolle QC2 (1000ng PHT) QC2 (1000ng PHT) 
 
2.13 Robustheit (Robustness, Ruggedness)  
Die Robustheit einer analytischen Methode ist ein Maß ihrer Fähigkeit, durch kleine, aber bewusste 
Veränderungen der Methodenparameter unbeeinflusst zu bleiben, und zeigt ihre Verlässlichkeit 
während der normalen Anwendung. 
 
Literatur 
[1] Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. For.Sci.Int. 165:216-224.  
[2] Entwurf zu "Anforderungen an die Validierung von Analysenmethoden", Anhang A, GTFCh, F. T. 
Peters 
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3. Durchführung der Validierung 
Um möglichst effizient und kostengünstig zu arbeiten, wurde eine Zusammenstellung erstellt, aus der 
ersichtlich wird, aus welchen Messungen welche Daten extrahiert werden können. 
 
3.1 Anzahl SPE Säulen die pro Schritt verwendet werden müssen 
Selektivität (6) 
 
Linearität (33) 
 
Kalibration (36) 
 
Wiederholpräzision (18) 
 
Laborpräzision (6) 
 
Robustheit (6) 
 
Wiederfindung (2) 
 
3.2 Anzahl Extraktionen und Messungen bei schrittweise Vorgehen 
Untersuchung Anzahl SPE Proben 
Selektivität (RH) 6 3 Leerproben ohne ISTD 
3 Leerproben mit ISTD 
Linearität (RH) 18 
+12 
+6 
+3 
39 
3(Kal 1-Kal6) 
3(aCSF ohne ISTD, aCSF mit ISTD) 
3(QC1 und QC2) 
3(SST) 
 
Kalibration (RH/AT) 36 3(Kal1-Kal6) 
Wiederholpräzision (RH/AT) 18 3(Kal1, Kal3, Kal6) 
Laborpräzision (RH/AT) 6 3(QC1) 
Robustheit (RH) 6 3(QC1 und QC2) 
Wiederfindung (RH) 2 QC1 und QC2 mit SPE Extraktion 
QC1 und QC2 ohne Extraktion 
Total SPE‘s: 113  
Total GS-NPD-MS Messungen 20 1+3+6+6+3+1 
 
3.3 Anzahl SPE Säulen die bei Kombination verwendet werden müssen 
Selektivität (6) 
 
    Kalibration (0) 
Linearität (78) 
    Wiederholpräzision (0)/Laborpräzision (0) 
 
Robustheit (6) 
 
 
Wiederfindung (2) 
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3.4 Anzahl Extraktionen und Messungen bei kombiniertem Vorgehen 
 
Untersuchung Anzahl SPE Proben 
Selektivität (RH) 6 3 Leerproben ohne ISTD 
3 Leerproben mit ISTD 
Linearität (RH /AT) 18 
+12 
+6 
+3 
39x2=78 
3(Kal 1-Kal6) 
3(aCSF ohne ISTD, aCSF mit ISTD) 
3(QC1 und QC2) 
3(SST) 
 
Kalibration  Aus Linearität 3(Kal1-Kal6) 
Wiederholpräzision  Aus Linearität 3(Kal1, Kal3, Kal6) 
Laborpräzision  Aus Linearität 3(QC1) 
Robustheit (RH) 6 3(QC1 und QC2) 
Wiederfindung (RH) 2 QC1 und QC2 mit SPE Extraktion 
QC1 und QC2 ohne Extraktion 
Total SPE‘s: 92  
Total GC-NPD-MS Messungen 11 1+6+3+1 
 
Gewinn gegenüber schrittweise Vorgehen: 21x SPE Säulen weniger 
      9x GC-NPD-MS Messungen weniger 
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STUDY PLAN 
 
TITLE OF THE STUDY: VALIDATION OF A METHOD FOR THE 
QUANTIFICATION OF PHENYTOIN IN DIALYZED LIQUOR 
SAMPLES BY LC-MS/MS 
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ABBREVIATIONS 
aCSF Artificial cerebrospinal fluid 
Blank Artificial cerebrospinal fluid sample processed without 
internal standard 
blq Below limit of quantification 
Cal Calibration 
Conc. Concentration 
CV Coefficient of variation 
Dev Deviation 
DWP Deep well plate 
e.g. For example 
ESI Electrospray ionization 
g Gram 
H2O Water 
HClO4 Perchloric acid 
HCOOH Formic acid 
HPLC High performance liquid chromatography 
ISTD Internal standard 
LC-MS/MS Liquid chromatography coupled on-line with tandem mass 
spectrometry 
LLOQ Lower limit of quantification 
M Molarity 
MC Main column 
MeCN Acetonitrile 
MeOH Methanol 
mg Milligram 
min Minute 
mL Milliliter 
mm Millimeter 
mM Millimolar 
MS Mass spectrometry 
ng Nanogram 
PHT Phenytoin 
PHT-D10 Phenytoin-D10 
PP Polypropylene 
QC Quality control  
SD Standard deviation 
TC Trapping column 
ULOQ Upper limit of quantification 
v + v Volume plus volume 
µm Micrometer 
µg Microgram 
µL Microliter 
% Percent  
°C Degree centigrade 
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1 GENERAL INFORMATION ABOUT THE STUDY 
Test facility:  Institut für Rechtsmedizin, Universität Bern, Bern 
 
Test item: Phenytoin  
 
Title of the study: Validation of a method for the quantification of Phenytoin in 
Microdialysate matrices by LC-MS/MS. 
1.1 OBJECTIVE 
The objective of this study is to validate a method for the quantification of Phenytoin in 
microdialysate samples by LC-MS/MS / HPLC. 
1.2 PROJECT ADMINISTRATION 
Study director: Raphael Hösli 
1.3 DEVIATION PROCEDURES 
All deviations to the study plan and the reasons for these deviations will be documented in 
the raw data. All deviations to the study plan will be described in the study report. 
1.4 ARCHIVING 
The originals of the study plan, (if applicable), raw data and the final study report will be 
archived. 
1.5 VALIDATION OF THE ANALYTICAL METHOD 
The analytical method was developed and will be validated in the test facility. The guideline 
“Guidance for Industry, Bioanalytical Method Validation, May 2001” (1) will be followed to 
conduct the validation of the analytical method. 
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2 MATERIALS AND METHODS 
2.1 TEST ITEMS 
Test items will be used for the preparation of Cal and QC samples. 
 
Identity: Phenytoin 
Alternative name: 5.5-Diphenylhydantion, 5.5-Diphenyl imidazolidin-2.4-dion 
Certificate of analysis: Internet CoA 
Storage: at ambient temperature  
Formula: C15H12N2O2 
Molecular weight: 252.28  
Purity: purum, ≥ 96.0% 
Batch number: 400570/1 33903312 
2.2 INTERNAL STANDARDS 
Internal standards will be used for the preparation of ISTD solutions. 
 
Identity: Phenytoin D10 (Cerillant) 
Certificate of analysis: will be reported in study report 
Storage: 6°C ± 4°C  
Formula: C15H2D10N2O2 
Molecular weight: 262.33 
Purity: will be reported in study report 
Batch number: will be reported in study report 
2.3 BLANK MATRIX 
1000 mL blank dilaysate (aCSF) containing NaCl: 8.5910 g, KCl: 0.2013 g, CaCl2: 0.1332 g 
and MgCl2x6H2O: 0.1728 g will be used for the preparation of Cal and QC samples. This 
solution can be self-prepared or purchased from Solna (Sweden). Its pH will be adjusted to 
7.4 (± 0.1) with 2 M NaOH. The aCSF solution will be stored at 6°C ± 4°C. 
2.4 APPARATUS, REAGENTS, AND MATERIALS 
All chemicals and equipment can be replaced by equivalent chemicals and equipment. 
 
LC-MS/MS system: 
 
Autosampler Dionex WPS-3000TSL Analy. Olten, Switzerland 
Column oven Cluzeau Info Labo CrocoCil 
Column thermostate Dionex TCC-3100, Olten, Switzerland (including switching 
valve) 
Solvent rack Dionex SRD-3600, Olten, Switzerland 
HPLC pumps 1 and 2 Dionex pump HPG-3200A, Olten, Switzerland  
HPLC pump 3 Dionex pump ISO-3100A, Olten, Switzerland 
Mass spectrometer MDS Sciex, Q Trap 3200, Toronto Canada 
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Nitrogen Liquid Nitrogen, Messer, Lenzburg, Switzerland 
 
 
Other equipment: 
 
Balances AE163 Mettler-Toledo; XS603S Mettler-Toledo 
Centrifuges Rotanta 460 R and / or Mikro 22R, Hettich Instruments, 
Andreas Hettich AG, Bäch, Switzerland 
Deep well plates 0.6 mL, Chemie Brunschwig AG, Basel, Switzerland and / or 
1 mL, Vitaris, Baar, Switzerland and / or Chemie Brunschwig 
AG, Basel, Switzerland and / or 1.2 mL, TreffLab, Milian 
S.A., Geneva, Switzerland 
HPLC vials 2.0 mL glass, BGB Analytik AG, Böckten, Switzerland 
Inserts 0.3 mL glass, BGB Analytik AG, Böckten, Switzerland 
Pipetman tips Axygen, Milian S.A., Geneva, Switzerland 
Pipettes Eppendorf, Milian S.A., Geneva, Switzerland, Socorex ISBA 
S.A., Lausanne, Switzerland and Gilson, Mettmenstetten, 
Switzerland 
PP tubes Various sizes of safe seal tubes and / or screw cap tubes, 
brown and / or transparent, 1.5 to 50 mL, Sarstedt, Sevelen, 
Switzerland and / or Milian S.A., Geneva, Switzerland 
Sealing mats Silicone, Chemie Brunschwig AG, Basel, Switzerland and / 
or Corning, Vitaris AG, Baar, Switzerland 
Glas flasks with caps Various sizes, 10 to 2000 mL, VWR International, Dietikon, 
Switzerland and 2.0 and / or 4.0 mL, BGB Analytik AG, 
Böckten, Switzerland  
Vortex mixer Vibrax-VXR, IKA, Fisher Scientific AG, Wohlen, Switzerland 
 
 
HPLC columns: 
 
Trapping column Phenomenex Gemini Polar, 2.0 x 10 mm, 5 µm, Brechbühler 
AG, Schlieren, Switzerland 
Main column Phenomenex Synergy Polar RP, RP, 2.0 x 50 mm, 
Brechbühler AG, Schlieren, Switzerland 
 
 
Chemicals: 
 
Acetonitrile HPLC grade, Chemie Brunschwig AG, Basel, Switzerland 
Methanol HPLC Gradient grade, Chemie Brunschwig AG, Basel, 
Switzerland 
Perchloric acid 20% purissimum pro analysi, Fluka Chemie GmbH, Buchs, 
Switzerland 
Water MiliQ quality, Milpore 
 
 
Software: 
 
Analyst software Version 1.5.x, AB Sciex, Toronto, Canada 
Microsoft Office Version 2007 
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2.5 DESCRIPTION OF THE HPLC SYSTEM 
Column switching / description of the method: 
 
Flow pumps 1 0.350 mL/min 
Flow pump 2 0.200 to 1.000 mL/min 
Oven temp: set to 50°C  
Autosampler cooler tray: set to 8°C 
Syringe volume: 100 µL  
Injection loop: 130 µL  
Injection volume: 1 - 100 µL  
 
Mobile phase A: H2O + HCOOH (100 + 0.1, v + v) 
Mobile phase B: MeCN + HCOOH (100 + 0.1, v + v) 
 
Table 1: Pump gradient program 
Pump 1 (mobile phase A) Pump 2 (mobile phase A and mobile phase B) 
Pump 3 
(mobile phase A) 
Time (min) B% Flow (mL/min) Time (min) B% Flow (mL/min)  Flow (mL/min) 
0.00 10 0.350 0.00 100 0.20 Trapping  2.00 
1.00 10 0.350 0.00 100 0.20  2.00 
2.00 97.5 0.350 1.00 100 0.20 Eluting 2.00 
4.00 97.5 0.350 1.20 100 0.02  2.00 
4.10 10 0.350 3.50 100 0.02  0.02 
5.00 10 0.350 3.60 100 1.00  0.02 
   4.50 100 1.00  0.02 
   4.60 100 0.02  2.00 
   5.00 100 0.02  2.00 
 
 
Retention times of the analytes: 
 
Phenytoin: approximately 2.8 min 
ISTD (PHT D10): approximately 2.8 min 
 
Autosampler washing solutions: 
 
First solution:  MeCN + HCOOH (100 + 0.1, v + v) 
2.6 DETECTOR SETTINGS 
Mass spectrometry settings:  
 
Source interface: Electrospray ionization  
Polarity: Positive 
Acquisition time (per sample): 5.5 min 
Scan type: MRM mode 
 
The m/z values of the different ions that will be used to measure the concentrations of the 
analyte and ISTDs in worked-up matrix samples are listed in Table 2. 
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Table 2: m/z values to be used for quantification in MRM mode 
 Precursor ion m/z Fragment ion m/z Dwell time (ms) 
Phenytoin 253 182 100 
ISTD (PHT-D10 ) 263 192 100 
2.7 DATA ACQUISITION AND CALCULATION 
Sample lists, acquisition method and data collection will be generated with Analyst version 
1.5.x, AB Sciex, Toronto, Canada. The acquired data will be processed with Analyst version 
1.5.x, AB Sciex, Toronto, Canada. The software is capable of smoothing peaks, drawing 
baselines, calculating peak heights and areas and determining concentrations by inverse 
prediction and statistical evaluation of the Cal curve fit.  
 
The concentrations of Phenytoin in Cal and QC species matrix samples will be back 
calculated from the Cal curves using the internal standardization method. Analyst verions 
1.5.x, AB Sciex, Toronto, Canada will be used to calculate a linear regression from the area 
ratio and the corresponding concentration data of the Cal samples. 
 
For Cal and QC samples the accuracy and precision of the validation runs will be calculated by 
Microsoft Excel. 
2.8 DATA REPORTING 
Statistical data for mean, overall mean and SD will be rounded according to the decimals 
given for the analytes. Statistical data for CV%, Dev% and accuracy will be rounded to 1 
decimal. Due to the rounding procedures, reported values may differ from the original raw 
data. Statistical evaluations will be made based on rounded matrix concentrations. 
2.9 FORMULAE 
2.9.1 Deviation 
Intra- and inter-assay deviation (Dev%) will be calculated for all determinations using the 
following equation: 
 
  
n
nm
c
c  -c*100Dev%   
 
Explanation of the symbols used in this equation: 
 
Dev% = Deviation of measured concentrations from the nominal 
concentration in % 
cm = Measured concentration in [ng/mL] 
cn = Nominal concentration in [ng/mL] 
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2.9.2 Mean 
Mean ( x ) will be calculated using the following equation: 
 
 n
x
x
n
1i i

   
 
Explanation of the symbols used in this equation: 
 
x  = Mean or overall mean concentration of specified Cal and QC 
levels of all valid determinations 
xi = Concentration of specified Cal and QC levels 
n = Number of assays 
2.9.3 Standard deviation 
Standard deviation (SD) will be calculated for all determinations using the following equation: 
 
  1 - nn
x -xn
SD
2n
1i
i
n
1i
2
i 




  
 
Explanation of the symbols used in this equation: 
 
SD = = Standard deviation 
xi = = Concentration of specified Cal and QC levels 
n = = Number of assays 
2.9.4 Accuracy 
Accuracy in % will be calculated for all determinations using the following equation: 
 
 100 * c
x  %Accuracy 
n
  
 
Explanation of the symbols used in this equation: 
 
Accurracy % = Accuracy in % of nominal concentration 
x  = Mean or overall mean concentration of specified Cal and QC 
levels from all valid determinations 
cn = Nominal concentration 
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2.9.5 Intra- and inter-assay reproducibility / precision 
Intra- and inter-assay precision (CV%) will be calculated for all determinations using the 
following equation: 
 
 100*x
SD  CV%   
 
Explanation of the symbols used in this equation: 
 
SD = Standard deviation in % 
x  = Mean or overall mean concentration of specified Cal and QC 
levels of all determinations 
 
 
 
3 EXPERIMENTAL PROCEDURE 
If any different amounts and / or volumes than indicated below will be used during the 
experimental part the corresponding amounts and / or volumes have to be adjusted. 
Preparations described in this chapter will be mixed well, if not mentioned to be handled else, 
before being used for the next step. 
3.1 PREPARATION OF STOCK SOLUTIONS 
The concentrations of the solutions are based on the free and non-ionized form of the drug. All 
solutions will be prepared in PP tubes / glass volumetric flasks / single use glass flasks  under 
consideration of the content. 
 
Solution KA (1.00 mg/mL of Phenytoin): 
Accurately weigh at least 10.00 mg of Phenytoin and dissolve in 10.00 mL MeOH in order to 
achieve a concentration of 1.00 mg/mL. 
 
Solution SA (1.00 mg/mL of Phenytoin): 
Accurately weigh at least 10.00 mg of Phenytoin and dissolve in 10.00 mL MeOH in order to 
achieve a concentration of 1.00 mg/mL. 
 
Stock solution ISTD (100 µg/mL in MeOH): 
 
1.0 mL ampoule of Phenytoin-D10 (Cerilliant). 
 
The preparations above will be shaken until dissolution is complete. Subsequently, they will 
be stored 6°C ± 4°C. 
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3.2 PREPARATION OF CALIBRATION SAMPLES 
Eight Cal samples with a concentration range from 10.00 to 2000 ng/mL for Phenytion will be 
prepared in blank aCSF from stock solutions KA (Table 3) 
 
K: 1.00 mg/mL = 1‘000 µg/mL= 1‘000‘000 ng/mL Phenytoin 
Table 3: Preparation of calibration samples  
Working 
solutions C8  C7  C6  C5  C4  C3  C2  C1  
[ng/mL] 100’000 50’000 25’000 12’500 5’000 2’500 1’000 500.0 
MeOH mL 1.80 1.00 1.00 1.00 1.20 1.00 1.20 1.00 
From solution K C8 C7 C6 C5 C4 C3 C2 
Add mL 0.20 1.00 1.00 1.00 0.80 1.00 0.80 1.00 
         
Calibration 
samples Cal8 Cal7 Cal6 Cal5 Cal4 Cal3 Cal2 Cal1 
aCSF(µL) 980 980 980 980 980 980 980 980 
From solution C8 C7 C6 C5 C4 C3 C2 C1 
Add (µL) 20 20 20 20 20 20 20 20 
Conc. of Phenytoin 
[ng/mL] 2000 1000 500.0 250.0 100.0 50.00 20.00 10.00 
 
Working solutions will be stored in PP tubes at 6°C ± 4°C. 
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3.3 PREPARATION OF QUALITY CONTROL SAMPLES 
Quality control samples at 5 different concentrations of Phenytoin will be prepared in blank 
aCSF from stock solutions SA (Tables 4) 10xQChigh samples will be prepared for dilution 
ability (see 5.6). 
 
SA: 1.00 mg/mL = 1000 µg/mL= 1‘000‘000 ng/mL Phenytoin 
 
Table 4: Preparation of quality control samples  
Working 
solutions Q4 Q3 Q2 Q2# Q1 QLLOQ 
[ng/mL] 800’000 80’000 20’000 6000 1500 500 
MeOH(µL) 80 1840 1500 1400 900 400 
From solution SA SA Q3 Q2 Q2# Q1 
Add(µL) 320 160 500 600 300 200 
       
Quality control 
samples 10 xQChigh QChigh 
QCmediu
m  QClow QCLLOQ 
aCSF 490 980 980  980 980 
From solution Q4 Q3 Q2  Q1 QLLOQ 
Add (µL) 10 20 20  20 20 
Conc. of Phenytoin [ng/mL] 16000 1600 400  30 10 
 
Working solutions will be stored in PP tubes at 6°C ± 4°C. 
 
Blank: aCSF sample free of analytes and processed without ISTD 
as described in the sample preparation procedure. 
QC0: aCSF sample free of analytes and processed with ISTD as 
described in the sample preparation procedure. 
3.4 PREPARATION OF INTERNAL STANDARD SOLUTIONS 
ISTD stock solution: 
100 µg/mL ampoule of Phenytoin-D10 (Cerilliant). 
 
ISTD1 solution: 100 µL of the 100 µg/mL is added to 9900 µL of MeOH. The solution will be 
mixed well by shaking. 
 
ISTD working solution: 5 mL of the ISTD1 is added to 95 mL of a 1 M perchloric acid 
aqueous solution. The solution will be mixed well by shaking. 
 
Subsequently the solutions will be stored at 6°C ± 4°C [50ng/mL]  
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3.5 SAMPLE PREPARATION 
Sample preparation for 25 µL of Blank, Cal and QC dialysate samples: 
1. The individual Blank, Cal and QC aCSF samples will be thawed in cold tap water or at 
ambient temperature.  
2. 25 µL of each sample will be aliquoted or previously aliquoted samples will be used.  
3. 75 µL of ISTD working solution is added. 
4. The samples will be centrifuged at about 4.000 u/min for about 30 minutes at 6°C ± 
4°C. 
5. Samples will be ready for injection into the LC-MS/MS system. 
 
All worked-up samples will always be stored at 6°C ± 4°C if not used immediately. 
 
4 VALIDATION: DESCRIPTION AND CRITERIA 
4.1 SELECTIVITY 
For selectivity 6 dialysate samples will be prepared and analyzed as Blank samples. The 
mean interference of these 6 samples has to be beyond 1/5 of the analytes’ mean response 
at the QCLLOQ level. 
4.2 SPECIFICITY 
For specificity, 6 dialysate samples will be spiked with Phenytoin at the level of the LLOQ, 
then worked-up and analyzed as QCLLOQ samples. 
The mean accuracy has to be within ± 20% of the nominal concentration. The mean precision 
of the 6 samples has to be within 20%. 
4.3 VALIDATION RUNS FOR ACCURACY AND PRECISION  
4.3.1 Composition of a validation run for accuracy and precision 
A validation run will include 2 sets of Cal samples 1 to 8 for Phenytoin, 2 Blanks, 2 QC0 
samples and a set of 6 QC samples at each of the 4 different concentrations (QCLLOQ, QClow, 
QCmedium and QChigh). Three of these validation runs will be separately prepared and 
measured. 
Standard deviation and CV% will be calculated for each Cal and QC level with more than 1 
result. Deviation in %, mean and accuracy in % will be evaluated for all valid results. All valid 
validation runs will be used for the calculation. 
4.3.2 Accuracy  
Accuracy for Cal samples will be calculated as inter-assay (between different runs) from the 
overall mean at each Cal level divided by the corresponding nominal concentration. Accuracy 
for QC samples will be calculated as intra-assay (within a run) and inter-assay from the mean 
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and overall mean at each QC level divided by the corresponding nominal concentration. Intra- 
and inter-assay accuracy have to be within ± 20% at the lowest Cal and QC level and within 
± 15% at all other Cal and QC levels. 
4.3.3 Precision  
Precision for Cal samples will be determined as inter-assay reproducibility. Precision for QC 
samples will be determined as intra- and inter-assay reproducibility. Inter-assay precision has 
to be within 20% at the lowest Cal level, intra- and inter-assay precision have to be within 
20% at the lowest QC level and within 15% at all other QC levels. 
4.3.4 Limits of quantification  
The lowest Cal level (Cal1) will be used as the LLOQ and the highest Cal level (Cal8) will be 
used as the ULOQ. 
The LLOQ in dialysate samples will be set to 10.00 ng/mL and the ULOQ to 2000 ng/mL for 
Phenytoin. 
4.3.5 Calculation of calibration samples 
Version 1.5.x, AB Sciex, Toronto, Canada will be used to perform a linear regression by 
plotting area ratio of Phenytoin versus (ISTD) against the corresponding ratios of Phenytoin 
nominal concentration versus ISTDs nominal concentrations. During method validation the 
weighting factor giving the best fit will be evaluated and selected for the linear regression. 
All Cal samples which fulfill the specifications will be used to generate the standard Cal curve. 
This means that for a valid run a standard Cal curve will include at least 12 to a maximum of 
16 Cal samples. Calibration samples which will be out of specifications will not be used for 
any further calculations. 
4.3.6 Acceptance criteria for the calibration curve 
 Analyte response at the LLOQ should be at least 5 times the response of the Blank. 
 The deviation of the lowest Cal samples from the nominal concentration has to be within 
± 20%. 
 The deviation of the other Cal samples from the nominal concentration has to be within 
± 15%. 
 At least 75% of all Cal samples (including at least 1 of the highest and 1 of the lowest 
Cal samples) have to fulfill the above criteria. 
 The correlation coefficient for the Cal curve linearity has to be  0.99. 
 The inter-assay accuracy and precision at the lowest Cal level from the nominal 
concentration have to be within (±) 20% while the inter-assay accuracy for the 
remaining Cal levels has to be within ± 15%. 
If a run will not fulfill the criteria the run will be reinjected and / or completely reanalyzed. 
4.3.7 Calculation of quality control samples 
The standard Cal curve will be used to back calculate the concentrations of Phenytoin in QC 
samples by using the measured corresponding area ratio. All results for the QC samples 
except for QC samples which deviate from the nominal concentration due to an error that 
may occur will be used for the calculation. 
  
Advances in Therapeutic Drug Monitoring with a Focus on Phenytoin Analysis 
 
 
Raphael Hösli Dissertation, University of Basel  111 
4.3.8 Acceptance criteria for quality control samples 
 
 The intra- and / or inter-assay accuracy and precision at the lowest QC level from the 
nominal concentration have to be within (±) 20% while the intra- and / or inter-assay 
accuracy and precision for the remaining QC levels have to be within (±) 15%. 
 QC0 samples should be blq. 
 If for Blank samples possible interfering peak(s) with the analyte(s) occurs, the peak 
area(s) of this / these peak(s) should be ≤ the area of an interfering peak(s) of the QC0 
samples. 
If a run will not fulfill the criteria the run will be reinjected and / or completely reanalyzed. 
4.4 RECOVERY  
For recovery 18 blank dialysate samples will be worked-up and spiked with Phenytoin as well 
as ISTD at the actual concentrations received in QClow, QCmedium and QChigh samples after 
work-up. For each of the 3 levels 6 replicates will be prepared. Additionally 6 original samples 
of each of the levels QClow, QCmedium and QChigh will be worked-up. 
The mean area of the spiked Blank samples will be compared with the mean area of the 
original QClow, QCmedium and QChigh samples at each level. The deviation between the mean 
areas at each level will be used as recovery for Phenytoin as well as for ISTD. The intra-
assay precision should be consistent and precise (CV% ≤ 25). 
4.5 STABILITY TESTS 
For the short-term, freeze-thaw and the long-term stability a set of 12 dialysate samples - 6 
of each concentration at QClow and QChigh level - will be used.  
Except for the long-term stability test the nominal concentration of the QClow and QChigh 
samples will be used as reference. 
The intra-assay accuracy and precision of the analyte's/analytes' mean concentrations in the 
QC samples at QClow and QChigh level have to be within ± 15% of their nominal concentration 
for short-term and freeze-thaw respectively as described from the actual level for the long-
term stability tests. 
4.5.1 Freeze-thaw stability  
Analyte stability will be determined for 3 freeze-thaw cycles. Samples will be stored at -25°C 
± 5°C for at least 24 hours and then thawed unassisted at ambient temperature. When 
completely thawed, the samples will be refrozen and stored for at least 12 hours at the 
mentioned temperature. The freeze-thaw cycle will be repeated twice. After the 3rd cycle the 
samples will be worked-up and analyzed. If this test shows, that the analyte is not stable for 
3 freeze-thaw cycles, the test will be repeated for 1, 2 and 3 freeze-thaw cycles. 
4.5.2 Short-term stability  
The samples will be thawed at ambient temperature and kept at this temperature for at least 
6 hours, frozen for at least 12 hours at -25°C ± 5°C, then thawed, worked-up and analyzed 
4.5.3 Long-term stability  
For the evaluation of the long-term stability QClow and QChigh samples will be spiked. A set of 
6 replicates will be measured immediately for each level. The mean of the measured 
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concentrations at each level will be used as the reference concentration for the stored QC 
samples. 
Long-term stability will be determined for a period of at least 3 and 6 months. Therefore 
freshly prepared QC samples will be stored at -25°C ± 5°C.  
After at least 3 and 6 months of storage the QC samples will be analyzed against freshly 
prepared Cal samples.  
4.5.4 Stock solution stability  
Stock solutions of Phnytoin will be kept for at least 6 hours at ambient temperature before 
being stored at -25°C ± 5°C for at least 6 months. 
After completion of each of the storage periods the peak areas of samples prepared using 
stored stock solutions will be compared with the peak areas of samples prepared using 
freshly prepared stock solutions. 
The intra-assay precision has to be within ± 15% for each stock solution. The deviation 
between the mean areas of the samples of stored and freshly prepared stock solutions has 
to be within ± 15% for each analyte.  
4.5.5 Post-preparative stability / reinjection stability 
Post-preparative stability will be evaluated to determine if an analytical run can be reinjected 
in the case of instrument failure. Therefore 1 of the validation runs (see 5.3) will be analyzed 
a second time after at least 1 day and maximum of 7 days. The described criteria for Cal 
curves, QC, accuracy and precision have to be met. 
The mean of the analyte's concentrations in the species1 matrix has to be within ± 15% from 
the mean of the analyte's concentrations of the t0 samples. 
4.6 SAMPLE DILUTION ABILITY 
The validity to dilute samples which will be found to be above the ULOQ after the first analysis 
during a study will be demonstrated by diluting 10xQChigh samples to QChigh samples with 
blank dialysate. 
4.7 CARRY OVER 
The carry over of Phenytoin will be determined with a test sequence of 1 Blank sample 
followed by 1 Cal8 sample and 4 Blank samples. The analyte's peak area of the Cal8 will be 
compared with the analytes' peak area of the Blank samples. The test sequence will be 
repeated 3 times. 
5 REPORTING 
The final report will include, but not be limited to: 
 
 The identification of the study and test items (including characteristics) 
 The study schedule 
 A description of all materials and methods used 
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 A description of all results (concentrations of the Cal and QC samples, accuracy, 
precision, linearity) 
 The storage locations of study plan, raw data, final report, and reference samples of 
the test items 
6 REFERENCES 
(1) FDA Guidance for Industry (Bioanalytical Method Validation, May 2001); 
(http://fda.gov/cder/guidance/index.htm). 
 
 
7 DISTRIBUTION 
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Copies: Study director 
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Introduction:  
Total drug concentration in blood/plasma is routinely determined in difficult- 
to-dose drugs therapeutic drug monitoring or (TDM). To adapt correct  
dosing in patients with changing drug-binding proteins like albumin, the  
knowledge of the free fraction of highly protein-bound drugs is required.  
Phenytoin (PHT), an antiepileptic with narrow therapeutic index, >90% 
albumin binding and a Vd of 0.7 L/kg b.w. needs dose individualization       
because of its non-linear pharmacokinetics with a slow dose-dependent 
elimination. Therefore, PHT TDM is mandatory for rapid i.v. loading and 
subsequent correct dosing as of shown in a study comparing Bayesian  
forecasting with conventional dosing in a tertiary care hospital [1].  
 
 
 
 
 
 
 
Methods:  
23 adult patients with a hypo-albuminaemia could be selected from a total  
of >2500 patients [1]. They were subdivided in 2 groups: the very low  
Albumin (alb < 25 g/L; n=12) and the low albumin group (35 > alb  25 g/L;  
n=11). Albumin and total PHT (dphT), determined with a routine EMIT lab  
assay, were analyzed in the central lab of the Kantonsspital Aarau. The free PHT 
(dphEF) levels were measured in a specialized lab for antiepileptics  
(Epi Klinik Zürich) by using the supernatant of the plasma sample after 
ultracentrifugation (30 kD cutoff, 20 min centrifugation time) and by a HPLC  
method. The Sheiner-Tozer equation was used to calculate the free PHT  
from dphT [μg/ml] and the albumin concentration [g/100 mL] (Figure1): 
 
 
 
 
 
 
 
 
 
 
 
 
The calculated and the measured free PHT fraction were compared 
using Sperman Rho (non-parametric) statistics together with mean,  
median, and Standard Deviation (SD) calculations.  
 
Results:  
The two methods correlated very well (Sperman’s Rho 0.907, p=0.000;  
n=23) and showed no significant differences (Figure2). The differences 
between measured and calculated values were < 6.5%.  
The results were comparable in the low and the very low albumin group with a 
max. deviation between the measured and the calculated free fraction of  
< 6.39% (SD = 1.4; median = 3.63) and < 6.17% (SD = 1.88; median = 2.80),  
respectively.  
In Table 1 the values of the calculated total PHT levels and the free PHT  
fraction for the investigated subjects are depicted. The one way ANOVA  
as well as the T-test showed no difference in the two groups. 
ANOVA p-value = 0.129, critical f-value = 4.32;  
T-test: p-value = 0.129, critical t-value = 2.08. 
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Figure 1: The Sheiner-Tozer formula  
Free PHT (dphEF) [g/L] is calculated from the total PHT (dphT) and the serum albumin 
concentration; 4,4 represents the mean serum albumin value [g/100mL].                                     
0.9 corrects for the protein bound PHT fraction (90%); 0.1 for the free PHT fraction (10%).  
 
Figure 2: Free PHT: measured (dphF) vs. calculated (dphEF)  
Regression analysis (n=23) between free PHT and calculated free PHT. (Albumin < 35g/L)  
 
 
 
 
 
 
 
 
 
 
 
Linear regression:                 95% confidence interval: - - - -         Sperman’s roh 0.907 (p=0.000)                  
 
 
 
Table 1: Individual data per patient including statistics (n=23) 
Total PHT levels and the free PHT fraction; measured and calculated (Sheiner-Tozer equation) 
values . SD: Standard deviation, MeanDev is the mean (absolute) deviation from the Mean Value. 
Aims:  
The aim of the study is to evaluate the utility of the Sheiner-Tozer equation  
for the free serum PHT level assessment in a hospital setting. We selected 
patients with low serum albumin < 35 g/L  in whom the total and the free 
serum PHT concentrations were measured and compared the measured  
free PHT levels with the calculated ones. 
 
Conclusion:  
From this study we conclude that the free PHT serum 
concentration can be calculated by the Sheiner-Tozer 
equation in hospitalized patients with hypo-albumin- 
aemia (19-35 g/L) with the appropriate precision.  
Thus, the Sheiner-Tozer method represents an useful,  
quick, and almost free of cost bedside approach. 
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calculated 
free PHT 
fraction 
[dphEF] 
[dphF] 
in % of 
[dphT] 
[dphEF] 
in % of 
[dphT] 
Difference 
[dphEF % 
-dphF %] 
Albumin 
[g/L] 
1 2.58 0.30 0.38 11.70 14.86 3.16 28 
2 3.20 0.35 0.49 11.00 15.33 4.33 27 
3 3.83 0.38 0.54 10.00 14.01 4.01 30 
4 2.88 0.51 0.56 17.90 19.64 1.74 20 
5 4.75 0.57 0.67 12.00 14.01 2.01 30 
6 2.50 0.59 0.44 23.70 17.53 6.17 23 
7 2.83 0.60 0.55 21.20 19.64 1.56 20 
8 4.78 0.67 0.78 14.10 16.36 2.26 25 
9 8.73 0.91 1.10 10.40 12.57 2.17 34 
10 3.68 0.96 0.75 26.20 20.47 5.73 19 
11 11.03 0.97 1.39 8.80 12.57 3.77 34 
12 8.35 0.98 1.28 11.70 15.33 3.63 27 
13 5.08 0.98 0.92 19.30 18.18 1.12 22 
14 9.80 1.24 1.66 12.70 16.92 4.22 24 
15 6.70 1.37 0.94 20.40 14.01 6.39 30 
16 10.38 1.53 1.76 14.70 16.92 2.22 24 
17 10.58 1.64 2.00 15.50 18.88 3.38 21 
18 11.05 1.70 2.09 15.40 18.88 3.48 21 
19 16.15 1.78 2.33 11.00 14.43 3.43 29 
20 10.68 1.78 1.87 16.70 17.53 0.83 23 
21 9.95 1.89 1.32 19.00 13.25 5.75 32 
22 9.30 1.93 1.90 20.80 20.47 0.33 19 
23 14.40 1.93 2.44 13.40 16.92 3.52 24 
SD 4.0 0.6 0.7         
Median 8.4 1.0 1.1       24.0 
Mean 7.5 1.1 1.2       25.5 
Mean Dev 
3.5 0.5 0.6       4.0 
One way Anova (free PHT values for Patient with: albumin <25 (n=12) compared to 
albumin ≥25 (n=11)) 
p-value critical f-value                           f-value 
0.129 4.32 2.50 
variance group <25: 0.289 variance group ≥25: 0.306 
Two-sample t-Test (free PHT values for Patient with: albumin <25 (n=12) compared 
to albumin ≥25 (n=11)) 
p-value critical t-value                          t-statistic 
0.129 2.08 1.58 
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Introduction: 
Phenytoin (PHT) is indicated to treat and/or prevent epilepsia in 
neurosurgical patients. Little is known about the fate of PHT in the brain 
(target organ) and the correlating concentrations in other biological 
samples commonly used for TDM like serum. To investigate this 
particular pharmacokinetic correlation, a sensitive, reliable, and cost-
effective analytical method has to be established and validated. GC-MS 
and LC-MS are possible methods to quantify PHT in biological samples. 
Therefore, the two methods were elaborated and validated for PHT 
using samples with concentrations expected in patients. Analytical data 
from ex vivo CNS microdialysis, artificial cerebrospinal fluid (aCSF), 
blood and saliva were compared for both methods.
Method: 
The GC-MS analysis needs a solid phase extraction (SPE) for clean-up of the 
samples (Fig 1). Derivatization of the residue was made with 
trimethylsulphonium hydroxide. As internal standard (IS), 5-(p-Methylphenyl)-
5-phenylhydantoin  (MPPH) was used. The calibration curve ranged from 50 
to 1200 ng/mL.
For the LC-MS analysis, d10-PHT (100 µg/mL in MeOH) was used as IS, 
diluted with HClO4 to 50 ng/mL. 75 µL of this solution was added to 25 µL 
sample for perchloric acid precipitation (Fig 2). The calibration curve ranged 
from 10 to 2000 ng/mL PHT. Both methods were validated according to ISO / 
FDA Guidance for Industry. Selectivity, sensitivity, recovery, limit of detection 
(LOD), limit of quantification (LOQ), accuracy, linearity, and extract stability of 
both procedures were assessed. The performance of the two methods were 
compared: sample volume needed, analysis time and costs.
Results: 
GC-MS: 
Retention time: PHT = 15.12min (Fig 3), MPPH = 16.15 (Fig 5). Selectivity 
and sensitivity: all blank samples were negative. Recovery: Quality control 
(QC) 100 ng/mL, QC 1000 ng/mL ≤ 8% min/max deviation from target value. 
LOD = 15 ng/mL, LOQ = 50 ng/mL  for all matrices. Accuracy: 1-10% for 
calibrator 2 (Cal2) (150 ng/mL) to Cal6 (1200 ng/mL) and 20% for Cal1 (50 
ng/mL). The calibration curve was linear (r20.995, aCSF *n=8, blood *n=2, 
and saliva *n=2). Dried extracts were stable ≥ 4 weeks (min/max deviation 
4%). Reinjection and storage (33h) on the autosampler showed no variations. 
The run time was 30 min. per analysis; the clean-up time for 25 samples took 
5 h. The cost for materials and consumables was about 8 CHF per sample. 
LC-MS: 
Retention time for PHT and d10-PHT were at about 2.8 min. (Fig 4 and Fig 6). 
Selectivity and sensitivity: for blank samples no interferences were detected. 
Recovery: min/max deviations from target value were 10% for the lowest QC 
and 3% for the highest QC. LOD <<10 ng/mL, LOQ = 10 ng/mL. Accuracy: 
1-8% for Cal2 (20 ng/mL) to Cal8 (2000 ng/mL) and 3% for Cal1 (10 ng/mL). 
The calibration curve was linear (r20.997, aCSF *n=6, blood *n=3, and 
saliva *n=3). Reinjection after 7 days; no difference in accuracy was 
detectable. The run time is 7 min. per analysis, preparation time for 182 
samples took 6 h. 
(*n = number of calibration curves)
Fig 3: GC-MS 50 ng/mL PHT (Cal1) 
black = TIC chromatogram; red, green, and 
blue chromatograms of the mass fragments at 
m/z 280, 203 and 194 
Fig 4: LC-MS 10 ng/mL 
(Cal1), PHT
Conclusions: 
• The LC-MS method shows better performance in terms of sample 
consumption, sample preparation time, run time per sample, 
robustness and linearity (Fig 7). Accuracy and precision are 
comparable.
• For LC-MS the linearity of the calibration covers a larger range (10 –
2000 ng/mL), covering the expected PHT concentrations in patients.
• For  larger clinical studies LC-MS is the preferred method compared to 
GC-MS.
Fig 5: GC-MS                                                
Internal standard  1200 ng/mL MPPH
Fig 6: LC-MS          
Internal standard 50 
ng/mL d10-PHT
Fig 7: Quantitative comparison of LC-MS and GC-MS in arbitrary units.
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Fig 1: Clean-up of samples 
for GC-MS analyses (SPE).  
Fig 2: Sample preparation in  deep well plates 
for LC-MS analyses for blood, saliva and aCSF 
samples.
LC-MS versus GC-MS in the analysis of phenytoin in patients’ samples: 
evaluation criteria and a scoring approach
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Introduction and Aim: 
Phenytoin PHT is an anticonvulsant indicated for treatment and prevention 
of epilepsy. Little is known about the pharmacokinetics (PK) of PHT in the 
brain and the concentration correlation to samples used for therapeutic 
drug monitoring (TDM). This applies especially to the critical ill 
neurosurgical patient at high epileptic risk.. As a prerequisite for PK 
investigations, a specific, sensitive, robust, and cost-effective analytical 
method in biological samples is mandatory. Therefore, two different, 
chromatographic methods (GC and LC) coupled with MS detection and the 
correlating sample preparation were  compared. They were validated 
according to ISO 17025 /FDA Guidance for Industry. For better visualization 
of the comparison a scoring approach was aimed.
Method: 
GC-MS: capillary column: 0.25µm, DB-5ms, 0.25mm x 30m (Agilent). 
Temperature setting:120ºC-300ºC (10ºC/min). Injection volume: 2µL (Auto 
injector, Agilent 7673, 10µL syringe). Run time 25min. 
Spectra analysis MassLib™ (www.masslib.com) identification by similarity 
and identity. Calibration: 6 conc. levels from 50 to 1200 ng/mL were used and 
included the expected sample concentration from patients. A solid-phase 
extraction (SPE) with Bond Elute® LRC Certify 130MG Varian Inc. for clean-
up of the samples ( 50µL) was used. The derivatization of the residue was 
made with trimethylsulphonium hydroxide. 5-(p-methylphenyl)-5-
phenylhydantoin (MPPH) was used as internal standard (IS). 
LC-MS: mobile phase A (H2O + HCOOH (100 + 0.1 v/v) and B (MeCN + 
HCOOH) were used. Pump1 with flow of  0.350 mL/min and pump2 with  flow 
0.200 to 1.000 mL/min (Dionex pump HPG-3200A). The trapping column 
Phenomenex Gemini Polar column, 2.0 x 10 mm, 5 µm was at room 
temperature. The main column Phenomenex Synergy Polar RP column , 2.0 
x 50 mm was placed in the column oven (Cluzeau Info Labo CrocoCil)  set on 
50°C. The system was coupled to a MS (MDS Sciex, Q Trap 3200) .             
d10-PHT (100 µg/mL in MeOH) was used as IS. This solution was diluted to 
50 ng/mL with HClO4 .75 µL were used to deproteinize a sample of 25 µL. 
The calibration curve ranged from 10 to 2000 ng/mL.
The validation was made according to ISO/FDA Guidance for Industry 
includeing selectivity, sensitivity, recovery, limit of detection (LOD), limit of 
quantification (LOQ), accuracy, linearity, and extract stability analyses. 
The performance of the methods was assessed by the sample volume 
needed, the time expenditure for an analysis in minutes, and the costs of 
materials in CHF. They were compared in arbitrary units.
Results: 
GC-MS: 
Retention time: PHT = 15.12min (Fig 3), MPPH = 16.15 (Fig 5). 
Selectivity and sensitivity: all blank samples were negative. 
Recovery: Quality control (QC) 100 ng/mL, QC 1000 ng/mL ≤ 8% min/max 
deviation from target value. LOD = 15 ng/mL, LOQ = 50 ng/mL for all 
matrices. Accuracy: 1-10% for calibrator 2 (Cal2) (150 ng/mL) to Cal6 (1200 
ng/mL) and 20% for Cal1 (50 ng/mL). The calibration curve Cal1 to Cal6 was 
linear (r20.995, aCSF *n=8, blood *n=2, and saliva *n=2). 
Dried extracts were stable ≥ 4 weeks (min/max deviation 4%). 
Reinjection and storage (33h) on the auto sampler showed no variations. 
Run time: 30 min. per analysis; the clean-up time for 25 samples took 5 h. 
Cost for materials and consumables was about 8 CHF per sample. 
LC-MS: 
Retention time for PHT and d10-PHT were at about 2.8 min. (Fig 4 and Fig 6). 
Selectivity and sensitivity: for blank samples no interferences were detected. 
Recovery: min/max deviations from target value were 10% for the lowest QC 
and 3% for the highest QC. LOD <<10 ng/mL, LOQ = 10 ng/mL. Accuracy: 
1-8% for Cal2 (20 ng/mL) to Cal8 (2000 ng/mL) and 3% for Cal1 (10 ng/mL). 
The calibration curve was linear (r20.997, aCSF *n=6, blood *n=3, and 
saliva *n=3). Reinjection after 7 days; no difference in accuracy was 
detectable. The run time is 7 min. per analysis, preparation time for 182 
samples took 6 h. 
(*n = number of calibration curves)
Fig 3:
GC-MS  50 ng/mL PHT (Cal1). 
Black = total ion chromatogram (TIC); red, green, and blue 
mass fragments at m/z 280, 203, 194 
Fig 4:
LC-MS 10 ng/mL (Cal1), 
PHT
Conclusions: 
• The LC-MS method showed better performance (relative scoring 
8.5 (Fig.8)).
• Less sample volume needed, reduced work and cost for sample 
preparation, and less chemicals needed. 
• LC-MS has the, shorter run-time, and the larger linearity in the 
range from 10 to 2000 ng/ml covering the expected sample 
concentrations. 
→ Therefore LC-MS is better suited for a extensive PK study.
Fig 5:
GC-MS Internal standard  1200 ng/mL MPPH 
black = TIC; red, green, and blue 
mass fragments at m/z 294, 217, 208
Fig 6:
LC-MS Internal standard 
50 ng/mL  d10-PHT
Fig 7:
Quantitative comparison of LC-MS and 
GC-MS in arbitrary units.
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Selectivity and 
sensitivity
blank samples were negative [0.5] blank samples were negative [0.5]
Recovery and deviation 
[min/max in %]
QC100 ng/mL ≤8%, 
QC 1000 ng/mL ≤6% 
QC 10 ng/mL 10% 
QC 1600 ng/mL 3% [1]
LOD 15 ng/mL <<10 ng [1]
LOQ 50 ng/mL 10 ng [1]
Accuracy (calibrators 
[cal]).
1-10% for cal2 (150 ng/ml) to cal6 
(1200 ng/mL) 
20% for cal1 (50 ng/mL)
1-8% for cal2 (20 ng/mL) to cal8 
(2000 ng/mL) 
3% for cal1 (10 ng/mL) [1]
Linearity (of calibr.  
curves)
r20.995, aCSF n=8, blood n=2, and 
saliva n=2 [0.5]
r20.997, aCSF n= 6, blood n=3, 
and saliva n=3 [0.5]
Stability [RT
on autosampler
> 4 weeks (min/max deviation 4%). 
no effect after reinjection  (33 h) [0.5]
Reinjection after 7 days: 
no difference in accuracy [0.5]
Run time 30 Min 7 min. [1]
Sample preparation time 5h for 25 samples 6h for 182 samples [1]
Costs 8CHF 3CHF [1]
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Fig 8:
Score of the investigated parameters. 
Winner got 1 point if equal each got 0.5.  
Comparison in arbitrary units
Fig 1:
Clean-up of biological samples 
(aCSF, blood or saliva) for GC-
MS analyses (SPE).  
Fig 2:
Sample preparation in  deep well plates for LC-MS 
analyses for blood, saliva and aCSF samples.
Determination of Phenytoin from Human Brain Microdialysis and other 
Biological Samples: Development and Validation of a GC-MS Method 
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Objectives
Phenytoin (PHT), an acidic lipophilic drug (m.w.=252.3, pKa=8.3, LogP=2.47), is routinely used to prevent 
and treat epilepsia. It has non-linear, individually variable pharmacokinetics, a small therapeutic index 
(Cpl:10-20µg/ml or 40-80mM), and is 90% serum protein-bound; it needs therapeutic drug monitoring.
The aims of this study were:
1.To define an appropriate sample extraction procedure for biological samples for GC-MS analysis of PHT.
2. To establish a GC-MS method suitable for PHT analysis in the samples and its validation according to 
ISO 17025.
3.To characterize the GC-MS method in order to compare it with an alternative LC-MS method to be 
developed. 
Materials and Methods
Extraction : 
For solid phase extraction (SPE) cartridges with non-polar C8 sorbent and a strong cation exchanger 
(SCX) were used (Bond Elute® LRC Certify, 130MG, Varian Inc.). 
Extraction procedure:
Conditioning: 1mL acetonitrile followed by 1mL citric buffer pH 5. 
Probes with internal standard (IS) were added and washed: 1mL citric buffer pH 5 + 1mL HAc 0,01M to 
acidify (pH≈3.5), residue vacuum-dried for 5min. PHT eluted with 2mL acetone; 1min vacuum to drain the 
SPE columns. Transfer into GC analysis vials and dried to solid at 50ºC (N2).
GC-MS: 
IS: 5-(p-methylphenyl)-5-phenylhydantoin (MPPH) m. w.=266.29, >99% purity (Sigma Aldrich)
Derivatization: Extracts were derivatized directly upon injection into the GC-MS with 50µL of TMSH (fig. 1)
GC:  capillary column: 0.25µm, DB-5ms, 0.25mm x 30m (Agilent). Temperature: 120ºC-300ºC (10ºC/min). 
Injection volume: 2µL (Auto injector, Agilent 7673, 10µL syringe size). Run time 25min. 
Spectra analysis: MassLib™ (www.masslib.com) identification by similarity and identity. 
Samples: 
100μL microdialysate samples from ex situ brain tumor tissue (frozen by -20ºC) were provided by the 
Kantonsspital Aarau, Switzerland. 
Artificial cerebrospinal fluid (aCSF) samples, CPDA-preserved blood (Blood Donor Centre of Bern, 
Switzerland), and saliva (from investigator) were used and spiked with PHT(purity >96% Fluka, 
Switzerland), Na-PHT injection solution (Phenhydan Desitin Pharma, Switzerland), or CRS: PHT Ph.Eur..
Chemicals: 
Were of analytical grade (Merck, Fluka). 
TMSH purchased from Macherey-Nagel
Validation procedure: 
According to ISO 17025. 12 PHT calibration points at 6 conc. levels from 50 to 1200 ng/mL were used.
Results (method characterization and validation):
GC method showed good PHT peak resolution, even in scan mode. 
IS:  MPPH was appropriate; ion fragments differ from PHT and are well separated (fig. 2). 
Fig. 2: GC/MS Identification and Quantification: Retention time: PHT = 15.12 min, MPPH =16.15 min
PHT  50ng/mL , [280,203,194,118] and MPPH 1200ng/mL [294,203,194,118]
Matrix effects: One-way ANOVA analysis revealed no significant differences between aCSF, blood, and 
saliva: F= 0.0002, p=0.9998, (tab: 1), (fig: 3).
Tab. 1: Correlation and linearity of PHT from different matrices: 
Fig. 3: Calibration curves for the matrixes                      Results of spiked samples aCSF n=18; blood and saliva n=2 per conc.
Selectivity and sensitivity: biological blank samples were negative, no false positives.
PHT limit of detection [LOD]: 50ng/mL (S/N ratio 4:1); PHT limit of quantification [LOQ]:100ng/mL
Stability of the extracts: dried extracts were stable >4 weeks at room temperature: QC1+/- 4%, QC2+/-1%. 
The stability of the dissolved extracts was >33 hrs (during stay in the auto sampler). 
Accuracy (measured with calibrators between 50-1200ng/mL):
Inter-individual variability: +/-10%. Intra-individual variability: 1-32% (highest at LOD; 1-10% for the others).
PHT recovery after SPE: (spiked samples; 100% in absence of SPE):  
94.1% for 100ng/mL, 94.32% for 1000ng/mL (n=3, r2=0.996).
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C1 50 70   +/- 45    32  +/- 1 43   +/- 0.1
C2 150 161  +/- 10 150  +/- 17 153   +/- 6 
C3 300 308  +/- 12 320  +/- 8 301  +/- 31
C4 600 594  +/- 7 640  +/- 1 614 +/- 3
C5 1000 905  +/- 10 929  +/- 13 984  +/- 3 
C6 1200 1272  +/- 3 1237  +/- 36 1206  +/- 12
Conclusions
1. The GC-MS method is suited for PHT determination in biological samples of treated patients 
with appropriate sensitivity: 50-100ng representing 10% of the lower free serum value. 
2. LOD & LOQ meet the requirements to monitor therapeutic dosing in liquor (≈100-200 ng/mL). 
3. The GC-MS method needs a SPE, PHT derivatization, has a relatively long run time (≈30 min). 
4. The SPE method can be used for all biological samples (dialysates, aCSF, blood, and saliva).
5. The validation meets analytical standards according to ISO 17025. 
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A Validated Phenytoin Analysis from CNS ex vivo Brain Microdialysis Samples,
Blood and Saliva by GC/MS 
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Materials and Methods
Extraction and Derivatization: 
Solid phase extraction cartridges (Bond Elute® LRC Certify; Varian) with 
acetonitrile-citrate buffer pH 5 (fig. 1). 
Fig. 2: Derivatization of PHT with trimethylsulfonium hydroxide (TMSH) 
(K. Yamauchi et al.; Trimethylsulfonium Hydroxide: A New Methylating Agent; J. Org. Chem., c'ol. 44, No. 4, 1979; p. 638)
Background and Aim of the study
Phenytoin (PHT), an acidic lipophilic drug, is used routinely in 
neurosurgical patients to prevent and treat epilepsia. The non-linear 
pharmacokinetics and the high variation of metabolism render a 
therapeutic drug monitoring (TDM) necessary. Data on PHT in CNS fluid 
of neurosurgical patients are lacking but should allow a better definition 
and monitoring of PHT pharmacokinetics at the site of action and 
compare them with other biological samples. 
Results
Validation of the GC-MS-Analysis
IS: MPPH was an appropriate IS. Ion fragments differ from PHT and are 
well separated. RT: PHT = 15.12 min, MPPH =16.15 min) (fig. 3). 
Fig. 3: GC/MS Identification and Quantification
50 ng/mL Phenytoin [280, 203, 194, 118]      1200 ng/mL MPPH [294, 203, 194, 118]
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The aim of this study was to define an appropriate sample 
extraction procedure and to establish a GC/MS method for 
PHT and its metabolites from  brain microdialysates, blood, 
and saliva; the validation of the method was also targeted.
The acetone elute was dried to solid (50°C) under nitrogen. Dissolution and 
methylation with TMSH (trimethylsulfone hydroxide) prior to GC-MS analysis.
GC-MS:
5-(p-methylphenyl)-5-phenylhydantoin (MPPH) was used as internal 
standard (IS). 
The extracts were derivatized directly upon injection into the GC-MS. 
Oven temperature settings: 120°C – 280°C (10°C/min). Injection volume: 
2µL (syringe size 10µL). Total run time (27min) showed good peak resolution 
(scan mode). MassLib™ (www.masslib.com) was used for spectra analysis 
(identification by similarity and identity). 
Samples:
Deep frozen (-20°C) 100 µL samples from ex situ brain tumor tissue 
microdialysis were provided by the Kantonsspital Aarau. Artificial (a)CSF was 
spiked for method evaluation and validation. CPDA-preserved blood was 
from the Blood Donor Centre of Bern. Saliva was provided by the first author.
Chemicals: 
Were of analytical grade (Merck, Fluka). 
Na-PHT injection solution (Phenhydan Desitin Pharma, Switzerland)). 
PHT (>96% Fluka, Switzerland), , PHT CRS (Ph.Eur.). 
MPPH >99% purity (Sigma Aldrich).
Validation procedure: 
According to ISO 17025. PHT: 12 points calibration at 6 conc. levels (ranging 
from 50 to 1200 ng/mL).
Tab. 1: Correlation and linearity of PHT from different matrices              
Results of spiked samples aCSF n=18, blood and saliva n= 2 per conc.
For differences between aCSF, blood, and saliva series a oneway ANOVA 
Linear best fit aCSF blood salvia
Correlation coefficient  (r) 0. 996    0.996 0.999
Slope (x) (calibration) 0.997 0.998 0.999
Axis intercept (y) 8.198 2.287 0.268
Calibrator [ng/mL] Mean aCSF ± SD rel [%] Meanblood Meansaliva
C1 50 70   ± 45    32  ± 1 43   ± 0.1
C2 150 161  ± 10 150  ± 17 153   ± 6 
C3 300 308  ± 12 320  ± 8 301  ± 31
C4 600 594  ± 7 640  ± 1 614 ± 3
C5 1000 905  ± 10 929  ± 13 984  ± 3 
C6 1200 1272  ± 3 1237  ± 36 1206  ± 12
On position „WASTE“:
Fig. 1: Sample solid phase extraction (SPE)
1 mL 1 mL 
Conclusions
1. The method is suited for PHT determination from brain 
microdialysate, blood, and saliva in treated patients . 
2. The validation meets analytical standards of ISO 17025. 
3. LOD and LOQ meet the requirements to monitor 
therapeutic dosing in liquor (ca. 100-200 ng/mL). 
4. The analytical procedure looks promising for the 
pharmacokinetic assessment of PHT in brain micro-
dialysate and other human biological samples.
analysis was calculated. 
The results showed no significant differences (F= 0.0002; p=0.9998).
Selectivity and sensitivity: The selectivity was demonstrated (fig. 3). 
Biological blank samples were negative, no false positives were obtained.
PHT limit of detection [LOD]: 50 ng/mL (S/N ratio 4:1)
PHT limit of quantification [LOQ]: 100 ng/mL
Stability of the extracts: PHT in the dried extracts was stable > 4 weeks. 
The stability of the dissolved extracts (during stay in the auto sampler) 
was >33 hrs.
Accuracy (measured with calibrators between 50-1200 ng/mL):
Interindividual variability  ± 10%. 
Intraindividual variability: 1-32% (highest at LOD; 1-10% for the others).
PHT Recovery after SPE (spiked samples; 100% in absence of SPE): 
94.1% for 100 ng/mL, 94.32% for 1000 ng/mL
(n=3, r = 0.996)
1 mL acetonitril     1  mL citric 
buffer pH5
Cal, S  
(SST, QC)
TMSH 50 µL
Procedure:
1. Conditioning with acetonitrile
2. Citric buffer pH 5
3. Adding calibrator [Cal], the 
samples [S], for system 
suitability testing [SST] and 
quality control [QC]
4. Washing with citric buffer  pH 5
5. pH adjustment with HAc 0,01M 
6. 5 min vacuum drying
7. Acetone to elute PHT
8. Vacuum for 1 min to drain
9. Transfer into GC-Vial
10.Dry to solid at 50°C (N2) 
11.Methylation: 50 µL of TMSH 
(fig. 2)
On position „COLLECT“:
2 mL aceton
citric buffer pH 5         0,01M HAc
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Methods
Extraction: Solid phase extraction cartridges (Bond Elute® LRC 
Certify; Varian) were used with acetonitrile-citrate buffer pH 5 (see 
fig. 1). The acetone-eluate was dried to solid (50°C) in a stream of 
nitrogen, dissolved and methylated with TMSH (Trimethylsulfone 
hydroxide) prior to GC-MS analysis.
GC-MS: 5-(p-Methylphenyl)-5-Phenylhydantoin (MPPH, > 99% 
purity, Sigma Aldrich) was used as internal standard. The 50 µL 
extracts were derivatized directly upon injection into the GC-MS. 
During the total run time of 27 min., good peak resolution (scan 
mode) was obtained. Settings: Temperature start 120°C, to a final 
temperature of 280°C with 10°C/min. All chromatographic peaks 
were checked with MassLib™ (www.masslib.com) allowing mass 
spectra identification by both similarity and identity. 
Samples: 200-500 µL biological samples were used, provided from 
the Kantonsspital Aarau (Prof. Hans Landolt, Head neurosurgery) 
and stored deep frozen (-24°C). Artificial CSF was spiked for method 
evaluation and validation. 
Chemicals: All of analytical grade (Merck, Fluka). Na-PHT injection 
solution (Phenhydan® Desitin Pharma, Switzerland), PHT (>96% 
Fluka), PHT CRS (Ph.Eur.)
Validation procedure: According to ISO 17025. A 12-point 
calibration for PHT at 6 different calibration levels, from 50 to 1200 
ng/mL was used. 
Fig 1: Sample extraction procedure
Conclusions
1. The method is suitable for PHT determination in 
extracellular CNS fluid . 
2. The validation meets analytical standards of ISO 17025. 
3. LOD and LOQ are sufficient to monitor therapeutic 
dosing, for liquor ca. 100-200 ng/mL.
4. The analytical procedure looks promising for the 
pharmacokinetic assessment of PHT in brain.
Fig 2: Derivatisation of PHT with trimethylsulfonium hydroxide [TMSH] .
[K. Yamauchi et al.; Trimethylsulfonium Hydroxide: A New Methylating Agent; J. Org. Chem., c 'ol. 44, No. 4, 1979; p. 638]
Background and Aim of the study
Phenytoin (PHT) is an acidic lipophilic drug and is used routinely 
on neurosurgical (ICU) patients to prevent and treat epilepsia. The 
non-linear pharmacokinetics and the high variation of metabolism 
render a therapeutic drug monitoring (TDM) necessary. 
Extracellular CNS fluid available from continuous microdialysis in 
ICU patients should allow a better definition and monitoring of PHT 
pharmacokinetics at the site of action. A GC-MS method was 
selected to monitor the parent compound in small CNS micro-
dialysis samples. 
The aim of the study was to define an appropriate sample 
extraction procedure and to demonstrate the suitability of the 
analytical method by validation according to ISO 17025.
On position „WASTE“:
1 mL Acetonitril     1 mL citric 
puffer pH5
Cal, QC, 
SST, S
1 mL citric puffer pH 5   1 mL 0,01M  
HAc
TMSH 50 µL
Procedure:
1. Conditioning with acetonitrile
2. Citric puffer pH 5
3. Adding calibrator [Cal], the 
samples [S], the system 
suitability test [SST] and the 
quality control [QC]
4. Wash wit citric puffer  pH 5
5. pH adjustment with HAc 0,01M 
6. 5 min drying with vacuum
7. Acetone to elute PHT
8. Vacuum for 1 min. to empty
9. Transfer from RG into GC-Vial
10.Evaporate solvent at 50°C (N2) 
11.Methylation: 50 µL of TMSH 
(see fig. 2)
On position „COLLECT“:
2 mL Aceton
Results
Validation of the GC-MS-Analysis
Internal standard 
MPPH was appropriate as internal standard. PHT and MPPH  have  
different  Ion fragments and could therefore easily been separated. The 
retention time differs by 1 minute (RT: PHT = 15.12 min., MPPH =16.15 
min).
Fig 3: GC-MS-Spectrum 
50 ng/mL                                           1200 ng/mL
Phenytoin [280, 203, 194, 118]         MPPH[294, 203, 194, 118]
Correlation and linearity of PHT
Correlation coefficient between 50 and 1200 ng/mL: r2 = 0.993 . 
Deviation from the target for calibrators: 40% [50 ng/mL], 7% [150 ng/mL], 
3% [300 ng/mL], 1% [600 ng/mL], 9% [1000 ng/mL] , 6% [1200 ng/mL]. 
Selectivity and sensitivity
The selectivity was demonstrated. The blank biological samples were 
negative, so no false positives were obtained.
Limit of detection [LOD]: 50 ng/mL (S/N-ratio 4:1) PHT
Limit of quantification [LOQ]: 100 ng/mL PHT
Stability of the extracts
PHT in the dried  extracts was stable > 4 weeks. The stability of the 
dissolved extracts (during analysis) is > 33 hrs.
Fig 4: Stability of QC1 
Accuracy (measured with calibrators)
Interindividual variability +/- 10%. 
Intraindividual variability: 1 - 32% (highest at LOD; 1 -10% for the others).
Recovery (spiked samples with and without SPE)  
The amount of PHT after SPE was 89% for 100 ng/mL, 93% for 1000 ng/mL 
and 45 -115% for 50 ng/mL (LOD) compared without SPE. 
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